## Gregg C Fonarow

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3924395/publications.pdf

Version: 2024-02-01

1,547 papers

143,182 citations

167 h-index 325 g-index

1568 all docs

1568 docs citations

1568 times ranked

74776 citing authors

#	Article	IF	CITATIONS
1	Meta-analysis Comparing the Efficacy of Dobutamine Versus Milrinone in Acute Decompensated Heart Failure and Cardiogenic Shock. Current Problems in Cardiology, 2023, 48, 101245.	1.1	4
2	Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. European Heart Journal Quality of Care & amp; Clinical Outcomes, 2022, 8, 31-38.	1.8	13
3	A Brief Overview of Recurrent Pericarditis Management and the Potential of Rilonacept as a New Therapeutic Option. American Journal of Cardiovascular Drugs, 2022, 22, 27-33.	1.0	2
4	Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. Journal of Cardiac Failure, 2022, 28, 191-201.	0.7	6
5	Right Ventricular Ejection Fraction and Beta-Blocker Effect in Heart Failure With Reduced Ejection Fraction. Journal of Cardiac Failure, 2022, 28, 65-70.	0.7	4
6	Identifying Treatments for Stage C2 Heart Failure. JAMA Cardiology, 2022, 7, 34.	3.0	5
7	Severe Hypoglycemia and Incident Heart Failure Among Adults With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e955-e962.	1.8	17
8	Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. European Journal of Heart Failure, 2022, 24, 169-180.	2.9	23
9	Community-Level Economic Distress, Race, and Risk of Adverse Outcomes After Heart Failure Hospitalization Among Medicare Beneficiaries. Circulation, 2022, 145, 110-121.	1.6	16
10	Initiation of Anti-Hypertensive Drugs and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction. American Journal of Medicine, 2022, 135, 737-744.	0.6	2
11	Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPTâ€HF risk model. ESC Heart Failure, 2022, 9, 178-185.	1.4	3
12	Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. JACC: Heart Failure, 2022, 10, 1-11.	1.9	11
13	Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. Journal of Cardiac Failure, 2022, 28, 370-384.	0.7	16
14	Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity?. American Heart Journal, 2022, 244, 135-148.	1.2	10
15	Achieving More Rapid Door-to-Needle Times and Improved Outcomes in Acute Ischemic Stroke in a Nationwide Quality Improvement Intervention. Stroke, 2022, 53, 1328-1338.	1.0	16
16	Inâ€hospital initiation of quadruple medical therapy for heart failure: making the postâ€discharge vulnerable phase far less vulnerable. European Journal of Heart Failure, 2022, 24, 227-229.	2.9	26
17	Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. Journal of Cardiac Failure, 2022, 28, 554-563.	0.7	4
18	Achievement and quality measure attainment in patients hospitalized with atrial fibrillation: Results from The Get With The Guidelines – Atrial Fibrillation (GWTG-AFIB) registry. American Heart Journal, 2022, 245, 90-99.	1.2	2

#	Article	IF	Citations
19	Cardiac autonomic neuropathy and risk of incident heart failure among adults with type 2 diabetes. European Journal of Heart Failure, 2022, 24, 634-641.	2.9	15
20	Sodium–glucose coâ€transporter 2 inhibitors as an early, firstâ€line therapy in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 431-441.	2.9	67
21	Exploring the Unmet Need in Acute Ischemic Stroke Patients Not Treated With Intravenous Alteplase: The Get With The Guidelinesâ€ <b>s</b> troke Registry. , 2022, 2, .		О
22	Annals for Hospitalists Inpatient Notes - Clinical Pearlsâ€"Stopping, Starting, and Optimizing Guideline-Directed Medical Therapy in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Annals of Internal Medicine, 2022, 175, HO2-HO3.	2.0	0
23	Association Between Endovascular Therapy Time to Treatment and Outcomes in Patients With Basilar Artery Occlusion. Circulation, 2022, 145, 896-905.	1.6	9
24	Robustness of outcomes in trials evaluating sodium–glucose coâ€transporter 2 inhibitors for heart failure. ESC Heart Failure, 2022, , .	1.4	4
25	Economic Issues in Heart Failure in the United States. Journal of Cardiac Failure, 2022, 28, 453-466.	0.7	40
26	Abstract 116: Unmet Need In Acute Ischemic Stroke Patients Not Treated With Alteplase. Stroke, 2022, 53,	1.0	0
27	Variability of adiposity indices and incident heart failure among adults with type 2 diabetes. Cardiovascular Diabetology, 2022, 21, 16.	2.7	6
28	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. Journal of the American College of Cardiology, 2022, 79, 504-510.	1.2	21
29	Association of readmission penalty amount with subsequent 30-day risk standardized readmission and mortality rates among patients hospitalized with heart failure: An analysis of get with the guidelines – heart failure participating centers. American Heart Journal, 2022, 246, 1-11.	1.2	0
30	Postprocedure Anticoagulation in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2022, 15, 251-263.	1.1	3
31	Association of Recent Use of Non–Vitamin K Antagonist Oral Anticoagulants With Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase. JAMA - Journal of the American Medical Association, 2022, 327, 760.	3.8	28
32	Proton Pump Inhibitors and In-Hospital Gastrointestinal Bleeding in Patients With Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy. Mayo Clinic Proceedings, 2022, 97, 682-692.	1.4	4
33	Abstract 35: Unmet Need In Acute Ischemic Stroke Patients Arriving After 4.5 Hours. Stroke, 2022, 53, .	1.0	0
34	Seasonal Variation of Atrial Fibrillation Admission and Quality of Care in the United States. Journal of the American Heart Association, 2022, 11, e023110.	1.6	5
35	Temporal Trends in Racial and Ethnic Disparities in Endovascular Therapy in Acute Ischemic Stroke. Journal of the American Heart Association, 2022, 11, e023212.	1.6	13
36	Preexisting frailty and outcomes in older patients with acute myocardial infarction. American Heart Journal, 2022, 249, 34-44.	1.2	4

#	Article	IF	CITATIONS
37	Classifying heart failure based on ejection fraction: imperfect but enduring. European Journal of Heart Failure, 2022, 24, 1154-1157.	2.9	7
38	The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from ⟨scp⟩CHAMPâ€HF⟨ scp⟩. European Journal of Heart Failure, 2022, 24, 762-770.	2.9	8
39	Performance of Management Strategies With Class I Recommendations Among Patients Hospitalized With ST-Segment Elevation Myocardial Infarction in China. JAMA Cardiology, 2022, 7, 484.	3.0	10
40	A Risk Stratification Scheme for In-Hospital Cardiogenic Shock in Patients With Acute Myocardial Infarction. Frontiers in Cardiovascular Medicine, 2022, 9, 793497.	1.1	1
41	Patterns of care for first-detected atrial fibrillation: Insights from the Get With The Guidelines® – Atrial Fibrillation registry. Heart Rhythm, 2022, 19, 1049-1057.	0.3	1
42	Diabetic kidney disease and risk of incident stroke among adults with type 2 diabetes. BMC Medicine, 2022, 20, 127.	2.3	11
43	Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With HeartÂFailure and Diabetes. JACC: Heart Failure, 2022, 10, 198-210.	1.9	16
44	Prioritizing prevention of <i>de novo</i> and worsening chronic heart failure. European Journal of Heart Failure, 2022, 24, 653-656.	2.9	2
45	Evaluation of Evidence-Based Dual Antiplatelet Therapy for Secondary Prevention in US Patients With Acute Ischemic Stroke. JAMA Internal Medicine, 2022, 182, 559.	2.6	6
46	2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary. Journal of Cardiac Failure, 2022, 28, 810-830.	0.7	42
47	Severe Hypoglycemia and Incidence of QT Interval Prolongation Among Adults With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2743-e2750.	1.8	8
48	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. Journal of the American College of Cardiology, 2022, 79, 1757-1780.	1.2	314
49	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR0000000000001063.	1.6	756
50	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR0000000000001062.	1.6	133
51	Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF. JACC: Heart Failure, 2022, 10, 266-275.	1.9	20
52	Age stratified sexâ€related differences in incidence, management, andÂoutcomes of cardiogenic shock. Catheterization and Cardiovascular Interventions, 2022, 99, 1984-1995.	0.7	4
53	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2022, 79, e263-e421.	1.2	774
54	In-Hospital Weight Loss and Outcomes in Patients With Heart Failure. Journal of Cardiac Failure, 2022, 28, 1116-1124.	0.7	2

#	Article	IF	CITATIONS
55	Kidney function assessment and endpoint ascertainment in clinical trials. European Heart Journal, 2022, 43, 1379-1400.	1.0	8
56	Association Between Early Oral $\hat{I}^2$ -Blocker Therapy and In-Hospital Outcomes in Patients With ST-Elevation Myocardial Infarction With Mild-Moderate Heart Failure: Findings From the CCC-ACS Project. Frontiers in Cardiovascular Medicine, 2022, 9, 828614.	1.1	3
57	Global Benefit of SGLT2 Inhibitors in HeartÂFailure With Reduced EjectionÂFraction. JACC Asia, 2022, 2, 154-156.	0.5	O
58	Health System–Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients with HFrEF: Results from the CONNECT-HF Trial. Journal of Cardiac Failure, 2022, , .	0.7	7
59	Burden of Microvascular Disease and Risk of Atrial Fibrillation in Adults with Type 2 Diabetes. American Journal of Medicine, 2022, 135, 1093-1100.e2.	0.6	2
60	Guideline-directed device therapies in heart failure: A clinical practice-based analysis using electronic health record data. American Heart Journal Plus, 2022, 16, 100139.	0.3	0
61	Insulin resistance and incident heart failure: a <scp>metaâ€analysis</scp> . European Journal of Heart Failure, 2022, 24, 1139-1141.	2.9	13
62	Abstract 248: IMPLEMENT-HF: An Initiative To Improve Guideline Adherence Across The Continuum. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, .	0.9	1
63	Trends in HF Hospitalizations AmongÂYoung Adults in the United States From 2004 to 2018. JACC: Heart Failure, 2022, 10, 350-362.	1.9	21
64	Abstract 15: The Design Of The Dashboard Activated Services And Telehealth For Heart Failure (DASH-HF) Study: A Pragmatic Quality Improvement Randomized Implementation Trial For Patients With Heart Failure With Reduced Ejection Fraction. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, .	0.9	0
65	Call to Action for Cardiovascular Disease in Women: Epidemiology, Awareness, Access, and Delivery of Equitable Health Care: A Presidential Advisory From the American Heart Association. Circulation, 2022, 145, 101161CIR0000000000001071.	1.6	59
66	Contemporary Trends and Comparison of Racial Differences in Hospitalizations of Adults With Congenital Heart Disease. American Journal of Cardiology, 2022, , .	0.7	0
67	Very Elevated High-Density Lipoprotein Cholesterol and Mortality—The Good Gone Bad?. JAMA Cardiology, 2022, , .	3.0	2
68	The need for increased pragmatism in cardiovascular clinical trials. Nature Reviews Cardiology, 2022, 19, 737-750.	6.1	22
69	Estimating the Benefits of Combination Medical Therapy in Heart Failure With Mildly Reduced and Preserved Ejection Fraction. Circulation, 2022, 145, 1741-1743.	1.6	17
70	Outcomes After Endovascular Thrombectomy With or Without Alteplase in Routine Clinical Practice. JAMA Neurology, 2022, 79, 768.	4.5	17
71	Trends in Use, Outcomes, and Disparities in Endovascular Thrombectomy in US Patients With Stroke Aged 80 Years and Older Compared With Younger Patients. JAMA Network Open, 2022, 5, e2215869.	2.8	15
72	Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMPâ€HF. Journal of the American Heart Association, 2022, 11, .	1.6	3

#	Article	IF	CITATIONS
73	Initiation of anti-hypertensive drugs and outcomes in patients with heart failure with preserved ejection fraction and persistent hypertension. Progress in Cardiovascular Diseases, 2022, , .	1.6	O
74	Machine Learning–Based Models Incorporating Social Determinants of Health vs Traditional Models for Predicting In-Hospital Mortality in Patients With Heart Failure. JAMA Cardiology, 2022, 7, 844.	3.0	28
75	US Surveillance of Acute Ischemic Stroke Patient Characteristics, Care Quality, and Outcomes for 2019. Stroke, 2022, 53, 3386-3393.	1.0	6
76	Analysis of Adverse Events Related to Impella Usage (from the Manufacturer and User Facility Device) Tj ETQq0	0 0 rgBT /0	Overlock 10 T
77	Acute myocardial infarction in the young with diabetes mellitus- national inpatient sample study with sex-based difference in outcomes. International Journal of Cardiology, 2021, 326, 35-41.	0.8	4
78	Heart Failure with Carfilzomib in Patients with Multiple Myeloma: A Meta-analysis of Randomized Controlled Trials. Journal of Cardiac Failure, 2021, 27, 610-612.	0.7	7
79	Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension. American Journal of Medicine, 2021, 134, e252-e263.	0.6	14
80	Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age With a Low Ejection Fraction After Coronary Revascularization. American Journal of Cardiology, 2021, 138, 26-32.	0.7	6
81	Temporal trends in risk profiles among patients hospitalized for heart failure. American Heart Journal, 2021, 232, 154-163.	1.2	8
82	Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice. JAMA Cardiology, 2021, 6, 267.	3.0	22
83	Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMPâ€HF registry. ESC Heart Failure, 2021, 8, 710-713.	1.4	3
84	Association of Medicaid Expansion With Rates of Utilization of Cardiovascular Therapies Among Medicaid Beneficiaries Between 2011 and 2018. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007492.	0.9	13
85	2020 Update to the 2016 ACC/AHA Clinical Performance and QualityÂMeasures for Adults With Atrial Fibrillation or Atrial Flutter. Journal of the American College of Cardiology, 2021, 77, 326-341.	1.2	19
86	Treatment of HF in an Era of MultipleÂTherapies. JACC: Heart Failure, 2021, 9, 1-12.	1.9	26
87	2020 Update to the 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circulation: Cardiovascular Quality and Outcomes, 2021. 14. e000100.	0.9	15
88	Discontinuation and nonâ€publication of heart failure randomized controlled trials: a call to publish all trial results. ESC Heart Failure, 2021, 8, 16-25.	1.4	11
89	Considering dose in pharmacological therapies for heart failure – Authors' reply. Lancet, The, 2021, 397, 275.	6.3	0
90	Highâ€protein vs. standardâ€protein diets in overweight and obese patients with heart failure and diabetes mellitus: findings of the Proâ€HEART trial. ESC Heart Failure, 2021, 8, 1342-1348.	1.4	18

#	Article	IF	CITATIONS
91	Clinical Characteristics and Outcomes Associated With Oral Anticoagulant Use Among Patients Hospitalized With Intracerebral Hemorrhage. JAMA Network Open, 2021, 4, e2037438.	2.8	21
92	United Network for Organ Sharing 2018 Heart Transplant Reallocation Policy. JAMA Cardiology, 2021, 6, 168.	3.0	4
93	Evaluation of Risk-Adjusted Home Time After Hospitalization for Heart Failure as a Potential Hospital Performance Metric. JAMA Cardiology, 2021, 6, 169.	3.0	17
94	National surveillance of stroke quality of care and outcomes by applying post-stratification survey weights on the Get With The Guidelines-StrokeÂpatient registry. BMC Medical Research Methodology, 2021, 21, 23.	1.4	3
95	Guideline-Concordant Antiarrhythmic Drug Use in the Get With The Guidelines–Atrial Fibrillation Registry. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008961.	2.1	11
96	2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2021, 77, 772-810.	1.2	612
97	Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors. Stroke and Vascular Neurology, 2021, 6, 384-394.	1.5	3
98	Regional Variations in Heart Failure Quality and Outcomes: Get With The Guidelines–Heart Failure Registry. Journal of the American Heart Association, 2021, 10, e018696.	1.6	23
99	Making heart failure count. European Journal of Heart Failure, 2021, 23, 917-918.	2.9	3
100	Abstract P384: Outcomes of Endovascular Therapy in Patients With Pre-Stroke Mobility Impairment. Stroke, 2021, 52, .	1.0	0
101	Predicting the EQ-5D utilities from the Kansas City Cardiomyopathy Questionnaire in patients with heart failure. European Heart Journal Quality of Care & Dinical Outcomes, 2021, 7, 388-396.	1.8	13
102	Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). American Journal of Cardiovascular Drugs, 2021, 21, 553-561.	1.0	5
103	Abstract P252: Discharge Antithrombotic Therapy for Ischemic Stroke Patients With Prior Aspirin Failure. Stroke, 2021, 52, .	1.0	0
104	Cardiac Rehabilitation for Patients WithÂHeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 1454-1469.	1.2	102
105	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure, 2021, 23, 352-380.	2.9	630
106	Abstract P133: Geospatial Mapping of Prehospital Delay in Acute Ischemic Stroke and Association With Social Vulnerability. Stroke, 2021, 52, .	1.0	0
107	Predictors of 30-Day Unplanned Readmission After Carotid Artery Stenting Using Artificial Intelligence. Advances in Therapy, 2021, 38, 2954-2972.	1.3	25
108	Sodium–glucose coâ€transporter 2 inhibitors for heart failure: clinical trial efficacy and clinical practice effectiveness. European Journal of Heart Failure, 2021, 23, 1023-1025.	2.9	1

#	Article	IF	CITATIONS
109	Correspondence to European Heart Journalâ€"Quality of Care and Clinical Outcomes in response to letter by Dalal H. <i>et al. </i> European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, e8-e8.	1.8	0
110	Universal Definition and Classification of Heart Failure. Journal of Cardiac Failure, 2021, 27, 387-413.	0.7	362
111	Patterns of Care for Atrial Fibrillation Before, During, and at Discharge From Hospitalization. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009003.	2.1	2
112	Trends in 30- and 90-Day Readmission Rates for Heart Failure. Circulation: Heart Failure, 2021, 14, e008335.	1.6	113
113	Impact of Percutaneous Coronary Intervention on Outcomes in Patients With HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 2432-2447.	1.2	17
114	Acute Ischemic Stroke in Patients With COVID-19. Stroke, 2021, 52, 1826-1829.	1.0	43
115	Palliative Care Services in Patients Admitted With Cardiogenic Shock in the United States: Frequency and Predictors of 30-Day Readmission. Journal of Cardiac Failure, 2021, 27, 560-567.	0.7	7
116	Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 522.	3.0	62
117	Is the Left Ventricular Ejection Fraction Measurement Still Preeminent?â€"New Measures to Quantify Subclinical Systolic Dysfunction. JAMA Cardiology, 2021, 6, 521.	3.0	4
118	Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. New England Journal of Medicine, 2021, 384, 1981-1990.	13.9	145
119	Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. American Heart Journal, 2021, 235, 82-96.	1.2	7
120	Association between sacubitril/valsartan initiation and realâ€world health status trajectories over 18Âmonths in heart failure with reduced ejection fraction. ESC Heart Failure, 2021, 8, 2670-2678.	1.4	7
121	Expediting the Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure—There Is No Time for Delay. JAMA Cardiology, 2021, 6, 507.	3.0	3
122	Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study ( <scp>US</scp> , <scp>UK</scp> and Sweden). European Journal of Heart Failure, 2021, 23, 1499-1511.	2.9	80
123	Loop Diuretic Prescription and Long-Term Outcomes in Heart Failure: Association Modification by Congestion. American Journal of Medicine, 2021, 134, 797-804.	0.6	6
124	Length of stay and readmission in older adults hospitalized for heart failure. Archives of Medical Science, 2021, 17, 891-899.	0.4	3
125	Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map. European Journal of Heart Failure, 2021, 23, 1468-1476.	2.9	29
126	Profile of Patients Hospitalized for Heart Failure Who Leave Against Medical Advice. Journal of Cardiac Failure, 2021, 27, 747-755.	0.7	3

#	Article	IF	Citations
127	Clinical inertia and medical therapy for heart failure: the unintended harms of â€~first, doÂnoÂharm'. European Journal of Heart Failure, 2021, 23, 1343-1345.	2.9	19
128	Association of Dual Eligibility for Medicare and Medicaid With Heart Failure Quality and Outcomes Among Get With The Guidelines–Heart Failure Hospitals. JAMA Cardiology, 2021, 6, 791.	3.0	14
129	LDL cholesterol levels and in-hospital bleeding in patients on high-intensity antithrombotic therapy: findings from the CCC-ACS project. European Heart Journal, 2021, 42, 3175-3186.	1.0	14
130	Income disparity and incident cardiovascular disease in older Americans. Progress in Cardiovascular Diseases, 2021, , .	1.6	3
131	Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failureâ€"Optimizing Therapy With the Need for Speed. JAMA Cardiology, 2021, 6, 743.	3.0	125
132	Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With HeartÂFailure. JACC: Heart Failure, 2021, 9, 471-481.	1.9	38
133	Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2021, 326, 314.	3.8	68
134	Kidney Function and Outcomes in Patients Hospitalized With HeartÂFailure. Journal of the American College of Cardiology, 2021, 78, 330-343.	1.2	90
135	Assessment of Trends in Guideline-Based Oral Anticoagulant Prescription for Patients With Ischemic Stroke and Atrial Fibrillation in China. JAMA Network Open, 2021, 4, e2118816.	2.8	8
136	Patient characteristics and acute cardiovascular event rates among patients with very highâ€risk and nonâ€very highâ€risk atherosclerotic cardiovascular disease. Clinical Cardiology, 2021, 44, 1457-1466.	0.7	3
137	Oral Anticoagulation and Adverse Outcomes after Ischemic Stroke in Heart Failure Patients without Atrial Fibrillation. Journal of Cardiac Failure, 2021, 27, 857-864.	0.7	6
138	Association Between 2010 Medicare Reform and Inpatient Rehabilitation Access in People With Intracerebral Hemorrhage. Journal of the American Heart Association, 2021, 10, e020528.	1.6	5
139	Cardiovascular Safety of Hydroxychloroquine in US Veterans With Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 1589-1600.	2.9	17
140	Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. Journal of Cardiac Failure, 2021, 27, 826-836.	0.7	30
141	Association Between Hospital Volumes and Clinical Outcomes for Patients With Nontraumatic Subarachnoid Hemorrhage. Journal of the American Heart Association, 2021, 10, e018373.	1.6	7
142	Clinical Characteristics, Management, and In-Hospital Outcomes in Patients With Stroke or Transient Ischemic Attack in China. JAMA Network Open, 2021, 4, e2120745.	2.8	29
143	Impact of Pulmonary Hypertension on In-Hospital Outcomes and 30-Day Readmissions Following Percutaneous Coronary Interventions. Mayo Clinic Proceedings, 2021, 96, 2058-2066.	1.4	3
144	Reply. JACC: Heart Failure, 2021, 9, 609-610.	1.9	0

#	Article	IF	CITATIONS
145	Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association, 2021, 10, e021459.	1.6	10
146	National Trends in Heart Failure Hospitalizations and Readmissions From 2010 to 2017. JAMA Cardiology, 2021, 6, 952.	3.0	98
147	The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence. Therapeutics and Clinical Risk Management, 2021, Volume 17, 823-830.	0.9	9
148	Associations of Medicaid Expansion With Access to Care, Severity, and Outcomes for Acute Ischemic Stroke. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007940.	0.9	8
149	Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for HeartÂFailure With Reduced Ejection Fraction. JACC: Heart Failure, 2021, 9, 876-886.	1.9	19
150	Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. JAMA Cardiology, 2021, 6, 1415.	3.0	19
151	Transforming the Paradigm for Lipid Lowering. JAMA Cardiology, 2021, , .	3.0	2
152	Outcomes of Endovascular Therapy in Patients With Prestroke Mobility Impairment. Stroke, 2021, 52, e725-e728.	1.0	0
153	Frequency, Characteristics, and Outcomes of Endovascular Thrombectomy in Patients With Stroke Beyond 6 Hours of Onset in US Clinical Practice. Stroke, 2021, 52, 3805-3814.	1.0	5
154	Treatment and Outcomes of Patients With Ischemic Stroke During COVID-19. Stroke, 2021, 52, 3225-3232.	1.0	19
155	Primary and Secondary Prevention Strategies for Gastrointestinal Bleeding in Patients with Left Ventricular Assist Device: A Systematic Review and Network Meta-analysis. Current Problems in Cardiology, 2021, 46, 100835.	1.1	6
156	Patient characteristics, care patterns, and outcomes of atrial fibrillation associated hospitalizations in patients with chronic kidney disease and end-stage renal disease. American Heart Journal, 2021, 242, 45-60.	1.2	1
157	HeartÂFailure Hospitalization and Guideline-Directed Prescribing Patterns Among HeartÂFailure With Reduced Ejection Fraction Patients. JACC: Heart Failure, 2021, 9, 28-38.	1.9	43
158	Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes. American Journal of Cardiovascular Drugs, 2021, 21, 499-512.	1.0	21
159	Association Between 2010 Medicare Reforms and Utilization of Postacute Inpatient Rehabilitation in Ischemic Stroke. American Journal of Physical Medicine and Rehabilitation, 2021, 100, 675-682.	0.7	5
160	Allâ€Cause Unplanned Readmissions in the United States. Insights from the Nationwide Readmission Database. Internal Medicine Journal, 2021, , .	0.5	8
161	Risk Adjustment Model for Preserved Health Status in Patients With Heart Failure and Reduced Ejection Fraction: The CHAMP-HF Registry. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008072.	0.9	2
162	Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. Circulation: Heart Failure, 2021, 14, e008351.	1.6	10

#	Article	IF	CITATIONS
163	Antithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke With Aspirin Treatment Failure. Stroke, 2021, 52, e777-e781.	1.0	2
164	Sex Differences in Ablation Strategy, Lesion Sets, and Complications of Catheter Ablation for Atrial Fibrillation: An Analysis From the GWTG-AFIB Registry. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009790.	2.1	14
165	National Trends in Heart Failure Hospitalization and Readmissions Associated With Policy Changesâ€"Reply. JAMA Cardiology, 2021, , .	3.0	2
166	In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors forÂHeartÂFailure With Reduced EjectionÂFraction. Journal of the American College of Cardiology, 2021, 78, 2004-2012.	1.2	48
167	Outcomes of Medicare beneficiaries hospitalised with transient ischaemic attack and stratification using the ABCD <sup>2</sup> score. Stroke and Vascular Neurology, 2021, 6, 314-318.	1.5	1
168	The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review, 2021, 7, e18.	1.2	22
169	Beta-Blocker Use and Outcomes in Nursing Home Residents with Heart Failure with Reduced Ejection Fraction. American Journal of Medicine, 2021, , .	0.6	2
170	Contextualizing Risk Among Patients With Heart Failure. JAMA - Journal of the American Medical Association, 2021, 326, 2261.	3.8	22
171	Abstract 10919: Prevalence, Awareness, Treatment, and Control of Hypertension in Hospitalized Patients with Atrial Fibrillation in China: Findings from the Improving Care for Cardiovascular Disease in China-Atrial Fibrillation Project. Circulation, 2021, 144, .	1.6	0
172	Abstract 10413: Clinical Outcomes with Metformin and Sulfonylurea Initiation Among Patients with Heart Failure and Diabetes: From Get with the Guidelines-Heart Failure. Circulation, 2021, 144, .	1.6	0
173	Abstract 10632: Variation in the Association Between Beta Blocker and/or Rasi Use After Discharge and Outcomes in Hfref by Age. Circulation, 2021, 144, .	1.6	0
174	Abstract 11785: National Hospitalizations for Supraventricular Tachycardia in the United States, 2010 Through 2017. Circulation, 2021, 144, .	1.6	0
175	Abstract 10950: Real-World Practice of Reperfusion and Revascularization in Patients with St-Segment Elevation Myocardial Infarction in China: Findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project. Circulation, 2021, 144, .	1.6	0
176	Abstract 10198: Association Between Admission Low-Density Lipoprotein Cholesterol and In-Hospital Mortality Among Inpatients with Acute Myocardial Infarction in China: Findings from CCC-ACS Project. Circulation, 2021, 144, .	1.6	0
177	Abstract 10738: Comparative Outcomes of Sacubitril/Valsartan Use Among Medicare Beneficiaries NaÃ'Ve to Renin-angiotensin System Inhibitors and Hospitalized with Heart Failure. Circulation, 2021, 144, .	1.6	0
178	Trends in Bleeding Events Among Patients With Acute Coronary Syndrome in China, 2015 to 2019: Insights From the CCC-ACS Project. Frontiers in Cardiovascular Medicine, 2021, 8, 769165.	1.1	1
179	Trends in Anticoagulation Prescription Spending Among Medicare Part D and Medicaid Beneficiaries Between 2014 and 2019. Journal of the American Heart Association, 2021, 10, e022644.	1.6	10
180	Abstract 12965: Race-Specific Models to Predict In-Hospital Mortality in Patients With Heart Failure Using Machine Learning: The American Heart Association Get With the Guidelines Registry. Circulation, 2021, 144, .	1.6	1

#	Article	IF	CITATIONS
181	Abstract 12969: Community-Level Socioeconomic Distress, Race, and Risk of Adverse Outcomes Following Heart Failure Hospitalization Among Medicare Beneficiaries. Circulation, 2021, 144, .	1.6	0
182	Abstract 12152: The Association of Improvement in Left Ventricular Ejection Fraction With Outcomes in Patients With Heart Failure With Reduced Ejection Fraction - Data From CHAMP-HF. Circulation, 2021, 144, .	1.6	0
183	Abstract 12150: Incorporation of Natriuretic Peptides With Clinical Risk-Scores to Predict Heart Failure Among Individuals With Dysglycemia. Circulation, 2021, 144, .	1.6	0
184	Early Effects of Starting Doses of Enalapril in Patients with Chronic Heart Failure in the SOLVD Treatment Trial. American Journal of Medicine, 2020, 133, e25-e31.	0.6	29
185	Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017. JAMA Internal Medicine, 2020, 180, 141.	2.6	17
186	Thrombolytic therapy in older acute ischemic stroke patients with gastrointestinal malignancy or recent bleeding. European Stroke Journal, 2020, 5, 47-55.	2.7	11
187	Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. American Heart Journal, 2020, 220, 41-50.	1.2	22
188	Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. American Heart Journal, 2020, 220, 145-154.	1.2	3
189	Renin–Angiotensin Inhibition and Outcomes in Nursing Home Residents With Heart Failure. American Journal of Therapeutics, 2020, 27, e235-e242.	0.5	1
190	Prior Heart Failure Hospitalization and Outcomes in Patients with Heart Failure with Preserved and Reduced Ejection Fraction. American Journal of Medicine, 2020, 133, 84-94.	0.6	26
191	Longitudinal trajectories of hospital performance across targeted cardiovascular conditions in the USA. European Heart Journal Quality of Care & Dutcomes, 2020, 6, 62-71.	1.8	3
192	Patient Perceptions and Familiarity With Medical Therapy for Heart Failure. JAMA Cardiology, 2020, 5, 292.	3.0	28
193	Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. American Heart Journal, 2020, 219, 21-30.	1.2	8
194	Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications. JAMA Cardiology, 2020, 5, 38.	3.0	6
195	The Hospital Readmissions Reduction Program. JACC: Heart Failure, 2020, 8, 1-11.	1.9	57
196	Cryptogenic stroke. Neurology: Clinical Practice, 2020, 10, 396-405.	0.8	5
197	Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation. American Heart Journal, 2020, 223, 65-71.	1.2	22
198	Safety and Outcomes of Intravenous tPA in Acute Ischemic Stroke Patients With Prior Stroke Within 3 Months. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006031.	0.9	12

#	Article	IF	CITATIONS
199	Temporal Trends in Racial Differences in 30-Day Readmission and Mortality Rates After Acute Myocardial Infarction Among Medicare Beneficiaries. JAMA Cardiology, 2020, 5, 136.	3.0	33
200	Heart Failure With Mid-range Ejection Fraction. Current Heart Failure Reports, 2020, 17, 1-8.	1.3	24
201	Strict Versus Lenient Versus Poor Rate Control Among Patients With Atrial Fibrillation and Heart Failure (from the Get With The Guidelines – Heart Failure Program). American Journal of Cardiology, 2020, 125, 894-900.	0.7	15
202	Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure. JAMA Cardiology, 2020, 5, 336.	3.0	16
203	Postâ€discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial. European Journal of Heart Failure, 2020, 22, 164-167.	2.9	3
204	Eligibility of sodium–glucose coâ€transporterâ€2 inhibitors among patients with diabetes mellitus admitted for heart failure. ESC Heart Failure, 2020, 7, 275-279.	1.4	6
205	Acute myocardial infarction in the young - National Trend Analysis with gender-based difference in outcomes. International Journal of Cardiology, 2020, 301, 21-28.	0.8	27
206	Probing the Effective Treatment Thresholds for Alteplase in Acute Ischemic Stroke With Regression Discontinuity Designs. Frontiers in Neurology, 2020, 11, 961.	1.1	3
207	Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19. American Journal of Cardiology, 2020, 132, 150-157.	0.7	18
208	Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF). American Journal of Cardiology, 2020, 132, 66-71.	0.7	1
209	Trends in Costs and Risk Factors of 30-Day Readmissions for Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2020, 137, 89-96.	0.7	5
210	Disease Burden Following Non-Cardioembolic Minor Ischemic Stroke or High-Risk TIA: A GWTG-Stroke Study. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105399.	0.7	12
211	Home Health Care Use and Post-Discharge Outcomes After HeartÂFailure Hospitalizations. JACC: Heart Failure, 2020, 8, 1038-1049.	1.9	20
212	Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelinesâ€Atrial Fibrillation. Journal of the American Heart Association, 2020, 9, e017024.	1.6	23
213	Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials. Circulation: Heart Failure, 2020, 13, e006605.	1.6	55
214	Loop Diuretic Prescription and 30-DayÂOutcomes in Older Patients WithÂHeartÂFailure. Journal of the American College of Cardiology, 2020, 76, 669-679.	1.2	41
215	Heart Failure Clinical Trial Operations During the COVID-19 Pandemic. Circulation: Heart Failure, 2020, 13, e007456.	1.6	6
216	Application of the Reverse Fragility Index to Statistically Nonsignificant Randomized Clinical Trial Results. JAMA Network Open, 2020, 3, e2012469.	2.8	50

#	Article	IF	Citations
217	Coronavirus Disease 2019 (COVID-19) and the Heartâ€"Is Heart Failure the Next Chapter?. JAMA Cardiology, 2020, 5, 1216.	3.0	59
218	Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2020, 5, 1236.	3.0	46
219	2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e000099.	0.9	45
220	Process Improvement in Heart Failure. Heart Failure Clinics, 2020, 16, xvii-xix.	1.0	0
221	Quality of Care and Outcomes Among Medicare Advantage vs Fee-for-Service Medicare Patients Hospitalized With Heart Failure. JAMA Cardiology, 2020, 5, 1349.	3.0	13
222	Procedural Patterns and Safety of Atrial Fibrillation Ablation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007944.	2.1	42
223	Machine learning does not improve upon traditional regression in predicting outcomes in atrial fibrillation: an analysis of the ORBIT-AF and GARFIELD-AF registries. Europace, 2020, 22, 1635-1644.	0.7	16
224	Trends in Reperfusion Therapy for In-Hospital Ischemic Stroke in the Endovascular Therapy Era. JAMA Neurology, 2020, 77, 1486.	4.5	37
225	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure. Circulation, 2020, 142, 1205-1218.	1.6	63
226	Medicaid Expansion and Utilization of Antihyperglycemic Therapies. Diabetes Care, 2020, 43, 2684-2690.	4.3	13
227	Antiplatelet patterns and outcomes in patients with atrial fibrillation not prescribed an anticoagulant after stroke. International Journal of Cardiology, 2020, 321, 88-94.	0.8	3
228	Cardiovascular Disease in Hospitalized Patients With a Diagnosis of Coronavirus From the Pre–COVID-19 Era in United States: National Analysis From 2016-2017. Mayo Clinic Proceedings, 2020, 95, 2674-2683.	1.4	12
229	2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure. Journal of the American College of Cardiology, 2020, 76, 2527-2564.	1.2	41
230	Reply. Journal of the American College of Cardiology, 2020, 76, 2418-2420.	1.2	3
231	Door-to-Needle Time and Long-term Outcomes in Patients With Stroke—Reply. JAMA - Journal of the American Medical Association, 2020, 324, 1467.	3.8	0
232	Temporary Emergency Guidance to STEMI Systems of Care During the COVID-19 Pandemic. Circulation, 2020, 142, 199-202.	1.6	28
233	Anticipating a New Era in Heart Transplantation. JAMA Cardiology, 2020, 5, 625.	3.0	2
234	Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007775.	2.1	6

#	Article	IF	CITATIONS
235	Hypokalaemia and outcomes in older patients hospitalized for heart failure. ESC Heart Failure, 2020, 7, 794-803.	1.4	8
236	Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke. JAMA - Journal of the American Medical Association, 2020, 323, 2170.	3.8	92
237	Comparative Effectiveness of Primary Prevention Implantable Cardioverterâ€Defibrillators in Older Heart Failure Patients With Diabetes Mellitus. Journal of the American Heart Association, 2020, 9, e012405.	1.6	2
238	Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice. Circulation: Cardiovascular Interventions, 2020, 13, e008274.	1.4	1
239	Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure. JAMA Cardiology, 2020, 5, 948.	3.0	77
240	Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions. European Heart Journal Quality of Care & Dutcomes, 2020, 6, 263-272.	1.8	16
241	COVID-19 Pandemic: Cardiovascular Complications and Future Implications. American Journal of Cardiovascular Drugs, 2020, 20, 311-324.	1.0	98
242	Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006182.	0.9	5
243	Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations. American Heart Journal, 2020, 226, 13-23.	1.2	7
244	Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial. Diabetes Care, 2020, 43, 1920-1928.	4.3	35
245	The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. European Heart Journal, 2020, 41, 1357-1364.	1.0	47
246	Testing for Coronary Artery Disease in Older Patients With New-Onset Heart Failure. Circulation: Heart Failure, 2020, 13, e006963.	1.6	13
247	Rationale and Design of the Aspirin Dosing—A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. JAMA Cardiology, 2020, 5, 598.	3.0	59
248	Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials. JAMA Cardiology, 2020, 5, 714.	3.0	76
249	Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality. JAMA Cardiology, 2020, 5, 751.	3.0	471
250	Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill. JAMA Cardiology, 2020, 5, 532.	3.0	8
251	Digoxin Initiation and Outcomes in Patients with Heart Failure (HFrEF and HFpEF) and Atrial Fibrillation. American Journal of Medicine, 2020, 133, 1460-1470.	0.6	18
252	Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2020, 13, e006833.	1.6	25

#	Article	IF	CITATIONS
253	PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial. American Heart Journal, 2020, 223, 98-105.	1.2	12
254	Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. Journal of Cardiac Failure, 2020, 26, 429-437.	0.7	46
255	Performance in Federal Value-Based Programs of Hospitals Recognized by the American Heart Association and American College of Cardiology for High-Quality Heart Failure and Acute Myocardial Infarction Care. JAMA Cardiology, 2020, 5, 515.	3.0	15
256	Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart, 2020, 106, 358-364.	1.2	16
257	Measuring and Improving the Quality of Heart Failure Care Globally. JAMA Network Open, 2020, 3, e1918642.	2.8	5
258	A marker of systemic inflammation or direct cardiac injury: should cardiac troponin levels be monitored in COVID-19 patients?. European Heart Journal Quality of Care & Dinical Outcomes, 2020, 6, 204-207.	1.8	20
259	Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). American Heart Journal, 2020, 226, 85-93.	1.2	13
260	Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). American Journal of Cardiology, 2020, 125, 1655-1660.	0.7	7
261	Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. American Journal of Medicine, 2020, 133, 1187-1194.	0.6	9
262	Guideline-concordant-phenotyping: Identifying patient indications for implantable cardioverter defibrillators from electronic health records. International Journal of Medical Informatics, 2020, 138, 104138.	1.6	3
263	Impact of a Copayment Reduction Intervention on Medication Persistence and Cardiovascular Events in Hospitals With and Without Prior Medication Financial Assistance Programs. Journal of the American Heart Association, 2020, 9, e014975.	1.6	8
264	With great power comes great… reliability. European Journal of Heart Failure, 2020, 22, 1708-1710.	2.9	0
265	Trends in prevalence of comorbidities in heart failure clinical trials. European Journal of Heart Failure, 2020, 22, 1032-1042.	2.9	68
266	Role of Data Registries in the Time of COVID-19. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006766.	0.9	22
267	Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. Circulation: Heart Failure, 2020, 13, e006645.	1.6	18
268	Association between depression and readmission of heart failure: A national representative database study. Progress in Cardiovascular Diseases, 2020, 63, 585-590.	1.6	23
269	Contemporary Treatment Patterns and Clinical Outcomes of Comorbid DiabetesÂMellitus and HFrEF. JACC: Heart Failure, 2020, 8, 469-480.	1.9	47
270	Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet, The, 2020, 396, 121-128.	6.3	376

#	Article	IF	CITATIONS
271	Target: Stroke Was Associated With Faster Intravenous Thrombolysis and Improved One-Year Outcomes for Acute Ischemic Stroke in Medicare Beneficiaries. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e007150.	0.9	8
272	Integrating remote monitoring into heart failure patients' care regimen: A pilot study. PLoS ONE, 2020, 15, e0242210.	1.1	21
273	Amyloidosis and 30-Day Outcomes Among Patients With HeartÂFailure. JACC: CardioOncology, 2020, 2, 710-718.	1.7	5
274	Implementação do Programa Boas Práticas em Cardiologia adaptado do Get With The Guidelines® em Hospitais Brasileiros: Desenho do Estudo e Fundamento. Arquivos Brasileiros De Cardiologia, 2020, 115, 92-99.	0.3	4
275	Smoking and Provision of Smoking Cessation Interventions among Inpatients with Acute Coronary Syndrome in China: Findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project. Global Heart, 2020, 15, 72.	0.9	9
276	Abstract 17121: Initiation of Anti-Hypertensive Therapy and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) and a History of Hypertension (HTN). Circulation, 2020, 142, .	1.6	0
277	Abstract 14583: Palliative Care Services in Patients Admitted With Cardiogenic Shock in the United States: Frequency and Predictors of 30-day Readmission. Circulation, 2020, 142, .	1.6	0
278	Abstract 17027: Generalizability of the US FDA Label for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in the GWTG-HF Registry. Circulation, 2020, 142, .	1.6	0
279	Abstract 12817: Comparison of New York Heart Association Classification and Patient-reported Outcomes Among Heart Failure Patients in U.S. Clinical Practice: CHAMP-HF. Circulation, 2020, 142, .	1.6	0
280	Abstract 15007: Association Of Dual Eligibility For Medicare And Medicaid With Heart Failure Quality And Outcomes Among Gwtg-hf Hospitals. Circulation, 2020, 142, .	1.6	0
281	Integrating remote monitoring into heart failure patients' care regimen: A pilot study. , 2020, 15, e0242210.		0
282	Integrating remote monitoring into heart failure patients' care regimen: A pilot study. , 2020, 15, e0242210.		0
283	Integrating remote monitoring into heart failure patients' care regimen: A pilot study. , 2020, 15, e0242210.		0
284	Integrating remote monitoring into heart failure patients' care regimen: A pilot study. , 2020, 15, e0242210.		0
285	Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes. Clinical Cardiology, 2019, 42, 256-263.	0.7	9
286	B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. Heart, 2019, 105, heartjnl-2018-313642.	1.2	22
287	Incremental prognostic value of renal function for stroke prediction in atrial fibrillation. International Journal of Cardiology, 2019, 274, 152-157.	0.8	7
288	Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison. Diabetes, Obesity and Metabolism, 2019, 21, 261-266.	2.2	7

#	Article	IF	Citations
289	Regional Differences in Secondary Prevention Therapy—Geography Should Not Be Destiny. JAMA Cardiology, 2019, 4, 873.	3.0	1
290	Intravenous Tissue Plasminogen Activator in Stroke Mimics. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005609.	0.9	37
291	Impediments to Implementing Guideline-Directed Medical Therapies. JAMA Cardiology, 2019, 4, 830.	3.0	4
292	Association Between Time to Treatment With Endovascular Reperfusion Therapy and Outcomes in Patients With Acute Ischemic Stroke Treated in Clinical Practice. JAMA - Journal of the American Medical Association, 2019, 322, 252.	3.8	229
293	Physicians Voluntarily Using an EHR-Based CDS Tool Improved Patients' Guideline-Related Statin Prescription Rates: A Retrospective Cohort Study. Applied Clinical Informatics, 2019, 10, 421-445.	0.8	4
294	Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke. JAMA Neurology, 2019, 76, 1192.	4.5	70
295	Recent Myocardial Infarction is Associated With Increased Risk in Older Adults With Acute Ischemic Stroke Receiving Thrombolytic Therapy. Journal of the American Heart Association, 2019, 8, e012450.	1.6	11
296	Digoxin Discontinuation and Outcomes inÂPatients With HeartÂFailure With Reduced EjectionÂFraction. Journal of the American College of Cardiology, 2019, 74, 617-627.	1.2	36
297	Body mass index and outcomes of cardiac resynchronization with implantable cardioverterâ€defibrillator therapy in older patients with heart failure. European Journal of Heart Failure, 2019, 21, 1093-1102.	2.9	12
298	Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. JAMA Cardiology, 2019, 4, 756.	3.0	10
299	Aberrant Brain Functional Connectivity Dynamic Responses to the Valsalva Maneuver in Heart Failure. Journal of Cardiac Failure, 2019, 25, 757-766.	0.7	6
300	Chest Pain Center Accreditation Is Associated With Improved Inâ€Hospital Outcomes of Acute Myocardial Infarction Patients in China: Findings From the CCCâ€ACS Project. Journal of the American Heart Association, 2019, 8, e013384.	1.6	34
301	Association of Hospital Racial Composition and Payer Mix With Mortality in Acute Coronary Syndrome. Journal of the American Heart Association, 2019, 8, e012831.	1.6	7
302	Representativeness of a HeartÂFailure Trial by Race and Sex. JACC: Heart Failure, 2019, 7, 980-992.	1.9	30
303	PARAGON-HF Clinical Trial Eligibility in a Population of Patients Hospitalized With Heart Failure. Journal of Cardiac Failure, 2019, 25, 1009-1011.	0.7	5
304	Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). American Journal of Cardiology, 2019, 124, 1900-1906.	0.7	19
305	Characteristics of Acute Heart Failure Hospitalizations Based on Presenting Severity. Circulation: Heart Failure, 2019, 12, e005171.	1.6	15
306	The Medicare Shared Savings Program and Outcomes for Ischemic Stroke Patients: a Retrospective Cohort Study. Journal of General Internal Medicine, 2019, 34, 2740-2748.	1.3	9

#	Article	IF	CITATIONS
307	Hospital distance, socioeconomic status, and timely treatment of ischemic stroke. Neurology, 2019, 93, e747-e757.	1.5	28
308	Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes inÂHeartÂFailure With Reduced EjectionÂFraction. JACC: Heart Failure, 2019, 7, 933-941.	1.9	31
309	Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure. American Journal of Cardiology, 2019, 124, 1790-1796.	0.7	28
310	Readmissions After Acute Myocardial Infarction: How Often Do Patients Return to the Discharging Hospital?. Journal of the American Heart Association, 2019, 8, e012059.	1.6	15
311	Cardiovascular Toxicities of ImmuneÂCheckpointÂlnhibitors. Journal of the American College of Cardiology, 2019, 74, 1714-1727.	1.2	124
312	Trends in Utilization of Surgical and Transcatheter Mitral Valve Repair in the United Statesâd. American Journal of Cardiology, 2019, 123, 1187-1189.	0.7	6
313	Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation. American Heart Journal, 2019, 211, 77-89.	1.2	64
314	Adherence to Guideline-Directed Stroke Prevention Therapy for Atrial Fibrillation Is Achievable. Circulation, 2019, 139, 1497-1506.	1.6	55
315	Use, Temporal Trends, and Outcomes of Endovascular Therapy After Interhospital Transfer in the United States. Circulation, 2019, 139, 1568-1577.	1.6	89
316	Sex Differences in In-Hospital Management and Outcomes of Patients With Acute Coronary Syndrome. Circulation, 2019, 139, 1776-1785.	1.6	148
317	Comparison of Clinical Care and In-Hospital Outcomes of Asian American and White Patients With Acute Ischemic Stroke. JAMA Neurology, 2019, 76, 430.	4.5	44
318	Long-term outcomes for heart failure patients with and without diabetes: From the Get With The Guidelines–Heart Failure Registry. American Heart Journal, 2019, 211, 1-10.	1.2	17
319	Heart Failure With Preserved EjectionÂFraction and Diabetes. Journal of the American College of Cardiology, 2019, 73, 602-611.	1.2	182
320	Relationship Between Hospital Characteristics and Early Adoption of Angiotensinâ€Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure. Journal of the American Heart Association, 2019, 8, e010484.	1.6	13
321	The Burden of Congestion in Patients Hospitalized With Acute Decompensated Heart Failure. American Journal of Cardiology, 2019, 124, 545-553.	0.7	29
322	Systolic Blood Pressure and OutcomesÂinÂPatients With HeartÂFailure With ReducedÂEjectionÂFraction. Journal of the American College of Cardiology, 2019, 73, 3054-3063.	1.2	50
323	Association of Changes in HeartÂFailure Treatment With Patients' Health Status. JACC: Heart Failure, 2019, 7, 615-625.	1.9	20
324	Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. American Heart Journal, 2019, 213, 81-90.	1.2	10

#	Article	IF	Citations
325	Digoxin Use and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. American Journal of Medicine, 2019, 132, 1311-1319.	0.6	11
326	Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease. JAMA Cardiology, 2019, 4, 691.	3.0	66
327	A paradoxical relationship between hemoglobin A1C and in-hospital mortality in intracerebral hemorrhage patients. Heliyon, 2019, 5, e01659.	1.4	4
328	Overcoming Barriers to DevelopmentÂofÂNovel Therapies forÂCardiovascular Disease. JACC Basic To Translational Science, 2019, 4, 269-274.	1.9	12
329	Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2019, 73, 2365-2383.	1.2	327
330	Thrombolysis in young adults with stroke. Neurology, 2019, 92, e2784-e2792.	1.5	20
331	Prevalence of Apparent Treatment-Resistant Hypertension in the United States According to the 2017 High Blood Pressure Guideline. Mayo Clinic Proceedings, 2019, 94, 776-782.	1.4	19
332	Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005358.	0.9	59
333	Identifying a lowâ€flow phenotype in heart failure with preserved ejection fraction: a secondary analysis of the RELAX trial. ESC Heart Failure, 2019, 6, 613-620.	1.4	13
334	Comparison of Patientâ€Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBITâ€AF Registry. Journal of the American Heart Association, 2019, 8, e011205.	1.6	11
335	Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus. Stroke, 2019, 50, 1497-1503.	1.0	10
336	Association of the New Peer Group–Stratified Method With the Reclassification of Penalty Status in the Hospital Readmission Reduction Program. JAMA Network Open, 2019, 2, e192987.	2.8	42
337	Prehospital statin use and low-density lipoprotein cholesterol levels at admission in acute coronary syndrome patients with history of myocardial infarction or revascularization: Findings from the Improving Care for Cardiovascular Disease in China (CCC) project. American Heart Journal, 2019, 212, 120-128.	1.2	15
338	Performance on management strategies with Class I Recommendation and A Level of Evidence among hospitalized patients with non–ST-segment elevation acute coronary syndrome in China: Findings from the Improving Care for Cardiovascular Disease in China–Acute Coronary Syndrome (CCC-ACS) project. American Heart Journal, 2019, 212, 80-90.	1.2	8
339	Medicare Shared Savings ACOs and Hospice Care for Ischemic Stroke Patients. Journal of the American Geriatrics Society, 2019, 67, 1402-1409.	1.3	10
340	Hospital Readmission Reduction ProgramÂfor Heart Failure. Journal of the American College of Cardiology, 2019, 73, 1013-1015.	1.2	4
341	When Payment Models Distort Perceptions and Care Delivery forPatients With Heart Failure. Journal of Cardiac Failure, 2019, 25, 227-229.	0.7	2
342	One- to 10-Day Versus 11- to 30-Day All-Cause Readmission and Mortality in Older Patients With Heart Failure. American Journal of Cardiology, 2019, 123, 1840-1844.	0.7	1

#	Article	IF	Citations
343	Cardiogenic shock during heart failure hospitalizations: Age-, sex-, and race-stratified trends in incidence and outcomes. American Heart Journal, 2019, 213, 18-29.	1.2	29
344	Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patients. American Heart Journal, 2019, 212, 101-112.	1.2	18
345	Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the) Tj ETQq $1\ 1\ C$	).784314 i 0.7	rgBT/Overloc
346	Do Women and Men Respond Similarly toÂTherapies in Contemporary HeartÂFailure Clinical Trials?. JACC: Heart Failure, 2019, 7, 267-271.	1.9	13
347	National Outcomes in Hospitalized Patients With Cancer and Comorbid Heart Failure. Journal of Cardiac Failure, 2019, 25, 516-521.	0.7	13
348	Target Doses of Heart Failure MedicalÂTherapy and Blood Pressure. JACC: Heart Failure, 2019, 7, 350-358.	1.9	67
349	In-Hospital Initiation of Angiotensin Receptor-Neprilysin Inhibitors—The Time Is Now. JAMA Cardiology, 2019, 4, 195.	3.0	5
350	Ultrafiltration versus diuretics for the treatment of fluid overload in patients with heart failure: a hospital cost analysis. Journal of Medical Economics, 2019, 22, 577-583.	1.0	9
351	Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care, 2019, 42, 2298-2306.	4.3	157
352	Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007612.	2.1	27
353	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 140, 2108-2118.	1.6	22
354	Home-time Is a Patient-Centered Outcome Variable for Stroke: An Executive Summary. Journal of Neuroscience Nursing, 2019, 51, 110-112.	0.7	6
355	Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines—Heart Failure. Journal of the American Heart Association, 2019, 8, e011560.	1.6	68
356	Heart Failure Self-care Associated With Brain Injury in Executive Control Regions. Journal of Cardiovascular Nursing, 2019, 34, 433-439.	0.6	5
357	Ejection fraction, Bâ€type natriuretic peptide and risk of stroke and acute myocardial infarction among patients with heart failure. Clinical Cardiology, 2019, 42, 277-284.	0.7	15
358	National Rate of Tobacco and Substance Use Disorders Among Hospitalized Heart Failure Patients. American Journal of Medicine, 2019, 132, 478-488.e4.	0.6	14
359	Glycated Hemoglobin and Outcomes of Heart Failure (from Get With the Guidelines-Heart Failure). American Journal of Cardiology, 2019, 123, 618-626.	0.7	5
360	Initiation, Continuation, Switching, and WithdrawalÂof Heart Failure Medical Therapies DuringÂHospitalization. JACC: Heart Failure, 2019, 7, 1-12.	1.9	109

#	Article	IF	CITATIONS
361	Bioelectrical impedance analysis of body composition and survival in patients with heart failure. Clinical Cardiology, 2019, 42, 129-135.	0.7	26
362	Thirty-Day Readmissions After Hospitalization for Hypertensive Emergency. Hypertension, 2019, 73, 60-67.	1.3	26
363	The association of pre- and posthospital medication adherence in myocardial infarction patients. American Heart Journal, 2019, 208, 74-80.	1.2	6
364	Effect of Medication Co-payment Vouchers on P2Y <sub>12</sub> Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction. JAMA - Journal of the American Medical Association, 2019, 321, 44.	3.8	67
365	Relation of Admission Blood Pressure to In-hospital and 90-Day Outcomes in Patients Presenting With Transient Ischemic Attack. American Journal of Cardiology, 2019, 123, 1083-1095.	0.7	4
366	Components and Trends in Door to Treatment Times for Endovascular Therapy in Get With The Guidelines-Stroke Hospitals. Circulation, 2019, 139, 169-179.	1.6	34
367	Medication dosing for heart failure with reduced ejection fraction — opportunities and challenges. European Journal of Heart Failure, 2019, 21, 286-296.	2.9	57
368	Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection Fraction. American Journal of Medicine, 2019, 132, 71-80.e1.	0.6	20
369	Assessment of Heart Failure Patients' Interest in Mobile Health Apps for Self-Care: Survey Study. JMIR Cardio, 2019, 3, e14332.	0.7	23
370	Derivation and external validation of a simple risk tool to predict 30-day hospital readmissions after transcatheter aortic valve replacement. EuroIntervention, 2019, 15, 155-163.	1.4	12
371	Sustained sexâ€based treatment differences in acute coronary syndrome care: Insights from the American Heart Association Get With The Guidelines Coronary Artery Disease Registry. Clinical Cardiology, 2018, 41, 758-768.	0.7	43
372	Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. Circulation, 2018, 138, 889-897.	1.6	23
373	Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBITâ€AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry. Journal of the American Heart Association, 2018, 7, .	1.6	6
374	Early Ambulation Among Hospitalized Heart Failure Patients Is Associated With Reduced Length of Stay and 30-Day Readmissions. Circulation: Heart Failure, 2018, 11, e004634.	1.6	20
375	Health Status Variation Across Practices in Outpatients With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004668.	0.9	15
376	Sex and Racial Disparities in Cardiac Rehabilitation Referral at Hospital Discharge and Gaps in Long†Term Mortality. Journal of the American Heart Association, 2018, 7, .	1.6	65
377	Timing of Postdischarge Followâ€Up and Medication Adherence Among Patients With Heart Failure. Journal of the American Heart Association, 2018, 7, .	1.6	13
378	Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Prior Coronary Artery Bypass Grafting. Circulation: Cardiovascular Interventions, 2018, 11, e006179.	1.4	31

#	Article	IF	Citations
379	Medicare Expenditures by Race/Ethnicity After Hospitalization for Heart Failure WithÂPreserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 388-397.	1.9	21
380	Digoxin use and lower risk of 30â€day allâ€cause readmission in older patients with heart failure and reduced ejection fraction receiving βâ€blockers. Clinical Cardiology, 2018, 41, 406-412.	0.7	15
381	Impact of Body Mass Index on Heart Failure by Race/Ethnicity From the Get WithÂThe Guidelines–Heart Failure (GWTG–HF) Registry. JACC: Heart Failure, 2018, 6, 233-242.	1.9	55
382	Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBITâ€AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). Journal of the American Heart Association, 2018, 7, .	1.6	143
383	Reply. Journal of the American College of Cardiology, 2018, 71, 586.	1.2	O
384	Evaluating Readmissionâ€"Need for More Clarity on Methodsâ€"Reply. JAMA Cardiology, 2018, 3, 265.	3.0	7
385	Absence of July Phenomenon in Acute Ischemic Stroke Care Quality and Outcomes. Journal of the American Heart Association, 2018, 7, .	1.6	3
386	Association of Intracerebral Hemorrhage Among Patients Taking Non–Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality. JAMA - Journal of the American Medical Association, 2018, 319, 463.	3.8	180
387	Lipid Testing and Statin Dosing After Acute Myocardial Infarction. Journal of the American Heart Association, 2018, 7, .	1.6	22
388	Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure. Circulation, 2018, 137, 1661-1670.	1.6	46
389	Diabetes and long-term outcomes of ischaemic stroke: findings from Get With The Guidelines-Stroke. European Heart Journal, 2018, 39, 2376-2386.	1.0	62
390	Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2018, 3, 288.	3.0	93
391	Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure. American Heart Journal, 2018, 200, 134-140.	1.2	8
392	Comparison of Survival After In-Hospital Cardiac Arrest in Patients With Versus Without Diabetes Mellitus. American Journal of Cardiology, 2018, 121, 671-677.	0.7	6
393	Troponin in Heart Failure. Heart Failure Clinics, 2018, 14, 57-64.	1.0	19
394	2017 ACC Expert Consensus Decision Pathway for Optimization of HeartÂFailure Treatment: Answers to 10ÂPivotal Issues About Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2018, 71, 201-230.	1.2	235
395	Contemporary Sex-Based Differences by Age in Presenting Characteristics, Use of an Early Invasive Strategy, and Inhospital Mortality in Patients With Non–ST-Segment–Elevation Myocardial Infarction in the United States. Circulation: Cardiovascular Interventions, 2018, 11, e005735.	1.4	47
396	Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry. American Heart Journal, 2018, 198, 123-128.	1.2	10

#	Article	IF	CITATIONS
397	A Hospital Level Analysis of 30-Day Readmission Performance for Heart Failure Patients and Long-Term Survival: Findings from Get With The Guidelines-Heart Failure. American Heart Journal, 2018, 200, 127-133.	1.2	13
398	Inâ€Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75ÂYears and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCCâ€ACS (Improving Care for Cardiovascular Disease in Chinaâ€Acute Coronary Syndrome) Project. Journal of the American Heart Association, 2018, 7, .	1.6	13
399	Association of Electronic Health Record Use With Quality of Care and Outcomes in Heart Failure: An Analysis of Get With The Guidelinesâ€"Heart Failure. Journal of the American Heart Association, 2018, 7,	1.6	16
400	Diabetes Mellitus and Cardiogenic Shock Complicating Acute Myocardial Infarction. American Journal of Medicine, 2018, 131, 778-786.e1.	0.6	23
401	Association of Hospital Performance Based on 30-Day Risk-Standardized Mortality Rate With Long-term Survival After Heart Failure Hospitalization. JAMA Cardiology, 2018, 3, 489.	3.0	37
402	Current Practice Trends for Use of Early Venous Thromboembolism Prophylaxis After Intracerebral Hemorrhage. Neurosurgery, 2018, 82, 85-92.	0.6	19
403	Lessons learned in acute heart failure. European Journal of Heart Failure, 2018, 20, 630-641.	2.9	33
404	Relationship of Hospital Teaching Status with In-Hospital Outcomes for ST-Segment Elevation Myocardial Infarction. American Journal of Medicine, 2018, 131, 260-268.e1.	0.6	3
405	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary. Heart Rhythm, 2018, 15, e190-e252.	0.3	448
406	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Heart Rhythm, 2018, 15, e73-e189.	0.3	262
407	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. Journal of the American College of Cardiology, 2018, 72, 1677-1749.	1.2	382
408	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. Circulation, 2018, 138, e210-e271.	1.6	250
409	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation, 2018, 138, e272-e391.	1.6	468
410	Similar clinical benefits from belowâ€ŧarget and target dose enalapril in patients with heart failure in the SOLVD Treatment trial. European Journal of Heart Failure, 2018, 20, 359-369.	2.9	17
411	What's Next for Acute Heart Failure Research?. Academic Emergency Medicine, 2018, 25, 85-93.	0.8	11
412	Preâ€discharge and early postâ€discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. European Journal of Heart Failure, 2018, 20, 281-291.	2.9	33
413	<scp>T</scp> he safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: <scp>I</scp> nsights from the TRANSLATEâ€ACS study. Catheterization and Cardiovascular Interventions. 2018. 91. 242-250.	0.7	4
414	Hospital evaluation of health literacy and associated outcomes in patients after acute myocardial infarction. American Heart Journal, 2018, 198, 97-107.	1.2	18

#	Article	IF	Citations
415	Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. European Journal of Heart Failure, 2018, 20, 677-686.	2.9	21
416	Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes. JAMA Cardiology, 2018, 3, 54.	3.0	77
417	Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure. JAMA Cardiology, 2018, 3, 44.	3.0	346
418	Availability and Use of Shared Data From Cardiometabolic Clinical Trials. Circulation, 2018, 137, 938-947.	1.6	17
419	Disease understanding in patients newly diagnosed with atrial fibrillation. Heart, 2018, 104, 494-501.	1.2	25
420	Response by Kumbhani et al to Letters Regarding Article, "Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure: Insights From Get With The Guidelines-Heart Failure― Circulation, 2018, 138, 2306-2307.	1.6	2
421	The Need for Speed. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e005234.	0.9	2
422	Shock Index Predicts Patientâ€Related Clinical Outcomes in Stroke. Journal of the American Heart Association, 2018, 7, e007581.	1.6	24
423	Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. European Journal of Heart Failure, 2018, 20, 1760-1763.	2.9	2
424	The Association of Frailty With In-Hospital Bleeding Among Older AdultsÂWith Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2018, 11, 2287-2296.	1.1	42
425	Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2018, 3, 1226.	3.0	38
426	Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation. JAMA Cardiology, 2018, 3, 1174.	3.0	111
427	Temperature and Precipitation Associate With Ischemic Stroke Outcomes in the United States. Journal of the American Heart Association, 2018, 7, e010020.	1.6	21
428	Association of Kidney Function With 30-Day and 1-Year Poststroke Mortality and Hospital Readmission. Stroke, 2018, 49, 2896-2903.	1.0	18
429	Quality of Care and Outcomes for Patients With Stroke in the United States Admitted During the International Stroke Conference. Journal of the American Heart Association, 2018, 7, e009842.	1.6	1
430	Validity of Performance and Outcome Measures for Heart Failure. Circulation: Heart Failure, 2018, 11, e005035.	1.6	12
431	Perceived Barriers to Sacubitril/Valsartan Use in Patients with Heart Failure. Journal of Cardiac Failure, 2018, 24, S99.	0.7	1
432	Evidence-Based Performance Measures and Outcomes in Patients With Acute Ischemic Stroke. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e001968.	0.9	9

#	Article	IF	Citations
433	Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes?. Circulation, 2018, 138, 2787-2797.	1.6	3
434	Unintended Harm Associated With the Hospital Readmissions Reduction Program. JAMA - Journal of the American Medical Association, 2018, 320, 2539.	3.8	28
435	Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in China: findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project. Cardiovascular Diabetology, 2018, 17, 147.	2.7	53
436	Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications. Current Cardiology Reports, 2018, 20, 112.	1.3	6
437	Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. Circulation: Heart Failure, 2018, 11, e005400.	1.6	36
438	Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation. Circulation: Heart Failure, 2018, 11, e005356.	1.6	7
439	Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBITâ€AF. Journal of the American Heart Association, 2018, 7, e008928.	1.6	21
440	Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non–Vitamin K Antagonist Oral Anticoagulants Preceding Stroke. Stroke, 2018, 49, 2237-2240.	1.0	25
441	International Comparison of Patient Characteristics and Quality of Care for Ischemic Stroke: Analysis of the China National Stroke Registry and the American Heart Association Get With The Guidelines––Stroke Program. Journal of the American Heart Association, 2018, 7, e010623.	1.6	29
442	Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA ⟨sub⟩2⟨ sub⟩ DS ⟨sub⟩2⟨ sub⟩ â€VASc Scores: Findings From the ORBITâ€AF I and II Registries. Journal of the American Heart Association, 2018, 7, e008764.	1.6	9
443	Embolic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients With Atrial Fibrillation (from the ORBIT-AF Registry). American Journal of Cardiology, 2018, 122, 1677-1683.	0.7	13
444	Discharge home health services referral and 30-day all-cause readmission in older adults with heart failure. Archives of Medical Science, 2018, 14, 995-1002.	0.4	17
445	Trends in Hospice Discharge and Relative Outcomes Among Medicare Patients in the Get With The Guidelines–Heart Failure Registry. JAMA Cardiology, 2018, 3, 917.	3.0	50
446	Health Status Disparities by Sex, Race/Ethnicity,Âand Socioeconomic Status in Outpatients With Heart Failure. JACC: Heart Failure, 2018, 6, 465-473.	1.9	65
447	Obesity and the Obesity Paradox in Heart Failure. Progress in Cardiovascular Diseases, 2018, 61, 151-156.	1.6	205
448	The Hospital Readmissions Reduction Program—learning from failure of a healthcare policy. European Journal of Heart Failure, 2018, 20, 1169-1174.	2.9	83
449	Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure. Circulation: Heart Failure, 2018, 11, e004646.	1.6	134
450	Comparison of Acute Ischemic Stroke Care and Outcomes Between Comprehensive Stroke Centers and Primary Stroke Centers in the United States. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004512.	0.9	63

#	Article	IF	CITATIONS
451	Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). American Heart Journal, 2018, 203, 25-29.	1.2	29
452	Longâ€Term Mortality of Older Patients With Acute Myocardial Infarction Treated in US Clinical Practice. Journal of the American Heart Association, 2018, 7, .	1.6	58
453	Meta-Analysis Comparing Outcomes of Smokers Versus Nonsmokers With Acute Coronary Syndrome Underwent Percutaneous Coronary Intervention. American Journal of Cardiology, 2018, 122, 973-980.	0.7	5
454	Association of the Affordable Care Act's Medicaid Expansion With Care Quality and Outcomes for Low-Income Patients Hospitalized With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004729.	0.9	31
455	The Current Landscape of AtrialÂFibrillation and Atrial Flutter ClinicalÂTrials. JACC: Clinical Electrophysiology, 2018, 4, 944-954.	1.3	5
456	Effect of a Multifaceted Quality Improvement Intervention on Hospital Personnel Adherence to Performance Measures in Patients With Acute Ischemic Stroke in China. JAMA - Journal of the American Medical Association, 2018, 320, 245.	3.8	80
457	Adverse Change in Employment Status After Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004528.	0.9	27
458	Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate. American Journal of Medicine, 2018, 131, 1473-1481.	0.6	26
459	Participation in Get With The Guidelines–Stroke and Its Association With Quality of Care for Stroke. JAMA Neurology, 2018, 75, 1331.	4.5	40
460	Brain structural changes associated with aberrant functional responses to the Valsalva maneuver in heart failure. Journal of Neuroscience Research, 2018, 96, 1610-1622.	1.3	11
461	Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Journal of Thrombosis and Thrombolysis, 2018, 46, 435-439.	1.0	9
462	High-sensitivity C-reactive protein elevation in patients with prior myocardial infarction in the United States. American Heart Journal, 2018, 204, 151-155.	1.2	10
463	Rationale and design of the improving Care for Cardiovascular Disease in China (CCC) project: a national registry to improve management of atrial fibrillation. BMJ Open, 2018, 8, e020968.	0.8	16
464	Medical Therapy for Heart Failure WithÂReduced Ejection Fraction. Journal of the American College of Cardiology, 2018, 72, 351-366.	1.2	775
465	Clinical phenomapping and outcomes after heart transplantation. Journal of Heart and Lung Transplantation, 2018, 37, 956-966.	0.3	10
466	Comparison of Causes and Associated Costs of 30-Day Readmission of Transcatheter Implantation Versus Surgical Aortic Valve Replacement in the United States (A National Readmission Database) Tj ETQq0 0 0 0	gB <b>T.†</b> Ovei	rlod#10 Tf 50
467	Comparison of Outcomes of Transfemoral Versus Transapical Approach for Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2018, 122, 1520-1526.	0.7	32
468	Vaccination Trends in Patients With HeartÂFailure. JACC: Heart Failure, 2018, 6, 844-855.	1.9	30

#	Article	IF	Citations
469	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2018, 72, e91-e220.	1.2	991
470	Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials. JAMA Cardiology, 2018, 3, 1011.	3.0	146
471	Home-Time After Discharge Among Patients Hospitalized With Heart Failure. Journal of the American College of Cardiology, 2018, 71, 2643-2652.	1.2	72
472	Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart, 2018, 104, 1850-1858.	1.2	23
473	Characteristics and Treatments of Patients Enrolled in the CHAMPâ€HF Registry Compared With Patients Enrolled in the PARADIGMâ€HF Trial. Journal of the American Heart Association, 2018, 7, .	1.6	26
474	Impact of end stage renal disease on in-hospital outcomes of patients with systolic and diastolic heart failure (insights from the Nationwide Inpatient Sample 2010 to 2014). International Journal of Cardiology, 2018, 266, 174-179.	0.8	6
475	The Hospital Readmissions Reduction Program. JACC: Heart Failure, 2018, 6, 607-609.	1.9	21
476	Therapeutic Strategies Following Major, Clinically Relevant Nonmajor,Âand Nuisance Bleeding in Atrial Fibrillation: Findings FromÂORBITâ€AF. Journal of the American Heart Association, 2018, 7, .	1.6	12
477	Mobile health applications in cardiovascular research. International Journal of Cardiology, 2018, 269, 265-271.	0.8	23
478	Relationship between Hospital 30â€Day Mortality Rates for Heart Failure and Patterns of Early Inpatient Comfort Care. Journal of Hospital Medicine, 2018, 13, 170-176.	0.7	3
479	Survival After Heart Transplantation in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy. Journal of Cardiac Failure, 2017, 23, 107-112.	0.7	18
480	Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 685-696.	0.4	49
481	Effect of weight loss on renal function in overweight and obese patients with heart failure. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, 95-98.	1.8	4
482	Management and Outcomes of ST-Segment Elevation Myocardial Infarction in US Renal Transplant Recipients. JAMA Cardiology, 2017, 2, 250.	3.0	18
483	Hospital Variation in Functional Recovery After Stroke. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	28
484	Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	82
485	Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function. American Journal of Cardiology, 2017, 119, 886-892.	0.7	9
486	Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. International Journal of Cardiology, 2017, 230, 301-303.	0.8	9

#	Article	IF	CITATIONS
487	Impact of an Expanded Hospital Recognition Program for Stroke Quality of Care. Journal of the American Heart Association, 2017, 6, .	1.6	7
488	Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non–Vitamin K Antagonist Oral Anticoagulants Before Stroke. Circulation, 2017, 135, 1024-1035.	1.6	48
489	Response by Hess et al to Letter Regarding Article, "Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Program― Circulation, 2017, 135, e22-e23.	1.6	2
490	Compliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines–Coronary Artery Disease (GWTG-CAD) program. American Heart Journal, 2017, 187, 78-87.	1.2	17
491	Costâ€Effectiveness of Remote Cardiac Monitoring With the <scp>CardioMEMS</scp> Heart Failure System. Clinical Cardiology, 2017, 40, 430-436.	0.7	76
492	Timely Reperfusion in Stroke and Myocardial Infarction Is Not Correlated. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	3
493	Healthcare Resource Availability, Quality of Care, and Acute Ischemic Stroke Outcomes. Journal of the American Heart Association, 2017, 6, .	1.6	17
494	Systolic–diastolic hypertension versus isolated systolic hypertension and incident heart failure in older adults: Insights from the Cardiovascular Health Study. International Journal of Cardiology, 2017, 235, 11-16.	0.8	26
495	Association of Obesity With In-Hospital Mortality of Cardiogenic Shock Complicating Acute Myocardial Infarction. American Journal of Cardiology, 2017, 119, 1548-1554.	0.7	23
496	Delays in Door-to-Needle Times and Their Impact on Treatment Time and Outcomes in Get With The Guidelines-Stroke. Stroke, 2017, 48, 946-954.	1.0	81
497	Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke. Stroke, 2017, 48, 686-691.	1.0	22
498	Initiation, Continuation, or Withdrawal of Angiotensinâ€Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association, 2017, 6, .	1.6	104
499	The Role of Biomarkers in Detection of Cardio-toxicity. Current Oncology Reports, 2017, 19, 42.	1.8	19
500	Seasonal and circadian variations of acute myocardial infarction: Findings from the Get With The Guidelines–Coronary Artery Disease (GWTG-CAD) program. American Heart Journal, 2017, 189, 85-93.	1.2	58
501	Association Between Hospital Volume and 30-Day Readmissions Following Transcatheter Aortic Valve Replacement. JAMA Cardiology, 2017, 2, 732.	3.0	68
502	Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry. American Heart Journal, 2017, 189, 177-183.	1.2	43
503	Extracorporeal Ultrafiltration for FluidÂOverload in Heart Failure. Journal of the American College of Cardiology, 2017, 69, 2428-2445.	1.2	88
504	Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With HeartÂFailure Eligible for Therapy. JACC: Heart Failure, 2017, 5, 388-392.	1.9	11

#	Article	IF	Citations
505	Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation, 2017, 135, e1054-e1091.	1.6	417
506	Factors associated with non–vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). American Heart Journal, 2017, 189, 40-47.	1.2	53
507	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for theÂManagement of Heart Failure. Journal of Cardiac Failure, 2017, 23, 628-651.	0.7	531
508	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 2017, 136, e137-e161.	1.6	2,130
509	Association of US Centers for Medicare and Medicaid Services Hospital 30-Day Risk-Standardized Readmission Metric With Care Quality and Outcomes After Acute Myocardial Infarction. JAMA Cardiology, 2017, 2, 723.	3.0	33
510	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for theÂManagement of Heart Failure. Journal of the American College of Cardiology, 2017, 70, 776-803.	1.2	2,256
511	Influence of atrial fibrillation on postâ€discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the <scp>ASTRONAUT</scp> trial. European Journal of Heart Failure, 2017, 19, 552-562.	2.9	23
512	Outcomes and Temporal Trends of Inpatient Percutaneous Coronary Intervention at Centers With and Without On-site Cardiac Surgery in the United States. JAMA Cardiology, 2017, 2, 25.	3.0	45
513	Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes. American Heart Journal, 2017, 189, 48-58.	1.2	29
514	Digoxin and 30-Day All-Cause Readmission in Long-Term Care Residents Hospitalized for Heart Failure. Journal of the American Medical Directors Association, 2017, 18, 761-765.	1.2	5
515	Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved EjectionÂFraction. JACC: Heart Failure, 2017, 5, 483-493.	1.9	41
516	Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization. Circulation, 2017, 135, 2077-2080.	1.6	28
517	Claims Data to Ascertain Clinical Events. JAMA Cardiology, 2017, 2, 758.	3.0	3
518	Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. Clinical Cardiology, 2017, 40, 746-751.	0.7	13
519	Early transition to comfort measures only in acute stroke patients. Neurology: Clinical Practice, 2017, 7, 194-204.	0.8	14
520	Evaluation of the SIPAT instrument to assess psychosocial risk in heart transplant candidates: A retrospective single center study. Heart and Lung: Journal of Acute and Critical Care, 2017, 46, 273-279.	0.8	35
521	The American Heart Association's Get With the Guidelines (GWTG)-Stroke development and impact on stroke care. Stroke and Vascular Neurology, 2017, 2, 94-105.	1.5	95
522	Association Between Previous Use of Antiplatelet Therapy and Intracerebral Hemorrhage Outcomes. Stroke, 2017, 48, 1810-1817.	1.0	52

#	Article	IF	CITATIONS
523	Reduced regional cerebral blood flow in patients with heart failure. European Journal of Heart Failure, 2017, 19, 1294-1302.	2.9	<b>7</b> 5
524	Invasive Management Strategies and Antithrombotic Treatments in Patients With Nonâ&"ST-Segmentâ&"Elevation Acute Coronary Syndrome in China. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	27
525	Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non–Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the) Tj ETQq1 1 0.3 lournal of Cardiology, 2017, 119, 1590-1595.	784314 rş	gBT <sub>3</sub> /Overlock
526	Isolated diastolic hypertension and incident heart failure in community-dwelling older adults: Insights from the Cardiovascular Health Study. International Journal of Cardiology, 2017, 238, 140-143.	0.8	19
527	Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Tj ETQq1 1 0.784:	31 <b>⊕</b> ngBT	/Overlock 10
528	INVASIVE MANAGEMENT STRATEGIES AND ANTI-THROMBOTIC TREATMENTS IN PATIENTS WITH NSTE-ACS IN CHINA. Journal of the American College of Cardiology, 2017, 69, 135.	1.2	0
529	Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?. Canadian Journal of Cardiology, 2017, 33, 768-776.	0.8	11
530	Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure, 2017, 5, 305-309.	1.9	101
531	Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy. JAMA Cardiology, 2017, 2, 685.	3.0	82
532	Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2017, 317, 1057.	3.8	179
533	Trends in health care expenditure among US adults with heart failure: The Medical Expenditure Panel Survey 2002-2011. American Heart Journal, 2017, 186, 63-72.	1.2	54
534	2016 AHA/ACC Clinical Performance and Quality MeasuresÂfor Prevention of SuddenÂCardiac Death. Journal of the American College of Cardiology, 2017, 69, 712-744.	1.2	23
535	Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2017, 2, 136.	3.0	50
536	Differences in Acute Ischemic Stroke Quality of Care and Outcomes by Primary Stroke Center Certification Organization. Stroke, 2017, 48, 412-419.	1.0	41
537	Thirty-Day Readmissions After Transcatheter Aortic Valve Replacement in the United States. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	128
538	Renal Dysfunction Is Associated With Poststroke Discharge Disposition and In-Hospital Mortality. Stroke, 2017, 48, 327-334.	1.0	58
539	Predictors and Prognostic Implications ofÂlncident Heart Failure in Patients WithÂPrevalent Atrial Fibrillation. JACC: Heart Failure, 2017, 5, 44-52.	1.9	91
540	2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, e000022.	0.9	9

#	Article	lF	Citations
541	Recommendations for the Implementation of Telehealth in Cardiovascular and Stroke Care: A Policy Statement From the American Heart Association. Circulation, 2017, 135, e24-e44.	1.6	163
542	Quality of Evidence Underlying the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines on the Management of Atrial Fibrillation. JAMA Cardiology, 2017, 2, 319.	3.0	17
543	Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. American Journal of Medicine, 2017, 130, 449-456.	0.6	25
544	Refining Classification of Heart Failure Based on Ejection Fraction. JACC: Heart Failure, 2017, 5, 808-809.	1.9	20
545	2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2017, 70, 2048-2090.	1.2	146
546	Incorporating Stroke Severity Into Hospital Measures of 30-Day Mortality After Ischemic Stroke Hospitalization. Stroke, 2017, 48, 3101-3107.	1.0	9
547	Heart Rate and Outcomes in HospitalizedÂPatients With Heart Failure With Preserved EjectionÂFraction. Journal of the American College of Cardiology, 2017, 70, 1861-1871.	1.2	34
548	The Hospital Readmission Reduction Program Is Associated With Fewer Readmissions, MoreÂDeaths. Journal of the American College of Cardiology, 2017, 70, 1931-1934.	1.2	79
549	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. American Heart Journal, 2017, 194, 132-140.	1.2	161
550	Increase in Endovascular Therapy in Get With The Guidelines-Stroke After the Publication of Pivotal Trials. Circulation, 2017, 136, 2303-2310.	1.6	106
551	Age Differences in Hospital Mortality for Acute Myocardial Infarction: Implications for Hospital Profiling. Annals of Internal Medicine, 2017, 167, 555.	2.0	8
552	Regional Variation in 30-Day Ischemic Stroke Outcomes for Medicare Beneficiaries Treated in Get With The Guidelines–Stroke Hospitals. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	14
553	Heart Failure With Mid-Range (Borderline) Ejection Fraction. JACC: Heart Failure, 2017, 5, 763-771.	1.9	141
554	Association of Chronic Kidney Disease With In-Hospital Outcomes of Transcatheter AorticÂValve Replacement. JACC: Cardiovascular Interventions, 2017, 10, 2050-2060.	1.1	106
555	Is Risk-Standardized In-Hospital Stroke Mortality an Adequate Proxy for Risk-Standardized 30-Day Stroke Mortality Data?. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	4
556	Contemporary Epidemiology, Management, and Outcomes of Patients Hospitalized for Heart Failure in China: Results From the China Heart Failure (China-HF) Registry. Journal of Cardiac Failure, 2017, 23, 868-875.	0.7	159
557	Management of Persistent Angina After Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATEâ€ACS Study. Journal of the American Heart Association, 2017, 6, .	1.6	23
558	Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiology, 2017, 2, 1069.	3.0	119

#	Article	IF	CITATIONS
559	Unexplained Variation for Hospitals' Use of Inpatient Rehabilitation and Skilled Nursing Facilities After an Acute Ischemic Stroke. Stroke, 2017, 48, 2836-2842.	1.0	37
560	Maximizing Cardiovascular Event Reduction by Expanding and Intensifying the Targets. Circulation, 2017, 136, 813-816.	1.6	4
561	Changes in parameters of right ventricular function with cardiac resynchronization therapy. Clinical Cardiology, 2017, 40, 1033-1043.	0.7	13
562	2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	71
563	Renin–angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and metaâ€analysis. ESC Heart Failure, 2017, 4, 402-408.	1.4	50
564	Care Patterns and Outcomes in AtrialÂFibrillation Patients With and Without Diabetes. Journal of the American College of Cardiology, 2017, 70, 1325-1335.	1.2	124
565	Clinical Effectiveness of Hydralazine–Isosorbide Dinitrate in African-American Patients With HeartÂFailure. JACC: Heart Failure, 2017, 5, 632-639.	1.9	17
566	Holding the Readmission Gates. JACC: Heart Failure, 2017, 5, 589-590.	1.9	0
567	Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure. Circulation: Heart Failure, 2017, 10, .	1.6	47
568	Utilization, Characteristics, and In-Hospital Outcomes of Coronary Artery Bypass Grafting in Patients With ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	12
569	Regional Variation in Utilization, In-hospital Mortality, and Health-Care Resource Use of Transcatheter Aortic Valve Implantation in the United States. American Journal of Cardiology, 2017, 120, 1869-1876.	0.7	17
570	Derivation and Validation of a Geriatricâ€Sensitive Perioperative Cardiac Risk Index. Journal of the American Heart Association, 2017, 6, .	1.6	27
571	Consequences of Reductions in Hospital Readmissions. JAMA - Journal of the American Medical Association, 2017, 318, 1933.	3.8	6
572	Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	29
573	Culprit Vessel–Only Versus Multivessel Percutaneous Coronary Intervention in Patients With Cardiogenic Shock Complicating ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	44
574	Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2017, 70, 2476-2486.	1.2	671
575	Incorporating Patient and Caregiver Experiences Into Cardiovascular Clinical Trial Design. JAMA Cardiology, 2017, 2, 1263.	3.0	11
576	Noninvasive Bioelectrical Impedance for Predicting Clinical Outcomes in Outpatients With Heart Failure. Critical Pathways in Cardiology, 2017, 16, 32-36.	0.2	28

#	Article	IF	Citations
577	Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT. Current Heart Failure Reports, 2017, 14, 217-222.	1.3	13
578	National Differences in Trends for Heart Failure Hospitalizations by Sex and Race/Ethnicity. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	138
579	Blood pressure and in-hospital outcomes in patients presenting with ischaemic stroke. European Heart Journal, 2017, 38, 2827-2835.	1.0	51
580	Cardioversion and subsequent quality of life and natural history of atrial fibrillation. American Heart Journal, 2017, 185, 59-66.	1.2	18
581	Treatment With Tissue Plasminogen Activator in the Golden Hour and the Shape of the 4.5-Hour Time-Benefit Curve in the National United States Get With The Guidelines-Stroke Population. Circulation, 2017, 135, 128-139.	1.6	129
582	Sex and Age Interactions and Differences in Outcomes After Intracerebral Hemorrhage. Journal of Women's Health, 2017, 26, 380-388.	1.5	17
583	Prediction of 30-Day All-Cause Readmissions in Patients Hospitalized for Heart Failure. JAMA Cardiology, 2017, 2, 204.	3.0	249
584	Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone. International Journal of Cardiology, 2017, 227, 462-466.	0.8	16
585	Safety and Efficacy of ExerciseÂTrainingÂinÂPatients With an Implantable Cardioverter-Defibrillator. JACC: Clinical Electrophysiology, 2017, 3, 117-126.	1.3	28
586	Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. Circulation, 2017, 135, 38-47.	1.6	16
587	Management and outcomes of patients with atrial fibrillation and $\langle i \rangle$ a history of $\langle l i \rangle$ cancer: the ORBIT-AF registry. European Heart Journal Quality of Care & European Outcomes, 2017, 3, 192-197.	1.8	69
588	Thirty-Day Readmission Rate and Costs After Percutaneous Coronary Intervention in the United States. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	49
589	Implantable Cardioverter Defibrillators for Nonischemic Cardiomyopathyâ€"Reply. JAMA Cardiology, 2017, 2, 1283.	3.0	0
590	Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBITâ€AF (Outcomes Registry for Better Informed Treatment for Atrial) Tj ETQq0	0 <b>0.</b> 6gBT /	Oveslock 10
591	Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease. Journal of the American Heart Association, 2017, 6, .	1.6	32
592	Relationships between Weight, Adiposity, Functional Status, and Left Ventricle Characteristics in Overweight and Obese Patients with Heart Failure. Journal of Diabetes and Obesity, 2017, 4, 1-5.	0.2	1
593	Response to Letter Regarding Article, "Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women― Circulation: Heart Failure, 2016, 9, .	1.6	0
594	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. Academic Emergency Medicine, 2016, 23, 922-931.	0.8	10

#	Article	IF	Citations
595	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of Cardiac Failure, 2016, 22, 659-669.	0.7	59
596	Assessment of Home-Time After Acute Ischemic Stroke in Medicare Beneficiaries. Stroke, 2016, 47, 836-842.	1.0	67
597	Characteristics and Outcomes of Adult Outpatients With Heart Failure and Improved or Recovered Ejection Fraction. JAMA Cardiology, 2016, 1, 510.	3.0	179
598	Telemedicine in Heart Failureâ€"Ineffective or Just III Used?â€"Reply. JAMA Internal Medicine, 2016, 176, 1035.	2.6	1
599	2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter. Journal of the American College of Cardiology, 2016, 68, 525-568.	1.2	55
600	2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 443-488.	0.9	32
601	Association of 30-Day Readmission MetricÂfor Heart Failure Under the HospitalÂReadmissions Reduction ProgramÂWith Quality of Care andÂOutcomes. JACC: Heart Failure, 2016, 4, 935-946.	1.9	68
602	Variation in Hospital Use and Outcomes Associated With Pulmonary Artery Catheterization in Heart Failure in the United States. Circulation: Heart Failure, 2016, 9, .	1.6	39
603	Impact of Insurance Status on Outcomes and Use of Rehabilitation Services in Acute Ischemic Stroke: Findings From Get With The Guidelinesâ€Stroke. Journal of the American Heart Association, 2016, 5, .	1.6	46
604	Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes. Journal of the American College of Cardiology, 2016, 68, 2597-2604.	1.2	401
605	Sex Differences in the Management and Outcomes of Heart Failure With Preserved Ejection Fraction in Patients Presenting to the Emergency Department With Acute Heart Failure. Journal of Cardiac Failure, 2016, 22, 781-788.	0.7	24
606	Cardiovascular clinical trials with noninferiority or equivalence designs from 2001 to 2012. International Journal of Cardiology, 2016, 214, 16-18.	0.8	2
607	Patient and Facility Variation in Costs of VA Heart Failure Patients. JACC: Heart Failure, 2016, 4, 551-558.	1.9	21
608	The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry–Get With the Guidelines (GWTG) Medicare-linked database. American Heart Journal, 2016, 178, 65-73.	1,2	54
609	Reply. JACC: Heart Failure, 2016, 4, 331-332.	1.9	0
610	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 2016, 134, e282-93.	1.6	494
611	Effect of Hepatitis C Positivity on Survival in Adult Patients Undergoing Heart Transplantation (from) Tj ETQq1	1 0.784314 0.7	rgBT /Overlo
612	Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men. JAMA Cardiology, 2016, 1, 282.	3.0	182

#	Article	IF	CITATIONS
613	Association of Get With The Guidelines-Stroke Program Participation and Clinical Outcomes for Medicare Beneficiaries With Ischemic Stroke. Stroke, 2016, 47, 1294-1302.	1.0	52
614	Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. American Heart Journal, 2016, 175, 28-35.	1.2	23
615	Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction. American Heart Journal, 2016, 177, 33-41.	1.2	13
616	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2016, 68, 1476-1488.	1.2	549
617	Prevalence and Prognosis of Hyperkalemia in Patients with Acute Myocardial Infarction. American Journal of Medicine, 2016, 129, 858-865.	0.6	35
618	Smoker's Paradox in Patients With STâ€Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Journal of the American Heart Association, 2016, 5, .	1.6	62
619	Heart Failure Therapies for End-Stage Chemotherapy–Induced Cardiomyopathy. Journal of Cardiac Failure, 2016, 22, 439-448.	0.7	31
620	Evidence-Based Policy Making: Assessment of the American Heart Association's Strategic Policy Portfolio. Circulation, 2016, 133, e615-53.	1.6	36
621	Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBITâ€AF I) Registry. Journal of the American Heart Association, 2016, 5, .	1.6	16
622	Rationale and design of the Improving Care for Cardiovascular Disease in China (CCC) project: A national effort to prompt quality enhancement for acute coronary syndrome. American Heart Journal, 2016, 179, 107-115.	1.2	74
623	Heart failure medications prescribed at discharge for patients with left ventricular assist devices. American Heart Journal, 2016, 179, 99-106.	1.2	8
624	How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal, 2016, 181, 145-152.	1.2	13
625	Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Circulation, 2016, 134, 1122-1124.	1.6	6
626	Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATEâ€ACS) Study. Journal of the American Heart Association, 2016, 5, .	1.6	9
627	Patient factors associated with quality of life in atrial fibrillation. American Heart Journal, 2016, 182, 135-143.	1.2	62
628	Response to Letter Regarding Article, "Temporal Trends and Variation in Early Scheduled Follow-up After a Hospitalization for Heart Failure: Findings from Get With The Guidelines-Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	0
629	Acute management of stroke patients taking non–vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. American Heart Journal, 2016, 182, 28-35.	1.2	12
630	Prior Antithrombotic Use Is Associated With Favorable Mortality and Functional Outcomes in Acute Ischemic Stroke. Stroke, 2016, 47, 2066-2074.	1.0	12

#	Article	IF	Citations
631	Mean platelet volume and mortality risk in a national incident hemodialysis cohort. International Journal of Cardiology, 2016, 220, 862-870.	0.8	16
632	Diabetes Mellitus and Outcomes of Cardiac Resynchronization With Implantable Cardioverter-Defibrillator Therapy in Older Patients With Heart Failure. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	25
633	Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE). American Heart Journal, 2016, 178, 198-205.	1.2	14
634	Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure. Circulation, 2016, 134, 517-526.	1.6	90
635	Use and Outcomes of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients ≥90 Years of Age. Stroke, 2016, 47, 2347-2354.	1.0	27
636	Costâ€Effectiveness of <scp>LDL</scp> â€C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. Clinical Cardiology, 2016, 39, 313-320.	0.7	74
637	Higher risk for incident heart failure and cardiovascular mortality among communityâ€dwelling octogenarians without pneumococcal vaccination. ESC Heart Failure, 2016, 3, 11-17.	1.4	21
638	Management Strategies and Outcomes of <scp>ST</scp> â€Segment Elevation Myocardial Infarction Patients Transferred After Receiving Fibrinolytic Therapy in the United States. Clinical Cardiology, 2016, 39, 9-18.	0.7	6
639	Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBITâ€AF Registry. Clinical Cardiology, 2016, 39, 119-125.	0.7	6
640	Trends in the Burden of Adult Congenital Heart Disease in <scp>US</scp> Emergency Departments. Clinical Cardiology, 2016, 39, 391-398.	0.7	33
641	The Potential Impact of Expanding Cardiac Rehabilitation in HeartÂFailure. Journal of the American College of Cardiology, 2016, 68, 977-978.	1.2	6
642	Trends in 30-Day Readmission Rates for Patients Hospitalized With Heart Failure. Circulation: Heart Failure, 2016, $9$ , .	1.6	127
643	Why are acute ischemic stroke patients not receiving IV tPA?. Neurology, 2016, 87, 1565-1574.	1.5	159
644	Hospital Variation in Home-Time After Acute Ischemic Stroke. Stroke, 2016, 47, 2627-2633.	1.0	33
645	Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines–Heart Failure registry. American Heart Journal, 2016, 182, 9-20.	1.2	115
646	Randomization—There Is No Substitute. JAMA Cardiology, 2016, 1, 633.	3.0	19
647	Combined neprilysin and renin–angiotensin system inhibition in heart failure with reduced ejection fraction: a metaâ€analysis. European Journal of Heart Failure, 2016, 18, 1238-1243.	2.9	56
648	Association of 30-Day All-Cause Readmission with Long-Term Outcomes in Hospitalized Older Medicare Beneficiaries with Heart Failure. American Journal of Medicine, 2016, 129, 1178-1184.	0.6	44

#	Article	IF	CITATIONS
649	Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease. Circulation: Heart Failure, 2016, 9, .	1.6	19
650	Substantial Progress Yet Significant Opportunity for Improvement in Stroke Care in China. Stroke, 2016, 47, 2843-2849.	1.0	93
651	Guideline-Appropriate Care and In-Hospital Outcomes in Patients With Heart Failure in Teaching and Nonteaching Hospitals. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 757-766.	0.9	22
652	Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. Circulation, 2016, 134, e579-e646.	1.6	532
653	Temporal Trends in Care and Outcomes of Patients Receiving Fibrinolytic Therapy Compared to Primary Percutaneous Coronary Intervention: Insights From the Get With The Guidelines Coronary Artery Disease (GWTG AD) Registry. Journal of the American Heart Association, 2016, 5, .	1.6	16
654	Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure. American Journal of Medicine, 2016, 129, 1067-1073.	0.6	42
655	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. Journal of Cardiac Failure, 2016, 22, 618-627.	0.7	4
656	Relation of Obesity to Survival After In-Hospital Cardiac Arrest. American Journal of Cardiology, 2016, 118, 662-667.	0.7	36
657	Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure. JAMA Cardiology, 2016, 1, 714.	3.0	89
658	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) Tj ETQq0	0 0 rgBT /0	Overlock 10 Tf
659	Left Ventricular Ejection Fraction. JACC: Heart Failure, 2016, 4, 511-513.	1.9	15
660	Precipitating Clinical Factors, HeartÂFailureÂCharacterization, and Outcomes inÂPatients Hospitalized With Heart FailureÂWith Reduced, Borderline, andÂPreservedÂEjection Fraction. JACC: Heart Failure, 2016, 4, 464-472.	1.9	179
661	Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With The Guidelines. American Heart Journal, 2016, 175, 1-8.	1.2	6
662	Trends in the Use of Guideline-Directed TherapiesÂAmong Dialysis Patients HospitalizedÂWith Systolic Heart Failure. JACC: Heart Failure, 2016, 4, 649-661.	1.9	16
663	Assessing Risks of Glucose Lowering Therapy in Heart Failure: Should We Rely on Post-hoc Analyses?. Current Cardiovascular Risk Reports, 2016, 10, 1.	0.8	O
664	Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiology, 2016, 1, 666.	3.0	130
665	Rhythm Control Versus Rate Control andÂClinical Outcomes in Patients WithÂAtrial Fibrillation. JACC: Clinical Electrophysiology, 2016, 2, 221-229.	1.3	33
666	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. American Journal of Cardiology, 2016, 117, 1144-1150.	0.7	23

#	Article	IF	CITATIONS
667	Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. American Journal of Medicine, 2016, 129, 592-599.e1.	0.6	49
668	Cardiac resynchronization therapy in chronic heart failure with moderately reduced left ventricular ejection fraction: Lessons from the Multicenter InSync Randomized Clinical Evaluation MIRACLE EF study. International Journal of Cardiology, 2016, 202, 349-355.	0.8	28
669	Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator. JAMA Neurology, 2016, 73, 50.	4.5	54
670	2015 ACC/AHA Focused Update of Secondary Prevention Lipid Performance Measures. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 68-95.	0.9	21
671	Preventing Stroke in Patients With Atrial Fibrillationâ€"A Steep Climb Away From Achieving Peak Performance. JAMA Cardiology, 2016, 1, 63.	3.0	11
672	Distinct Short-Term Outcomes in Patients With Mild Versus Rapidly Improving Stroke Not Treated With Thrombolytics. Stroke, 2016, 47, 1278-1285.	1.0	16
673	Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials. American Journal of Cardiology, 2016, 117, 1845-1850.	0.7	11
674	Coenzyme Q10 and Heart Failure. Circulation: Heart Failure, 2016, 9, e002639.	1.6	108
675	Variables Measured During Cardiopulmonary Exercise Testing as Predictors of Mortality in Chronic Systolic Heart Failure. Journal of the American College of Cardiology, 2016, 67, 780-789.	1.2	157
676	Association of Body Mass Index WithÂCareÂand Outcomes in Patients WithÂAtrialÂFibrillation. JACC: Clinical Electrophysiology, 2016, 2, 355-363.	1.3	45
677	The Prevention of Hospital Readmissions in Heart Failure. Progress in Cardiovascular Diseases, 2016, 58, 379-385.	1.6	179
678	Inflammatory Mediators and Clinical Outcome in Patients With Advanced Heart Failure Receiving Cardiac Resynchronization Therapy. American Journal of Cardiology, 2016, 117, 617-625.	0.7	11
679	Temporal Trends of Digoxin Use in PatientsÂHospitalized With Heart Failure. JACC: Heart Failure, 2016, 4, 348-356.	1.9	38
680	Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. Circulation: Heart Failure, 2016, 9, e002630.	1.6	28
681	Effectiveness of Remote Patient Monitoring After Discharge of Hospitalized Patients With Heart Failure. JAMA Internal Medicine, 2016, 176, 310.	2.6	528
682	Trends in Heart Failure Clinical Trials From 2001–2012. Journal of Cardiac Failure, 2016, 22, 171-179.	0.7	22
683	Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. American Heart Journal, 2016, 174, 29-36.	1.2	82
684	Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	1.6	10

#	Article	IF	CITATIONS
685	Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the) Tj ETQq $1\ 1$	0.784314	rgBT <sub>15</sub> /Overlo <mark>c</mark> l
686	Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	24
687	Clinical Effectiveness of Hydralazine–Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. Circulation: Heart Failure, 2016, 9, e002444.	1.6	29
688	Sex and Race/Ethnicity–Related Disparities in Care and Outcomes After Hospitalization for Coronary Artery Disease Among Older Adults. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, S36-44.	0.9	57
689	Gaps in Adherence to Guideline-DirectedÂMedical Therapy Before Defibrillator Implantation â^—. Journal of the American College of Cardiology, 2016, 67, 1070-1073.	1.2	14
690	New medications for heart failure. Trends in Cardiovascular Medicine, 2016, 26, 485-492.	2.3	26
691	Epidemiology and aetiology of heart failure. Nature Reviews Cardiology, 2016, 13, 368-378.	6.1	1,181
692	Discharge heart rate and $\hat{I}^2$ -blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry. American Heart Journal, 2016, 173, 172-178.	1.2	28
693	Unplanned Inpatient and Observation Rehospitalizations After Acute Myocardial Infarction. Circulation, 2016, 133, 493-501.	1.6	26
694	Statin use, intensity, and 3-year clinical outcomes among older patients with coronary artery disease. American Heart Journal, 2016, 173, 27-34.	1.2	17
695	Use of Pulmonary Artery Catheterization in US Patients With Heart Failure, 2001-2012. JAMA Internal Medicine, 2016, 176, 129.	2.6	35
696	Relation Between Hospital Length of Stay and Quality of Care in Patients With Acute Coronary Syndromes (from the American Heart Association's Get With the Guidelines—Coronary Artery Disease) Tj ETC	)q0 <b>@⊅</b> rgB	T / <b>O</b> serlock 10
697	Association of Arterial Pulse Pressure WithÂLong-Term Clinical Outcomes in Patients With Heart Failure. JACC: Heart Failure, 2016, 4, 42-49.	1.9	30
698	Assessing the Risk of Progression FromÂAsymptomatic Left Ventricular Dysfunction to Overt Heart Failure. JACC: Heart Failure, 2016, 4, 237-248.	1.9	94
699	Treatment patterns and short-term outcomes in ischemic stroke in pregnancy or postpartum period. American Journal of Obstetrics and Gynecology, 2016, 214, 723.e1-723.e11.	0.7	69
700	Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure. JACC: Heart Failure, 2016, 4, 95-105.	1.9	158
701	Trends in Coronary Angiography, Revascularization, and Outcomes of Cardiogenic Shock Complicating Non–ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2016, 117, 1-9.	0.7	66
702	Association of Body Mass Index with Mortality in Peritoneal Dialysis Patients: A Systematic Review and Meta-Analysis. Peritoneal Dialysis International, 2016, 36, 315-325.	1.1	43

#	Article	IF	Citations
703	Lateralized Resting-State Functional Brain Network Organization Changes in Heart Failure. PLoS ONE, 2016, 11, e0155894.	1.1	12
704	Improving Quality of Cardiac Care: A Global Mandate. Revista Espanola De Cardiologia (English Ed ), 2015, 68, 924-927.	0.4	2
705	Complete Heart Block Complicating ST-Segment Elevation Myocardial Infarction. JACC: Clinical Electrophysiology, 2015, 1, 529-538.	1.3	18
706	ACC/AHA/STS Statement on the Future of Registries and the Performance Measurement Enterprise. Annals of Thoracic Surgery, 2015, 100, 1926-1941.	0.7	8
707	Differences in health care use and outcomes by the timing of in-hospital worsening heart failure. American Heart Journal, 2015, 170, 1124-1132.	1.2	8
708	Relationship of physical activity and healthy eating with mortality and incident heart failure among communityâ€dwelling older adults with normal body mass index. ESC Heart Failure, 2015, 2, 20-24.	1.4	13
709	Global variation in clinical profile, management, and postâ€discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ⟨scp⟩ASTRONAUT⟨/scp⟩ trial. European Journal of Heart Failure, 2015, 17, 591-600.	2.9	58
710	Improving patient satisfaction through physician education, feedback, and incentives. Journal of Hospital Medicine, 2015, 10, 497-502.	0.7	78
711	Mejorar la calidad de la asistencia cardiaca: un imperativo mundial. Revista Espanola De Cardiologia, 2015, 68, 924-927.	0.6	4
712	Future of Quality and Outcomes Research in Stroke. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S66-8.	0.9	1
713	Variation and Trends in the Documentation of National Institutes of Health Stroke Scale in GWTG-Stroke Hospitals. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S90-8.	0.9	29
714	Global and regional brain mean diffusivity changes in patients with heart failure. Journal of Neuroscience Research, 2015, 93, 678-685.	1.3	38
715	Inâ€hospital worsening heart failure. European Journal of Heart Failure, 2015, 17, 1104-1113.	2.9	60
716	Length of hospital stay and 30â€day readmission following heart failure hospitalization: insights from the <scp>EVEREST</scp> trial. European Journal of Heart Failure, 2015, 17, 1022-1031.	2.9	52
717	Insulin resistance in heart failure: widening the divide between reduced and preserved ejection fraction?. European Journal of Heart Failure, 2015, 17, 991-993.	2.9	3
718	ACC/AHA/STS Statement on the Future of Registries and the Performance Measurement Enterprise. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 634-648.	0.9	20
719	Association of Acute and Chronic Hyperglycemia With Acute Ischemic Stroke Outcomes Postâ€Thrombolysis: Findings From Get With The Guidelinesâ€Stroke. Journal of the American Heart Association, 2015, 4, e002193.	1.6	88
720	Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction. Circulation, 2015, 132, 174-181.	1.6	45

#	Article	IF	CITATIONS
721	Contemporary Cardiovascular Device Clinical Trials (Trends and Patterns 2001 to 2012). American Journal of Cardiology, 2015, 116, 307-312.	0.7	2
722	Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure. American Journal of Medicine, 2015, 128, 715-721.	0.6	36
723	Pretransplant Coagulopathy and Inâ€hospital Outcomes Among Heart Transplant Recipients: A Propensityâ€Matched Nationwide Inpatient Sample Study. Clinical Cardiology, 2015, 38, 300-308.	0.7	9
724	Early Medication Nonadherence After Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 347-356.	0.9	55
725	Contemporary Trends and Predictors of Postacute Service Use and Routine Discharge Home After Stroke. Journal of the American Heart Association, 2015, 4, .	1.6	59
726	Perception Versus Actual Performance in Timely Tissue Plasminogen Activation Administration in the Management of Acute Ischemic Stroke. Journal of the American Heart Association, 2015, 4, .	1.6	12
727	Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverterâ€Defibrillator for Primary Prevention. Journal of the American Heart Association, 2015, 4, e002061.	1.6	14
728	Association of Chronic Renal Insufficiency With Inâ€Hospital Outcomes After Percutaneous Coronary Intervention. Journal of the American Heart Association, 2015, 4, e002069.	1.6	48
729	Racial/Ethnic and Sex Differences in Emergency Medical Services Transport Among Hospitalized US Stroke Patients: Analysis of the National Get With The Guidelines–Stroke Registry. Journal of the American Heart Association, 2015, 4, e002099.	1.6	69
730	Reduced Regional Brain Cortical Thickness in Patients with Heart Failure. PLoS ONE, 2015, 10, e0126595.	1.1	42
731	Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study. BMJ, The, 2015, 351, h3786.	3.0	54
732	Outcomes of Acute Myocardial Infarction in Patients with Hypertrophic Cardiomyopathy. American Journal of Medicine, 2015, 128, 879-887.e1.	0.6	18
733	The Reply. American Journal of Medicine, 2015, 128, e19.	0.6	0
734	2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials. Circulation, 2015, 132, 302-361.	1.6	364
735	Obesity and the Obesity Paradox in Heart Failure. Canadian Journal of Cardiology, 2015, 31, 195-202.	0.8	72
736	The vulnerable phase after hospitalization for heart failure. Nature Reviews Cardiology, 2015, 12, 220-229.	6.1	238
737	Factors associated with variations in hospital expenditures for acute heart failure in the United States. American Heart Journal, 2015, 169, 282-289.e15.	1.2	44
738	Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients WithÂHeart Failure. JACC: Heart Failure, 2015, 3, 136-145.	1.9	265

#	Article	IF	CITATIONS
739	Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. JACC: Heart Failure, 2015, 3, 159-167.	1.9	30
740	Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the <scp>ASTRONAUT</scp> trial. European Journal of Heart Failure, 2015, 17, 98-108.	2.9	30
741	Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation. Circulation, 2015, 131, 488-494.	1.6	224
742	Trends in Endovascular Therapy and Clinical Outcomes Within the Nationwide Get With The Guidelines-Stroke Registry. Stroke, 2015, 46, 989-995.	1.0	62
743	Racial and Ethnic Differences in Heart Failure Etiology, Prognosis, and Management. Current Cardiovascular Risk Reports, 2015, 9, 1.	0.8	2
744	Primary Prevention Implantable Cardioverter-Defibrillators in Older Racial and Ethnic Minority Patients. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 145-151.	2.1	14
745	The Reply. American Journal of Medicine, 2015, 128, e15-e16.	0.6	0
746	Site selection for heart failure clinical trials in the USA. Heart Failure Reviews, 2015, 20, 375-383.	1.7	13
747	Effect of the 2014 Atrial Fibrillation Guideline Revisions on the Proportion of Patients Recommended for Oral Anticoagulation. JAMA Internal Medicine, 2015, 175, 848.	2.6	20
748	Risk of Heart Failure and Death After Prolonged Smoking Cessation. Circulation: Heart Failure, 2015, 8, 694-701.	1.6	57
749	Clinical Effectiveness of Statin Therapy After Ischemic Stroke: Primary Results From the Statin Therapeutic Area of the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. Circulation, 2015, 132, 1404-1413.	1.6	43
750	Rationale and design of a cluster-randomized multifaceted intervention trial to improve stroke care quality in China: The GOLDEN BRIDGE–Acute Ischemic Stroke. American Heart Journal, 2015, 169, 767-774.e2.	1.2	20
751	Regional differences in use and outcomes of left ventricular assist devices: Insights from the Interagency Registry for Mechanically Assisted Circulatory Support Registry. Journal of Heart and Lung Transplantation, 2015, 34, 912-920.	0.3	12
752	Lack of Impact of Electronic Health Records on Quality of Care and Outcomes for Ischemic Stroke. Journal of the American College of Cardiology, 2015, 65, 1964-1972.	1.2	18
753	Reply. American Journal of Cardiology, 2015, 116, 164-165.	0.7	0
754	Characteristics, quality of care, and in-hospital outcomes of Asian-American heart failure patients: Findings from the American Heart Association Get With The Guidelines-Heart Failure Program. International Journal of Cardiology, 2015, 189, 141-147.	0.8	4
755	Characteristics and Outcomes of Patients With Advanced Chronic Systolic Heart Failure Receiving Care at the Veterans Affairs Versus Other Hospitals. Circulation: Heart Failure, 2015, 8, 17-24.	1.6	11
756	Cluster-Randomized Trial of Personalized Site Performance Feedback in Get With The Guidelines-Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 421-427.	0.9	22

#	Article	IF	Citations
757	Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 393-402.	0.9	173
758	Workplace Wellness Recognition for Optimizing Workplace Health. Circulation, 2015, 131, e480-97.	1.6	69
759	Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary AtrialÂFibrillation Cohort. Journal of the American College of Cardiology, 2015, 65, 2691-2698.	1.2	76
760	Regional hippocampal damage in heart failure. European Journal of Heart Failure, 2015, 17, 494-500.	2.9	63
761	Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2015, 313, 2433.	3.8	50
762	Trends in characteristics of cardiovascular clinical trials 2001-2012. American Heart Journal, 2015, 170, 263-272.e2.	1.2	26
763	2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, e5-e23.	0.4	97
764	2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials. Journal of the American College of Cardiology, 2015, 66, 403-469.	1.2	428
765	Association of Physical Activity or Fitness With Incident Heart Failure. Circulation: Heart Failure, 2015, 8, 853-861.	1.6	51
766	Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 383-392.	0.9	52
767	A systematic review and meta-analysis on the association between quality of hospital care and readmission rates in patients with heart failure. American Heart Journal, 2015, 170, 1005-1017.e2.	1.2	35
768	Heart Rate at Hospital Discharge in Patients With Heart Failure Is Associated With Mortality and Rehospitalization. Journal of the American Heart Association, 2015, 4, .	1.6	60
769	Heart Failure Management in Skilled Nursing Facilities. Circulation: Heart Failure, 2015, 8, 655-687.	1.6	51
770	Team-Based Care for Outpatients with Heart Failure. Heart Failure Clinics, 2015, 11, 379-405.	1.0	26
771	Rationale and design of the Aquapheresis Versus Intravenous Diuretics and Hospitalization for Heart Failure (AVOID-HF) trial. American Heart Journal, 2015, 170, 471-482.	1.2	26
772	Resting Heart Rate and Risk of Incident Heart Failure: Three Prospective Cohort Studies and a Systematic Metaâ€Analysis. Journal of the American Heart Association, 2015, 4, e001364.	1.6	51
773	<scp>REPORTâ€HF</scp> : the unique blend of global heart failure registry and longitudinal cohort study. European Journal of Heart Failure, 2015, 17, 472-474.	2.9	3
774	Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study. Nephrology Dialysis Transplantation, 2015, 30, 829-835.	0.4	59

#	Article	IF	Citations
775	Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research: Implementing the patient-driven research paradigm to aid decision making in stroke care. American Heart Journal, 2015, 170, 36-45.e11.	1.2	49
776	Heart Failure Management in Skilled Nursing Facilities. Journal of Cardiac Failure, 2015, 21, 263-299.	0.7	30
777	Improving cardiovascular clinical trials conduct in the United States: Recommendation from clinicians, researchers, sponsors, and regulators. American Heart Journal, 2015, 169, 305-314.	1.2	20
778	Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study. American Heart Journal, 2015, 170, 62-69.	1.2	111
779	Reply. JACC: Heart Failure, 2015, 3, 269-270.	1.9	0
780	Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations. Heart Failure Reviews, 2015, 20, 393-400.	1.7	3
781	Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation—Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal, 2015, 169, 647-654.e2.	1.2	202
782	Drip and Ship Thrombolytic Therapy for Acute Ischemic Stroke. Stroke, 2015, 46, 732-739.	1.0	96
783	Regional Variation in the Incidence and Outcomes of In-Hospital Cardiac Arrest in the United States. Circulation, 2015, 131, 1415-1425.	1.6	118
784	Trends in Management and Outcomes of ST-Elevation Myocardial Infarction in Patients With End-Stage Renal Disease in the United States. American Journal of Cardiology, 2015, 115, 1033-1041.	0.7	28
785	Outcomes in Mild Acute Ischemic Stroke Treated With Intravenous Thrombolysis. JAMA Neurology, 2015, 72, 423.	4.5	97
786	Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. American Heart Journal, 2015, 170, 141-148.e1.	1.2	211
787	Heart rate is associated with progression of atrial fibrillation, independent of rhythm. Heart, 2015, 101, 894-899.	1.2	52
788	Quality of Care and Ischemic Stroke Risk After Hospitalization for Transient Ischemic Attack. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S117-S124.	0.9	15
789	Patient Characteristics and Outcomes After Hemorrhagic Stroke in Pregnancy. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S170-8.	0.9	36
790	Smoking Paradox in Patients Hospitalized With Coronary Artery Disease or Acute Ischemic Stroke. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S73-80.	0.9	28
791	ACC/AHA/STS Statement on the Future of Registries and the Performance Measurement Enterprise. Journal of the American College of Cardiology, 2015, 66, 2230-2245.	1.2	95
792	Clinical characteristics and in hospital outcomes of heart transplant recipients with allograft vasculopathy undergoing percutaneous coronary intervention: Insights from the National Cardiovascular Data Registry. American Heart Journal, 2015, 170, 1086-1091.	1.2	15

#	Article	IF	Citations
793	Temporal Trends and Sex Differences inÂRevascularization and Outcomes of ST-Segment Elevation Myocardial Infarction in Younger Adults in the UnitedÂStates. Journal of the American College of Cardiology, 2015, 66, 1961-1972.	1.2	196
794	Utility of Socioeconomic Status in Predicting 30-Day Outcomes After Heart Failure Hospitalization. Circulation: Heart Failure, 2015, 8, 473-480.	1.6	55
795	Association of BNP and Troponin Levels with Outcome among Cardiac Resynchronization Therapy Recipients. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 581-590.	0.5	15
796	The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. European Heart Journal, 2015, 36, ehv476.	1.0	316
797	2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials. Journal of Nuclear Cardiology, 2015, 22, 1041-1144.	1.4	41
798	Characteristics, Treatments, and Outcomes of Hospitalized Heart Failure Patients Stratified by Etiologies of Cardiomyopathy. JACC: Heart Failure, 2015, 3, 906-916.	1.9	54
799	Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures. Circulation, 2015, 132, 1347-1353.	1.6	81
800	Temporal Trends and Factors Associated With Cardiac Rehabilitation Referral Among Patients Hospitalized With HeartÂFailure. Journal of the American College of Cardiology, 2015, 66, 917-926.	1.2	142
801	"Targeting the Heart―in Heart Failure. JACC: Heart Failure, 2015, 3, 661-669.	1.9	50
802	Discharge Hospice Referral and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries Hospitalized for Heart Failure. Circulation: Heart Failure, 2015, 8, 733-740.	1.6	30
803	Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBITâ€AF). Journal of the American Heart Association, 2015, 4, e002031.	1.6	41
804	Team-based Care for Heart Failure. Heart Failure Clinics, 2015, 11, xi-xii.	1.0	2
805	Temporal Trends for Secondary Prevention Measures Among Patients Hospitalized with Coronary Artery Disease. American Journal of Medicine, 2015, 128, 426.e1-426.e9.	0.6	31
806	Impact of Cardiorespiratory Fitness on the Obesity Paradox in Patients With Systolic Heart Failure. American Journal of Cardiology, 2015, 115, 209-213.	0.7	74
807	Targeted versus standard feedback: Results from a Randomized Quality Improvement Trial. American Heart Journal, 2015, 169, 132-141.e2.	1.2	9
808	Relation of Dyspnea Severity on Admission for Acute Heart Failure With Outcomes and Costs. American Journal of Cardiology, 2015, 115, 75-81.	0.7	35
809	Reply. American Journal of Cardiology, 2015, 115, 156.	0.7	0
810	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directionsâ€"A Consensus Document from the <scp>SAEM</scp>   <scp>HFSA</scp> Acute Heart Failure Working Group. Academic Emergency Medicine, 2015, 22, 94-112.	0.8	41

#	Article	IF	Citations
811	Concomitant Diabetes Mellitus and Heart Failure. Current Problems in Cardiology, 2015, 40, 7-43.	1.1	75
812	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions. A Consensus Document From the Society for Academic Emergency Medicine/Heart Failure Society of America Acute Heart Failure Working Group. Journal of Cardiac Failure, 2015, 21, 27-43.	0.7	73
813	Water and Sodium in Heart Failure: A Spotlight on Congestion. Heart Failure Reviews, 2015, 20, 13-24.	1.7	34
814	Gaps in the Heart Failure Guidelines. Cardiac Failure Review, 2015, 1, 50.	1.2	1
815	Action Potential-Evoked Calcium Release Is Impaired in Single Skeletal Muscle Fibers from Heart Failure Patients. PLoS ONE, 2014, 9, e109309.	1.1	4
816	ACC/AHA/AACVPR/AAFP/ANA Concepts for Clinician–Patient Shared Accountability in Performance Measures. Circulation, 2014, 130, 1984-1994.	1.6	26
817	Stroke Outcomes Measures Must Be Appropriately Risk Adjusted to Ensure Quality Care of Patients. Stroke, 2014, 45, 1589-1601.	1.0	54
818	Quality of Care and Outcomes for In-Hospital Ischemic Stroke. Stroke, 2014, 45, 231-238.	1.0	87
819	Inâ€Hospital Worsening Heart Failure and Associations With Mortality, Readmission, and Healthcare Utilization. Journal of the American Heart Association, 2014, 3, .	1.6	48
820	Clinical Effectiveness of Cardiac Resynchronization Therapy Versus Medical Therapy Alone Among Patients With Heart Failure. Circulation: Heart Failure, 2014, 7, 926-934.	1.6	20
821	2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. Circulation, 2014, 130, 1749-1767.	1.6	685
822	Trends in Incidence, Management, and Outcomes of Cardiogenic Shock Complicating STâ€Elevation Myocardial Infarction in the United States. Journal of the American Heart Association, 2014, 3, e000590.	1.6	438
823	Incident heart failure in relation to vascular disease: Insights from the Health, Aging, and Body Composition Study. European Journal of Heart Failure, 2014, 16, 526-534.	2.9	18
824	Regional Variation Across the United States in Management and Outcomes of ⟨scp⟩ST⟨/scp⟩â€Elevation Myocardial Infarction: Analysis of the 2003 to 2010 Nationwide Inpatient Sample Database. Clinical Cardiology, 2014, 37, 204-212.	0.7	23
825	Nonâ€5Tâ€Elevation Myocardial Infarction in the United States: Contemporary Trends in Incidence, Utilization of the Early Invasive Strategy, and Inâ€Hospital Outcomes. Journal of the American Heart Association, 2014, 3, .	1.6	78
826	Quality of Care for Patients With Acute Coronary Syndromes as a Function of Hospital Revascularization Capability: Insights From Get With The Guidelinesâ€≺scp>CAD. Clinical Cardiology, 2014, 37, 285-292.	0.7	16
827	Transient and persistent worsening renal function during hospitalization for acute heart failure. American Heart Journal, 2014, 168, 891-900.	1.2	36
828	Hemoconcentration-guided Diuresis in HeartÂFailure. American Journal of Medicine, 2014, 127, 1154-1159.	0.6	43

#	Article	IF	Citations
829	Response to Letter Regarding Article, "Four-Variable Risk Model in Men and Women With Heart Failure― Circulation: Heart Failure, 2014, 7, 381-381.	1.6	0
830	Strategies to Reduce Heart Failure Readmissionsâ€"Reply. JAMA - Journal of the American Medical Association, 2014, 311, 1160.	3.8	1
831	Cerebral Blood Flow Velocity and Vasomotor Reactivity During Autonomic Challenges in Heart Failure. Nursing Research, 2014, 63, 194-202.	0.8	8
832	Four-Variable Risk Model in Men and Women With Heart Failure. Circulation: Heart Failure, 2014, 7, 88-95.	1.6	43
833	Short―and Longâ€ŧerm Rehospitalization and Mortality for Heart Failure in 4 Racial/Ethnic Populations. Journal of the American Heart Association, 2014, 3, e001134.	1.6	67
834	Hospital Case Volume Is Associated With Mortality in Patients Hospitalized With Subarachnoid Hemorrhage. Neurosurgery, 2014, 75, 500-508.	0.6	36
835	Development and Initial Testing of the Stroke Rapid-Treatment Readiness Tool. Journal of Neuroscience Nursing, 2014, 46, 267-273.	0.7	5
836	Representativeness of RELAX-AHF Clinical Trial Population in Acute Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 259-268.	0.9	37
837	Temporal Trends in Incidence and Outcomes of Peripartum Cardiomyopathy in the United States: A Nationwide Populationâ€Based Study. Journal of the American Heart Association, 2014, 3, e001056.	1.6	227
838	Orthostatic Hypotension and Incident Heart Failure in Community-Dwelling Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69A, 223-230.	1.7	33
839	Impact of an Expanded Hospital Recognition Program for Heart Failure Quality of Care. Journal of the American Heart Association, 2014, 3, e000950.	1.6	11
840	Patterns of Care Quality and Prognosis Among Hospitalized Ischemic Stroke Patients With Chronic Kidney Disease. Journal of the American Heart Association, 2014, 3, e000905.	1.6	31
841	Door-to-Needle Times for Tissue Plasminogen Activator Administration and Clinical Outcomes in Acute Ischemic Stroke Before and After a Quality Improvement Initiative. JAMA - Journal of the American Medical Association, 2014, 311, 1632.	3.8	469
842	Association Between Prophylactic Implantable Cardioverter-Defibrillators and Survival in Patients With Left Ventricular Ejection Fraction Between 30% and 35%. JAMA - Journal of the American Medical Association, 2014, 311, 2209.	3.8	35
843	Racial/Ethnic Differences in Process of Care and Outcomes Among Patients Hospitalized With Intracerebral Hemorrhage. Stroke, 2014, 45, 3243-3250.	1.0	35
844	ACC/AHA 2013 Methodology for Developing Clinical Data Standards: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. Circulation, 2014, 129, 2346-2357.	1.6	16
845	ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures. Circulation, 2014, 129, 2329-2345.	1.6	329
846	Get With The Guidelines AFIB. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 770-777.	0.9	45

#	Article	IF	Citations
847	Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. Nephrology Dialysis Transplantation, 2014, 29, 1554-1562.	0.4	84
848	Clinical Effectiveness of Cardiac Resynchronization and Implantable Cardioverter-Defibrillator Therapy in Men and Women With Heart Failure. Circulation: Heart Failure, 2014, 7, 146-153.	1.6	39
849	Impact of Time of Presentation on Process Performance and Outcomes in ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 656-663.	0.9	26
850	Clinical Commentary on "Certain Uncertainty: Life After Stroke From the Patient's Perspective― Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 970-970.	0.9	14
851	Venous Thromboembolism in the Get With The Guidelines-Stroke Acute Ischemic Stroke Population: Incidence and Patterns of Prophylaxis. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 123-129.	0.7	31
852	Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack. American Journal of Medicine, 2014, 127, 728-738.	0.6	25
853	Beta-blockers in older patients with heart failure and preserved ejection fraction: Class, dosage, and outcomes. International Journal of Cardiology, 2014, 173, 393-401.	0.8	45
854	ACC/AHA 2013 Methodology for Developing Clinical Data Standards. Journal of the American College of Cardiology, 2014, 63, 2323-2334.	1.2	24
855	Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. American Heart Journal, 2014, 167, 601-609.e1.	1.2	135
856	Coronary Artery Disease in Patients with Heart Failure: Incidental, Coincidental, or a Target for Therapy?. American Journal of Medicine, 2014, 127, 574-578.	0.6	2
857	Adherence and Persistence in the Use of Warfarin After Hospital Discharge Among Patients With Heart Failure and Atrial Fibrillation. Journal of Cardiac Failure, 2014, 20, 23-30.	0.7	20
858	Clevidipine in acute heart failure: Results of the A Study of Blood Pressure Control in Acute Heart Failure—A Pilot Study (PRONTO). American Heart Journal, 2014, 167, 529-536.	1.2	80
859	Gender Bias Trends in Implantable Cardioverter-Defibrillator Therapy. Current Cardiovascular Risk Reports, 2014, 8, 1.	0.8	2
860	Therapeutic Targets in Heart Failure. Journal of the American College of Cardiology, 2014, 63, 2188-2198.	1.2	124
861	The Global Health and Economic Burden ofÂHospitalizations for Heart Failure. Journal of the American College of Cardiology, 2014, 63, 1123-1133.	1.2	1,640
862	Developing Therapies for Heart Failure WithÂPreservedÂEjection Fraction. JACC: Heart Failure, 2014, 2, 97-112.	1.9	267
863	Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation. Circulation, 2014, 129, 2005-2012.	1.6	73
864	Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal, 2014, 167, 735-742.e2.	1.2	120

#	Article	IF	CITATIONS
865	Prescribing warfarin at discharge for heart failure patients: Findings from the Get With The Guidelines-Heart Failure Registry. International Journal of Cardiology, 2014, 172, e322-e323.	0.8	2
866	An Effective Approach to High Blood Pressure Control. Journal of the American College of Cardiology, 2014, 63, 1230-1238.	1.2	174
867	Brain metabolites in autonomic regulatory insular sites in heart failure. Journal of the Neurological Sciences, 2014, 346, 271-275.	0.3	16
868	An Effective Approach to High Blood Pressure Control. Hypertension, 2014, 63, 878-885.	1.3	251
869	Diabetes Medications and Heart Failure. Circulation, 2014, 130, 1565-1567.	1.6	22
870	ACC/AHA/AACVPR/AAFP/ANA Concepts for Clinician–Patient Shared Accountability in Performance Measures. Journal of the American College of Cardiology, 2014, 64, 2133-2145.	1.2	15
871	Authors' Reply. Clinical Cardiology, 2014, 37, 323-323.	0.7	0
872	Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. American Heart Journal, 2014, 168, 721-730.e3.	1.2	289
873	Guideline-Directed Low-Density Lipoprotein Management in High-Risk Patients With Ischemic Stroke. Stroke, 2014, 45, 3343-3351.	1.0	28
874	Catheter ablation of postinfarction ventricular tachycardia: Ten-year trends in utilization, in-hospital complications, and in-hospital mortality in the United States. Heart Rhythm, 2014, 11, 2056-2063.	0.3	120
875	Strategies Used by Hospitals to Improve Speed of Tissue-Type Plasminogen Activator Treatment in Acute Ischemic Stroke. Stroke, 2014, 45, 1387-1395.	1.0	81
876	Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal, 2014, 168, 487-494.	1.2	107
877	Associations Between Anticoagulation Therapy and Risks of Mortality and Readmission Among Patients With Heart Failure and Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 670-679.	0.9	5
878	Hospitalized Hemorrhagic Stroke Patients with Renal Insufficiency: Clinical Characteristics, Care Patterns, and Outcomes. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 2265-2273.	0.7	26
879	Calcium Channel Blockers and Outcomes in Older Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 945-952.	1.6	32
880	Clinical Effectiveness of CRT and ICDÂTherapy in Heart Failure Patients byÂRacial/Ethnic Classification. Journal of the American College of Cardiology, 2014, 64, 797-807.	1.2	32
881	Lack of Association Between Spironolactone Use and 30-Day All-Cause Readmission In Hospitalized Medicare Beneficiaries With Systolic Heart Failure Eligible for Spironolactone Therapy. Journal of Cardiac Failure, 2014, 20, S58.	0.7	1
882	Mineralocorticoid Receptor Antagonist Use in Hospitalized Patients With Heart Failure, Reduced Ejection Fraction, and Diabetes Mellitus (from the EVEREST Trial). American Journal of Cardiology, 2014, 114, 743-750.	0.7	8

#	Article	IF	Citations
883	Cerebral Impairment in Heart Failure. Current Heart Failure Reports, 2014, 11, 321-329.	1.3	24
884	2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. Journal of the American College of Cardiology, 2014, 64, 1929-1949.	1.2	656
885	Chronic Kidney Disease and Bleeding Complications After Intravenous Thrombolytic Therapy for Acute Ischemic Stroke. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 929-935.	0.9	35
886	Racial differences in mortality in patients with advanced systolic heart failure: Potential role of right ventricular ejection fraction. International Journal of Cardiology, 2014, 177, 255-260.	0.8	1
887	Sources of Hospital-Level Variation in Major Bleeding Among Patients With Non–ST-Segment Elevation Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 236-243.	0.9	7
888	Impact of Atrial Fibrillation and Heart Failure, Independent of Each Other and in Combination, on Mortality in Community-Dwelling Older Adults. American Journal of Cardiology, 2014, 114, 909-913.	0.7	24
889	Permanent pacemaker utilization in older patients with syncope and carotid sinus syndrome. International Journal of Cardiology, 2014, 176, 1137-1138.	0.8	O
890	Hospital Variation in Intravenous Inotrope Use for Patients Hospitalized With Heart Failure. Circulation: Heart Failure, 2014, 7, 251-260.	1.6	28
891	Race/Ethnic Differences in the Risk of Hemorrhagic Complications Among Patients With Ischemic Stroke Receiving Thrombolytic Therapy. Stroke, 2014, 45, 2263-2269.	1.0	81
892	ACC/AHA Statement on Cost/Value Methodology in ClinicalÂPractice Guidelines and Performance Measures. Journal of the American College of Cardiology, 2014, 63, 2304-2322.	1.2	353
893	Obesity and the Obesity Paradox in Heart Failure. Progress in Cardiovascular Diseases, 2014, 56, 409-414.	1.6	193
894	Insurance Status and Outcome after Intracerebral Hemorrhage: Findings from Get With The Guidelines-Stroke. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 283-292.	0.7	31
895	Early Post-Discharge Bleeding and Antiplatelet Therapy Discontinuation Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2014, 63, 1700-1702.	1.2	10
896	Antigen carbohydrate 125 and creatinine on admission for prediction of renal function response following loop diuretic administration in acute heart failure. International Journal of Cardiology, 2014, 174, 516-523.	0.8	30
897	Outcomes registry for better informed treatment of atrial fibrillation II: Rationale and design of the ORBIT-AF II registry. American Heart Journal, 2014, 168, 160-167.	1.2	62
898	Temporal trends in clinical characteristics of patients without known cardiovascular disease with a first episode of myocardial infarction. American Heart Journal, 2014, 167, 480-488.e1.	1.2	18
899	Digoxin Use and Lower 30-day All-cause Readmission for Medicare Beneficiaries Hospitalized for Heart Failure. American Journal of Medicine, 2014, 127, 61-70.	0.6	50
900	Outcomes of Medicare Beneficiaries With Heart Failure and Atrial Fibrillation. JACC: Heart Failure, 2014, 2, 41-48.	1.9	52

#	Article	IF	CITATIONS
901	The Reply. American Journal of Medicine, 2014, 127, e13.	0.6	0
902	Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction. American Heart Journal, 2014, 167, 369-375.e2.	1.2	57
903	Spironolactone Use and Higher Hospital Readmission for Medicare Beneficiaries With Heart Failure, Left Ventricular Ejection Fraction & Lt;45%, and Estimated Glomerular Filtration Rate & Lt;45 ml/min/1.73Âm2. American Journal of Cardiology, 2014, 114, 79-82.	0.7	22
904	Relation of Smoking Status to Outcomes After Cardiopulmonary Resuscitation for In-Hospital Cardiac Arrest. American Journal of Cardiology, 2014, 114, 169-174.	0.7	30
905	Use of Renin–Angiotensin System Blockers in Acute Coronary Syndromes. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 227-235.	0.9	10
906	Temporal trends in the use of intraaortic balloon pump associated with percutaneous coronary intervention in the United States, 1998-2008. American Heart Journal, 2014, 168, 363-373.e12.	1.2	17
907	Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries. American Heart Journal, 2014, 168, 142-149.	1.2	34
908	Management and Outcomes of ST-Elevation Myocardial Infarction in Nursing Home Versus Community-Dwelling Older Patients: A Propensity Matched Study. Journal of the American Medical Directors Association, 2014, 15, 593-599.	1.2	11
909	Digoxin and 30-day All-cause Hospital Admission in Older Patients with Chronic Diastolic Heart Failure. American Journal of Medicine, 2014, 127, 132-139.	0.6	19
910	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Failure Reviews, 2014, 19, 135-152.	1.7	48
911	Comparative Effectiveness of Cardiac Resynchronization Therapy With an Implantable Cardioverter-Defibrillator Versus Defibrillator Therapy Alone. Annals of Internal Medicine, 2014, 160, 603.	2.0	27
912	Association between inflammatory biomarkers and adiposity in obese patients with heart failure and metabolic syndrome. Experimental and Therapeutic Medicine, 2014, 8, 181-186.	0.8	13
913	Opportunities for Improving Global Cardiovascular Quality of Care and Outcomes. Journal of the American Heart Association, 2014, 3, e001432.	1.6	0
914	Gaps in the Heart Failure Guidelines. European Cardiology Review, 2014, 9, 104.	0.7	2
915	Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management. Reviews in Cardiovascular Medicine, 2014, 15, 11-23.	0.5	62
916	Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management. Reviews in Cardiovascular Medicine, 2014, 15, 11-23.	0.5	50
917	Abstract 207: Hospital Case Volume is Associated With Mortality in Patients Hospitalized With Subarachnoid Hemorrhage. Stroke, 2014, 45, .	1.0	0
918	2013 ACCF/AHA Guideline for the Management ofÂHeartÂFailure: Executive Summary. Journal of the American College of Cardiology, 2013, 62, 1495-1539.	1.2	276

#	Article	IF	CITATIONS
919	QRS Duration, Bundle-Branch Block Morphology, and Outcomes Among Older Patients With Heart Failure Receiving Cardiac Resynchronization Therapy. JAMA - Journal of the American Medical Association, 2013, 310, 617.	3.8	86
920	Heart failure clinical trials: how do we define success?. Nature Reviews Cardiology, 2013, 10, 492-494.	6.1	2
921	Intact skeletal muscle mitochondrial enzyme activity but diminished exercise capacity in advanced heart failure patients on optimal medical and device therapy. Clinical Research in Cardiology, 2013, 102, 547-554.	1.5	8
922	Use of Evidence-based Cardiac Prevention Therapy Among Outpatients with Atrial Fibrillation. American Journal of Medicine, 2013, 126, 625-632.e1.	0.6	34
923	Rehospitalization for Heart Failure. Journal of the American College of Cardiology, 2013, 61, 391-403.	1.2	582
924	Digoxin Reduces 30-day All-cause Hospital Admission in Older Patients with Chronic Systolic Heart Failure. American Journal of Medicine, 2013, 126, 701-708.	0.6	54
925	Early Invasive Versus Initial Conservative Treatment Strategies in Octogenarians with UA/NSTEMI. American Journal of Medicine, 2013, 126, 1076-1083.e1.	0.6	37
926	Performance measures to promote quality improvement in sudden cardiac arrest prevention and treatment. American Heart Journal, 2013, 165, 862-868.	1.2	11
927	Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. American Heart Journal, 2013, 165, 979-986.e1.	1.2	74
928	Clinical Effectiveness of Anticoagulation Therapy Among Older Patients With Heart Failure and Without Atrial Fibrillation: Findings From the ADHERE Registry Linked to Medicare Claims. Journal of Cardiac Failure, 2013, 19, 401-407.	0.7	7
929	Association of Beta-Blocker Use and Selectivity With Outcomes in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease (from OPTIMIZE-HF). American Journal of Cardiology, 2013, 111, 582-587.	0.7	71
930	2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation, 2013, 128, e240-327.	1.6	2,335
931	Use of aldosterone antagonists at discharge after myocardial infarction: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry–Get with the Guidelines (GWTG). American Heart Journal, 2013, 166, 709-715.	1.2	26
932	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. Heart Failure Reviews, 2013, 18, 107-122.	1.7	51
933	Rate-control versus Rhythm-control Strategies and Outcomes in Septuagenarians with Atrial Fibrillation. American Journal of Medicine, 2013, 126, 887-893.	0.6	42
934	Rate versus rhythm control for management of atrial fibrillation in clinical practice: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. American Heart Journal, 2013, 165, 622-629.	1.2	61
935	Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. European Heart Journal, 2013, 34, 1489-1497.	1.0	175
936	Nitrate Therapy for Heart Failure. JACC: Heart Failure, 2013, 1, 183-191.	1.9	28

#	Article	IF	Citations
937	Prognostic implications of renal dysfunction in patients hospitalized with heart failure: data from the last decade of clinical investigations. Heart Failure Reviews, 2013, 18, 167-176.	1.7	24
938	Renin-Angiotensin Inhibition in Diastolic Heart Failure and Chronic Kidney Disease. American Journal of Medicine, 2013, 126, 150-161.	0.6	29
939	Progress or lack of progress in hospitalized heart failure. Expert Review of Cardiovascular Therapy, 2013, 11, 1079-1083.	0.6	3
940	Design and rationale of studies of neurohormonal blockade and outcomes in diastolic heart failure using OPTIMIZE-HF registry linked to Medicare data. International Journal of Cardiology, 2013, 166, 230-235.	0.8	29
941	Risk-Standardizing Survival for In-Hospital Cardiac Arrest to Facilitate Hospital Comparisons. Journal of the American College of Cardiology, 2013, 62, 601-609.	1.2	87
942	Trends in Acute Kidney Injury and Outcomes After Early Percutaneous Coronary Intervention in Patients ≥75 Years of Age With Acute Myocardial Infarction. American Journal of Cardiology, 2013, 112, 1279-1286.	0.7	24
943	Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: Findings from the Get With The Guideline–Heart Failure Registry. American Heart Journal, 2013, 166, 1063-1071.e3.	1.2	55
944	Angiotensin-converting Enzyme Inhibitors and Outcomes in Heart Failure and Preserved Ejection Fraction. American Journal of Medicine, 2013, 126, 401-410.	0.6	33
945	Impact of Atrial Fibrillation on Outcomes in Heart Failure. Heart Failure Clinics, 2013, 9, 437-449.	1.0	2
946	Pro-HEART $\hat{a}\in$ " A randomized clinical trial to test the effectiveness of a high protein diet targeting obese individuals with heart failure: Rationale, design and baseline characteristics. Contemporary Clinical Trials, 2013, 36, 371-381.	0.8	15
947	Cardiovascular Care Facts. Journal of the American College of Cardiology, 2013, 62, 1931-1947.	1.2	135
948	Are we targeting the right metric for heart failure? Comparison of hospital 30-day readmission rates and total episode of care inpatient days. American Heart Journal, 2013, 165, 987-994.e1.	1.2	46
949	The Potential Role of Nonpharmacologic Electrophysiology-Based Interventions in Improving Outcomes in Patients Hospitalized for Heart Failure. Heart Failure Clinics, 2013, 9, 331-343.	1.0	0
950	Epidemiology of Hospitalized Heart Failure. Heart Failure Clinics, 2013, 9, 271-276.	1.0	13
951	Prevention of heart failure in older adults may require higher levels of physical activity than needed for other cardiovascular events. International Journal of Cardiology, 2013, 168, 1905-1909.	0.8	34
952	Associations Between Use of the Hospitalist Model and Quality of Care and Outcomes of Older Patients Hospitalized for Heart Failure. JACC: Heart Failure, 2013, 1, 445-453.	1.9	30
953	Forecasting the Impact of Heart Failure in the United States. Circulation: Heart Failure, 2013, 6, 606-619.	1.6	2,206
954	Dysphagia Screening and Hospital-acquired Pneumonia in Patients with Acute Ischemic Stroke: Findings from Get with the Guidelines–Stroke. Journal of Stroke and Cerebrovascular Diseases, 2013, 22, e301-e309.	0.7	44

#	Article	IF	CITATIONS
955	Measuring heart failure care by 30-day readmission: Rethinking the quality of outcome measures. American Heart Journal, 2013, 166, 605-610.e2.	1.2	8
956	Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: Insights from the SOLVD Treatment trial. International Journal of Cardiology, 2013, 167, 151-156.	0.8	58
957	Visual Assessment of Brain Magnetic Resonance Imaging Detects Injury to Cognitive Regulatory Sites in Patients With Heart Failure. Journal of Cardiac Failure, 2013, 19, 94-100.	0.7	38
958	Reduced right ventricular ejection fraction and increased mortality in chronic systolic heart failure patients receiving beta-blockers: Insights from the BEST trial. International Journal of Cardiology, 2013, 163, 61-67.	0.8	16
959	Relationship Between Clinical Trial Site Enrollment With Participant Characteristics, Protocol Completion, and Outcomes. Journal of the American College of Cardiology, 2013, 61, 571-579.	1.2	58
960	ACCF/AHA Clinical Practice Guideline Methodology Summit Report. Journal of the American College of Cardiology, 2013, 61, 213-265.	1.2	119
961	Reply. Journal of the American College of Cardiology, 2013, 62, 166-167.	1.2	0
962	Racial/Ethnic Differences in B-Type Natriuretic Peptide Levels and Their Association With Care and Outcomes Among Patients Hospitalized With Heart Failure. JACC: Heart Failure, 2013, 1, 345-352.	1.9	32
963	Incremental Cost-Effectiveness of Guideline-Directed Medical Therapies for Heart Failure. Journal of the American College of Cardiology, 2013, 61, 1440-1446.	1.2	38
964	Validated, Electronic Health Record Deployable Prediction Models for Assessing Patient Risk of 30-Day Rehospitalization and Mortality in Older Heart Failure Patients. JACC: Heart Failure, 2013, 1, 245-251.	1.9	95
965	Prediabetes is not an independent risk factor for incident heart failure, other cardiovascular events or mortality in older adults: Findings from a population-based cohort study. International Journal of Cardiology, 2013, 168, 3616-3622.	0.8	44
966	Drug Therapy to Reduce EarlyÂReadmissionÂRiskÂin Heart Failure. JACC: Heart Failure, 2013, 1, 361-364.	1.9	10
967	Heart Failure is Associated With Impaired Anti-Inflammatory and Antioxidant Properties of High-Density Lipoproteins. American Journal of Cardiology, 2013, 112, 1770-1777.	0.7	34
968	Temporal Trends and Predictors in the Use of Aldosterone Antagonists Post-Acute Myocardial Infarction. Journal of the American College of Cardiology, 2013, 61, 35-40.	1.2	46
969	Early intravenous heart failure therapy and outcomes among older patients hospitalized for acute decompensated heart failure: Findings from the Acute Decompensated Heart Failure Registry Emergency Module (ADHERE-EM). American Heart Journal, 2013, 166, 349-356.	1.2	49
970	Reply. Journal of the American College of Cardiology, 2013, 61, 2491.	1.2	1
971	Is Hospital Admission for Heart Failure Really Necessary?. Journal of the American College of Cardiology, 2013, 61, 121-126.	1.2	120
972	Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes. Heart Failure Clinics, 2013, 9, 285-290.	1.0	37

#	Article	IF	Citations
973	Prognostic Significance of Serum Total Cholesterol and Triglyceride Levels in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). American Journal of Cardiology, 2013, 111, 574-581.	0.7	54
974	Relation of Serum Magnesium Levels and Postdischarge Outcomes in Patients Hospitalized for Heart Failure (from the EVEREST Trial). American Journal of Cardiology, 2013, 112, 1763-1769.	0.7	8
975	Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation. American Heart Journal, 2013, 165, 567-574.e6.	1.2	54
976	Anticoagulation in heart failure: current status and future direction. Heart Failure Reviews, 2013, 18, 797-813.	1.7	28
977	2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery Disease. Journal of the American College of Cardiology, 2013, 61, 992-1025.	1.2	148
978	Aldosterone Antagonists and Outcomes in Real-World Older Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2013, 1, 40-47.	1.9	38
979	Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nature Reviews Nephrology, 2013, 9, 99-111.	4.1	145
980	2013 ACCF/AHA Guideline for the Management of HeartÂFailure. Journal of the American College of Cardiology, 2013, 62, e147-e239.	1.2	7,017
981	Strategies and Opportunities for Drug Development in Heart Failure. JAMA - Journal of the American Medical Association, 2013, 309, 1593.	3.8	40
982	Death and Rehospitalization after Transient Ischemic Attack or Acute Ischemic Stroke: One-year Outcomes from the Adherence Evaluation of Acute Ischemic Stroke–Longitudinal Registry. Journal of Stroke and Cerebrovascular Diseases, 2013, 22, e181-e188.	0.7	24
983	Comparative Effectiveness Research in Heart Failure Therapies. Heart Failure Clinics, 2013, 9, 79-92.	1.0	6
984	Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure. JAMA - Journal of the American Medical Association, 2013, 309, 1125.	3.8	297
985	Predictors of Adherence to Performance Measures in Patients with Acute Myocardial Infarction. American Journal of Medicine, 2013, 126, 74.e1-74.e9.	0.6	47
986	Assessing Stroke Patients for Rehabilitation During the Acute Hospitalization: Findings From the Get With The Guidelines–Stroke Program. Archives of Physical Medicine and Rehabilitation, 2013, 94, 38-45.	0.5	40
987	Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Failure Reviews, 2013, 18, 123-134.	1.7	118
988	Use and Associated Risks of Concomitant Aspirin Therapy With Oral Anticoagulation in Patients With Atrial Fibrillation. Circulation, 2013, 128, 721-728.	1.6	132
989	2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery Disease. Circulation, 2013, 127, 1052-1089.	1.6	136
990	Time to Treatment With Intravenous Tissue Plasminogen Activator and Outcome From Acute Ischemic Stroke. JAMA - Journal of the American Medical Association, 2013, 309, 2480.	3.8	662

#	Article	IF	CITATIONS
991	Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. European Heart Journal, 2013, 34, 835-843.	1.0	418
992	Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. European Heart Journal, 2013, 34, 3117-3127.	1.0	53
993	Lipid Profile, Lipid-lowering Medications, and Intracerebral Hemorrhage After tPA in Get With The Guidelines–Stroke. Stroke, 2013, 44, 1354-1359.	1.0	23
994	Global Variation in Quality of Care Among Patients Hospitalized With Acute Heart Failure in an International Trial. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 534-542.	0.9	25
995	ACCF/AHA Clinical Practice Guideline Methodology Summit Report. Circulation, 2013, 127, 268-310.	1.6	101
996	Risks and Benefits of Anticoagulation in Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 461-469.	0.9	78
997	2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery Disease. Critical Pathways in Cardiology, 2013, 12, 65-105.	0.2	23
998	Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines–Stroke Hospitals. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 543-549.	0.9	247
999	Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates?. Circulation: Heart Failure, 2013, 6, 727-732.	1.6	103
1000	Timing and Duration of Interventions in Clinical Trials for Patients With Hospitalized Heart Failure. Circulation: Heart Failure, 2013, 6, 1095-1101.	1.6	18
1001	Comparison of Performance Achievement Award Recognition With Primary Stroke Center Certification for Acute Ischemic Stroke Care. Journal of the American Heart Association, 2013, 2, e000451.	1.6	18
1002	Paradoxical Association of Smoking With Inâ∈Hospital Mortality Among Patients Admitted With Acute Ischemic Stroke. Journal of the American Heart Association, 2013, 2, e000171.	1.6	64
1003	American Heart Association Guide for Improving Cardiovascular Health at the Community Level, 2013 Update. Circulation, 2013, 127, 1730-1753.	1.6	201
1004	Need for Increased Awareness and Evidence-Based Therapies for Patients Hospitalized for Heart Failure. JAMA - Journal of the American Medical Association, 2013, 310, 2035.	3.8	37
1005	Acute Ischemic Stroke and Timing of Treatmentâ€"Reply. JAMA - Journal of the American Medical Association, 2013, 310, 1856.	3.8	1
1006	Racial and Ethnic Differences in Outcomes in Older Patients With Acute Ischemic Stroke. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 284-292.	0.9	67
1007	Use of Hydralazineâ€Isosorbide Dinitrate Combination in African American and Other Race/Ethnic Group Patients With Heart Failure and Reduced Left Ventricular Ejection Fraction. Journal of the American Heart Association, 2013, 2, e000214.	1.6	33
1008	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. Circulation, 2013, 128, 1810-1852.	1.6	2,807

#	Article	IF	Citations
1009	Temporal Trends in Treatment and Outcomes for Advanced Heart Failure With Reduced Ejection Fraction From 1993–2010. Circulation: Heart Failure, 2013, 6, 411-419.	1.6	60
1010	Achievement of Guideline-Concordant Care and In-Hospital Outcomes in Patients With Coronary Artery Disease in Teaching and Nonteaching Hospitals. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 58-65.	0.9	25
1011	Age Differences in the Use of Implantable Cardioverterâ€Defibrillators Among Older Patients Hospitalized with Heart Failure. Journal of Cardiovascular Electrophysiology, 2013, 24, 664-671.	0.8	11
1012	Relationship of Race/Ethnicity With Doorâ€toâ€Balloon Time and Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for ⟨scp⟩ST⟨/scp⟩â€Elevation Myocardial Infarction: Findings From Get With the Guidelines–Coronary Artery Disease. Clinical Cardiology, 2013, 36, 749-756.	0.7	44
1013	Anemia and Associated Clinical Outcomes in Patients With Heart Failure Due to Reduced Left Ventricular Systolic Function. Clinical Cardiology, 2013, 36, 611-620.	0.7	26
1014	Factors Associated with Improvement in Utilization of Cardiac Resynchronization Therapy in Eligible Heart Failure Patients: Findings from IMPROVE HF. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 433-443.	0.5	7
1015	Postdischarge International Normalized Ratio Testing and Longâ€term Clinical Outcomes of Patients With Heart Failure Receiving Warfarin: Findings From the ⟨scp⟩ADHERE⟨ scp⟩ Registry Linked to Medicare Claims. Clinical Cardiology, 2013, 36, 757-765.	0.7	3
1016	Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. Journal of the American Heart Association, 2013, 2, e000535.	1.6	92
1017	Racial Differences in the Prevalence and Outcomes of Atrial Fibrillation Among Patients Hospitalized With Heart Failure. Journal of the American Heart Association, 2013, 2, e000200.	1.6	43
1018	A Risk Score for Inâ€Hospital Death in Patients Admitted With Ischemic or Hemorrhagic Stroke. Journal of the American Heart Association, 2013, 2, e005207.	1.6	73
1019	Patterns of Emergency Medical Services Use and Its Association With Timely Stroke Treatment. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 262-269.	0.9	144
1020	Synthesizing Lessons Learned From Get With The Guidelines. Circulation, 2013, 128, 2447-2460.	1.6	106
1021	Renin-Angiotensin System Antagonists and Mortality in Patients With Heart Failure. JAMA - Journal of the American Medical Association, 2013, 309, 1107.	3.8	0
1022	Comment on "The Relationship Between the C-statistic of a Risk-adjustment Model and the Accuracy of Hospital Report Cards. Medical Care, 2013, 51, 633.	1.1	0
1023	Assessment of the quality of existing patient educational tools focused on sudden cardiac arrest: a systematic evaluation by the Sudden Cardiac Arrest Thought Leadership Alliance. Patient Preference and Adherence, 2013, 7, 361.	0.8	6
1024	Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines-Stroke Hospitals. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 543-549.	0.9	132
1025	Anticoagulation and Clinical Outcomes in Heart Failure Patients With Atrial Fibrillation: Findings From the ADHERE Registry. Journal of Atrial Fibrillation, 2013, 6, 953.	0.5	0
1026	2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS Key Data Elements and Definitions for Peripheral Atherosclerotic Vascular Disease. Circulation, 2012, 125, 395-467.	1.6	55

#	Article	IF	CITATIONS
1027	Incremental Reduction in Risk of Death Associated With Use of Guidelineâ€Recommended Therapies in Patients With Heart Failure: A Nested Caseâ€Control Analysis of IMPROVE HF. Journal of the American Heart Association, 2012, 1, 16-26.	1.6	64
1028	The Authors' reply: Figure 1. Heart, 2012, 98, 91.2-92.	1.2	0
1029	Trends in Use of Implantable Cardioverter-Defibrillator Therapy Among Patients Hospitalized for Heart Failure. Circulation, 2012, 125, 1094-1101.	1.6	124
1030	Modest Increase in Peak VO <sub>2</sub> Is Related to Better Clinical Outcomes in Chronic Heart Failure Patients. Circulation: Heart Failure, 2012, 5, 579-585.	1.6	239
1031	Relationship of National Institutes of Health Stroke Scale to 30â€Day Mortality in Medicare Beneficiaries With Acute Ischemic Stroke. Journal of the American Heart Association, 2012, 1, 42-50.	1.6	116
1032	Dietary Sodium Intake in Heart Failure. Circulation, 2012, 126, 479-485.	1.6	111
1033	Care and Outcomes of Asian-American Acute Myocardial Infarction Patients: Findings From the American Heart Association Get With The Guidelines-Coronary Artery Disease Program. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 126-133.	0.9	28
1034	Presence of Atrial Fibrillation Is Independently Associated With Adverse Outcomes in Patients Hospitalized With Heart Failure. Circulation: Heart Failure, 2012, 5, 191-201.	1.6	106
1035	Guideline Adherence After ST-Segment Elevation Versus Non-ST Segment Elevation Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 654-661.	0.9	42
1036	Get With The Guidelines Program Participation, Process of Care, and Outcome for Medicare Patients Hospitalized With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 37-43.	0.9	115
1037	Patterns, Predictors, Variations, and Temporal Trends in Emergency Medical Service Hospital Prenotification for Acute Ischemic Stroke. Journal of the American Heart Association, 2012, 1, e002345.	1.6	36
1038	An evidence-based score to detect prevalent peripheral artery disease (PAD). Vascular Medicine, 2012, 17, 342-351.	0.8	22
1039	Targeting myocardial substrate metabolism in heart failure: potential for new therapies. European Journal of Heart Failure, 2012, 14, 120-129.	2.9	130
1040	Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study. European Journal of Heart Failure, 2012, 14, 1179-1188.	2.9	41
1041	Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization for acute heart failure. European Journal of Heart Failure, 2012, 14, 974-984.	2.9	31
1042	Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZEâ€HF. European Journal of Heart Failure, 2012, 14, 395-403.	2.9	85
1043	Use of Tissue-Type Plasminogen Activator Before and After Publication of the European Cooperative Acute Stroke Study III in Get With The Guidelines-Stroke. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 321-326.	0.9	38
1044	National Survey of Hospital Strategies to Reduce Heart Failure Readmissions. Circulation: Heart Failure, 2012, 5, 680-687.	1.6	97

#	Article	IF	Citations
1045	Comparison of 30-Day Mortality Models for Profiling Hospital Performance in Acute Ischemic Stroke With vs Without Adjustment for Stroke Severity. JAMA - Journal of the American Medical Association, 2012, 308, 257-64.	3.8	153
1046	Trends in Clinical, Demographic, and Biochemical Characteristics of Patients With Acute Myocardial Infarction From 2003 to 2008: A Report From the American Heart Association Get With The Guidelines Coronary Artery Disease Program. Journal of the American Heart Association, 2012, 1, e001206.	1.6	31
1047	Care and Outcomes of Hispanic Patients Admitted With Heart Failure With Preserved or Reduced Ejection Fraction. Circulation: Heart Failure, 2012, 5, 167-175.	1.6	48
1048	Emergency Medical Service Hospital Prenotification Is Associated With Improved Evaluation and Treatment of Acute Ischemic Stroke. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 514-522.	0.9	192
1049	Representativeness of the Get With The Guidelines–Stroke Registry. Stroke, 2012, 43, 44-49.	1.0	108
1050	Stroke Quality Metrics. Stroke, 2012, 43, 155-162.	1.0	44
1051	Times From Symptom Onset to Hospital Arrival in the Get With The Guidelines–Stroke Program 2002 to 2009. Stroke, 2012, 43, 1912-1917.	1.0	136
1052	Race and Improvements in the Use of Guideline-Recommended Therapies for Patients With Heart Failure: Findings From IMPROVE HF. Journal of the National Medical Association, 2012, 104, 287-298.	0.6	8
1053	B-type natriuretic peptide assessment in ambulatory heart failure patients. Journal of Cardiovascular Medicine, 2012, 13, 360-367.	0.6	3
1054	Associations Between Aldosterone Antagonist Therapy and Risks of Mortality and Readmission Among Patients With Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2012, 308, 2097.	3.8	125
1055	Outcomes Associated With Warfarin Use in Older Patients With Heart Failure and Atrial Fibrillation and a Cardiovascular Implantable Electronic Device: Findings From the ADHERE Registry Linked to Medicare Claims. Clinical Cardiology, 2012, 35, 649-657.	0.7	11
1056	Trends in death attributed to heart failure over the past two decades in Europe. European Journal of Heart Failure, 2012, 14, 234-239.	2.9	124
1057	Troponin I in acute decompensated heart failure: insights from the ASCENDâ€HF study. European Journal of Heart Failure, 2012, 14, 1257-1264.	2.9	101
1058	Risk Score for Intracranial Hemorrhage in Patients With Acute Ischemic Stroke Treated With Intravenous Tissue-Type Plasminogen Activator. Stroke, 2012, 43, 2293-2299.	1.0	196
1059	Impairment of activities of daily living and incident heart failure in communityâ€dwelling older adults. European Journal of Heart Failure, 2012, 14, 581-587.	2.9	47
1060	Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction. Circulation, 2012, 126, 65-75.	1.6	681
1061	Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: Findings from IMPROVE HF. American Heart Journal, 2012, 163, 49-56.e2.	1.2	127
1062	Patient and hospital characteristics associated with traditional measures of inpatient quality of care for patients with heart failure. American Heart Journal, 2012, 163, 239-245.e3.	1.2	25

#	Article	IF	CITATIONS
1063	Data quality in the American Heart Association Get With The Guidelines-Stroke (GWTG-Stroke): Results from a National Data Validation Audit. American Heart Journal, 2012, 163, 392-398.e1.	1.2	145
1064	Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction. American Heart Journal, 2012, 163, 430-437.e3.	1.2	89
1065	In response to Nagarajan's letter to the editor "Improvement in ejection fraction—but do not forget the basics, the medications― American Heart Journal, 2012, 163, e29.	1.2	0
1066	International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation. American Heart Journal, 2012, 163, 804-811.	1.2	32
1067	Design and rationale of a retrospective clinical effectiveness study of aldosterone antagonist therapy in patients with heart failure. American Heart Journal, 2012, 163, 946-953.e1.	1.2	3
1068	B-type natriuretic peptide level and postdischarge thrombotic events in older patients hospitalized with heart failure: Insights from the Acute Decompensated Heart Failure National Registry. American Heart Journal, 2012, 163, 994-1001.	1.2	12
1069	Prevalence, Clinical Phenotype, and Outcomes Associated With Normal B-Type Natriuretic Peptide Levels in Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2012, 110, 870-876.	0.7	214
1070	Renin-Angiotensin Inhibition in Systolic Heart Failure and Chronic Kidney Disease. American Journal of Medicine, 2012, 125, 399-410.	0.6	69
1071	Association between smoking and outcomes in older adults with atrial fibrillation. Archives of Gerontology and Geriatrics, 2012, 55, 85-90.	1.4	8
1072	Antigen carbohydrate 125 and brain natriuretic peptide serial measurements for risk stratification following an episode of acute heart failure. International Journal of Cardiology, 2012, 159, 21-28.	0.8	43
1073	Utilization of Hospice and Predicted Mortality Risk Among Older Patients Hospitalized With Heart Failure: Findings From GWTG-HF. Journal of Cardiac Failure, 2012, 18, 471-477.	0.7	21
1074	Use of Bioelectrical Impedance Analysis To Assess Body Composition in Heart Failure Patients. Journal of Cardiac Failure, 2012, 18, S86.	0.7	2
1075	Baseline characteristics, quality of care, and outcomes of younger and older Medicare beneficiaries hospitalized with heart failure: Findings from the Alabama Heart Failure Project. International Journal of Cardiology, 2012, 162, 39-44.	0.8	23
1076	Home Monitoring for Heart Failure Management. Journal of the American College of Cardiology, 2012, 59, 97-104.	1.2	171
1077	ACCF/AHA/AMA-PCPI 2011 Performance Measures for Adults With Heart Failure. Journal of the American College of Cardiology, 2012, 59, 1812-1832.	1.2	59
1078	Age and Gender Differences in Quality of Care and Outcomes for Patients with ST-segment Elevation Myocardial Infarction. American Journal of Medicine, 2012, 125, 1000-1009.	0.6	128
1079	Abnormalities of Calcium Handling Proteins in Skeletal Muscle Mirror Those of the Heart in Humans With Heart Failure: A Shared Mechanism?. Journal of Cardiac Failure, 2012, 18, 724-733.	0.7	27
1080	Impaired Cerebellar and Limbic Responses to the Valsalva Maneuver in Heart Failure. Cerebellum, 2012, 11, 931-938.	1.4	27

#	Article	IF	CITATIONS
1081	Risks of Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Receiving Warfarin and Treated With Intravenous Tissue Plasminogen Activator. JAMA - Journal of the American Medical Association, 2012, 307, 2600-8.	3.8	142
1082	Lack of Association Between Electronic Health Record Systems and Improvement in Use of Evidenceâ€Based Heart Failure Therapies in Outpatient Cardiology Practices. Clinical Cardiology, 2012, 35, 187-196.	0.7	21
1083	A Pointâ€byâ€Point Response to Recent Arguments Against the Use of Statins in Primary Prevention. Clinical Cardiology, 2012, 35, 404-409.	0.7	13
1084	Quality of Care and Outcomes Among Patients With Acute Myocardial Infarction by Level of Kidney Function at Admission: Report From the Get With The Guidelines Coronary Artery Disease Program. Clinical Cardiology, 2012, 35, 541-547.	0.7	18
1085	Trends in Smoking Cessation Counseling: Experience From American Heart Associationâ€Get With The Guidelines. Clinical Cardiology, 2012, 35, 396-403.	0.7	7
1086	Reperfusion Strategies and Quality of Care in 5339 Patients Age 80 Years or Older Presenting With STâ€Elevation Myocardial Infarction: Analysis from Get With The Guidelinesâ€Coronary Artery Disease. Clinical Cardiology, 2012, 35, 632-640.	0.7	28
1087	Factors Associated with Improvement in Guidelineâ€Based Use of ICDs in Eligible Heart Failure Patients. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 135-145.	0.5	12
1088	Effect of Warfarin on Outcomes in Septuagenarian Patients With Atrial Fibrillation. American Journal of Cardiology, 2012, 109, 370-377.	0.7	16
1089	Predicting Costs Among Medicare Beneficiaries With Heart Failure. American Journal of Cardiology, 2012, 109, 705-711.	0.7	27
1090	Medication Dosing in Outpatients With Heart Failure After Implementation of a Practiceâ€Based Performance Improvement Intervention: Findings From IMPROVE HF. Congestive Heart Failure, 2012, 18, 9-17.	2.0	69
1091	Clinical Risk Prediction Tools in Patients Hospitalized With Heart Failure. Reviews in Cardiovascular Medicine, 2012, 13, 14-23.	0.5	20
1092	Global and regional putamen volume loss in patients with heart failure. European Journal of Heart Failure, 2011, 13, 651-655.	2.9	35
1093	Epidemiology and risk profile of heart failure. Nature Reviews Cardiology, 2011, 8, 30-41.	6.1	1,608
1094	Systematic Review of the Incidence of Sudden Cardiac Death in the United States. Journal of the American College of Cardiology, 2011, 57, 794-801.	1.2	287
1095	ACCF/AHA 2011 Key Data Elements and Definitions of a Base Cardiovascular Vocabulary for Electronic Health Records. Journal of the American College of Cardiology, 2011, 58, 202-222.	1.2	62
1096	The Importance of Consistent, High-Quality Acute Myocardial Infarction and Heart Failure Care. Journal of the American College of Cardiology, 2011, 58, 637-644.	1.2	29
1097	Payment Source, Quality of Care, and Outcomes in Patients Hospitalized With Heart Failure. Journal of the American College of Cardiology, 2011, 58, 1465-1471.	1.2	47
1098	Changes in Myocardial Infarction Guideline Adherence as a Function of Patient Risk. Journal of the American College of Cardiology, 2011, 58, 1760-1765.	1,2	42

#	Article	IF	CITATIONS
1099	Brain axonal and myelin evaluation in heart failure. Journal of the Neurological Sciences, 2011, 307, 106-113.	0.3	93
1100	Effect of Nesiritide in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 2011, 365, 32-43.	13.9	1,133
1101	Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). American Heart Journal, 2011, 161, 418-424.e3.	1.2	35
1102	Association of race/ethnicity with clinical risk factors, quality of care, and acute outcomes in patients hospitalized with heart failure. American Heart Journal, 2011, 161, 746-754.	1.2	83
1103	Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. American Heart Journal, 2011, 161, 1024-1030.e3.	1.2	196
1104	Phase II trials in heart failure: The role of cardiovascular imaging. American Heart Journal, 2011, 162, 3-15.e3.	1.2	13
1105	Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: Findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD). American Heart Journal, 2011, 162, 283-290.e2.	1.2	17
1106	Quality of care for sudden cardiac arrest: Proposed steps to improve the translation of evidence into practice. American Heart Journal, 2011, 162, 222-231.	1,2	9
1107	Diabetes, quality of care, and in-hospital outcomes in patients hospitalized with heart failure. American Heart Journal, 2011, 162, 480-486.e3.	1.2	21
1108	Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AF. American Heart Journal, 2011, 162, 606-612.e1.	1.2	137
1109	Improvement in use of anticoagulation therapy in patients with ischemic stroke: Results from Get With The Guidelines–Stroke. American Heart Journal, 2011, 162, 692-699.e2.	1.2	34
1110	Regional differences in clinical profile, quality of care, and outcomes among Hispanic patients hospitalized with acute myocardial infarction in the Get with Guidelines–Coronary Artery Disease (GWTG-CAD) Registry. American Heart Journal, 2011, 162, 988-995.e4.	1.2	13
1111	Temporal trends in gastrointestinal bleeding associated with percutaneous coronary intervention: Analysis of the 1998-2006 Nationwide Inpatient Sample (NIS) database. American Heart Journal, 2011, 162, 1062-1068.e5.	1.2	46
1112	Use and Predictors of Heart Failure Disease Management Referral in Patients Hospitalized With Heart Failure: Insights From the Get With the Guidelines Program. Journal of Cardiac Failure, 2011, 17, 431-439.	0.7	17
1113	Waist Circumference, Body Mass Index, and Survival in Systolic Heart Failure: The Obesity Paradox Revisited. Journal of Cardiac Failure, 2011, 17, 374-380.	0.7	139
1114	Predictors of Hospital Length of Stay in Heart Failure: Findings from Get With the Guidelines. Journal of Cardiac Failure, 2011, 17, 649-656.	0.7	73
1115	Statins Do Not Significantly Affect Muscle Sympathetic Nerve Activity in Humans With Nonischemic Heart Failure: A Double-Blind Placebo-Controlled Trial. Journal of Cardiac Failure, 2011, 17, 879-886.	0.7	22
1116	Coronary artery disease, coronary revascularization, and outcomes in chronic advanced systolic heart failure. International Journal of Cardiology, 2011, 151, 69-75.	0.8	29

#	Article	IF	Citations
1117	Benefits of Statin Therapy Based on Plasma Carbohydrate Antigen 125 Values Following an Admission for Acute Heart Failure. Revista Espanola De Cardiologia (English Ed ), 2011, 64, 1100-1108.	0.4	3
1118	Relative roles of heart transplantation and long-term mechanical circulatory support in contemporary management of advanced heart failure $\hat{a} \in \tilde{a}$ a critical appraisal 10 years after REMATCH. European Journal of Cardio-thoracic Surgery, 2011, 40, 781-782.	0.6	15
1119	Response to Letter by Khan et al Regarding Article, "Hospital-Level Variation in Mortality and Rehospitalization for Medicare Beneficiaries With Acute Ischemic Stroke― Stroke, 2011, 42, .	1.0	0
1120	A Qualitative Assessment of Practices Associated With Shorter Door-to-Needle Time for Thrombolytic Therapy in Acute Ischemic Stroke. Journal of Neuroscience Nursing, 2011, 43, 329-336.	0.7	22
1121	Improving Quality of Care and Outcomes for Heart Failure - Role of Registries Circulation Journal, 2011, 75, 1783-1790.	0.7	39
1122	Do Anthropometric Indices Accurately Reflect Directly Measured Body Composition in Men and Women With Chronic Heart Failure?. Congestive Heart Failure, 2011, 17, 89-91.	2.0	23
1123	Characteristics and Outcomes Among Heart Failure Patients With Anemia and Renal Insufficiency With and Without Blood Transfusions (Public Discharge Data from California 2000–2006). American Journal of Cardiology, 2011, 107, 69-73.	0.7	23
1124	Patient and Practice Factors Associated With Improvement in Use of Guideline-Recommended Therapies for Outpatients With Heart Failure (from the IMPROVE HF Trial). American Journal of Cardiology, 2011, 107, 250-258.	0.7	6
1125	The Editor's Roundtable: Implantable Cardioverter-Defibrillators in Primary Prevention of Sudden Cardiac Death and Disparity-Related Barriers to Implementation. American Journal of Cardiology, 2011, 107, 583-590.	0.7	1
1126	Warfarin Use and Outcomes in Patients With Advanced Chronic Systolic Heart Failure Without Atrial Fibrillation, Prior Thromboembolic Events, or Prosthetic Valves. American Journal of Cardiology, 2011, 107, 552-557.	0.7	29
1127	In-Hospital Major Bleeding During ST-Elevation and Non–ST-Elevation Myocardial Infarction Care: Derivation and Validation of a Model from the ACTION Registry®-GWTG™. American Journal of Cardiology, 2011, 107, 1136-1143.	0.7	202
1128	Relation of Baseline Systolic Blood Pressure and Long-Term Outcomes in Ambulatory Patients With Chronic Mild to Moderate Heart Failure. American Journal of Cardiology, 2011, 107, 1208-1214.	0.7	92
1129	Patterns and Predictors of Evidence-Based Medication Continuation Among Hospitalized Heart Failure Patients (from Get With the Guidelines–Heart Failure). American Journal of Cardiology, 2011, 107, 1818-1823.	0.7	67
1130	Associations of Patient Demographic Characteristics and Regional Physician Density With Early Physician Follow-Up Among Medicare Beneficiaries Hospitalized With Heart Failure. American Journal of Cardiology, 2011, 108, 985-991.	0.7	39
1131	A Propensity-Matched Study of the Comparative Effectiveness of Angiotensin Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Heart Failure Patients Age ≥65 Years. American Journal of Cardiology, 2011, 108, 1443-1448.	0.7	11
1132	A Propensity-Matched Study of the Association of Diabetes Mellitus With Incident Heart Failure and Mortality Among Community-Dwelling Older Adults. American Journal of Cardiology, 2011, 108, 1747-1753.	0.7	11
1133	Relation Among Body Mass Index, Exercise Training, and Outcomes in Chronic Systolic Heart Failure. American Journal of Cardiology, 2011, 108, 1754-1759.	0.7	43
1134	Pharmacologic Prophylaxis for Venous Thromboembolism and 30â€Day Outcomes Among Older Patients Hospitalized With Heart Failure: An Analysis From the ADHERE National Registry Linked to Medicare Claims. Clinical Cardiology, 2011, 34, 682-688.	0.7	12

#	Article	IF	CITATIONS
1135	Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: The Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry®–Get With The Guidelines (GWTG)â,,¢ acute myocardial infarction mortality model and risk score. American Heart Journal, 2011, 161, 113-122.e2.	1.2	149
1136	The potential application of electrophysiology diagnostics and therapeutics in acute heart failure syndromes. Heart Failure Reviews, 2011, 16, 437-439.	1.7	3
1137	High platelet count as a link between renal cachexia and cardiovascular mortality in end-stage renal disease patients. American Journal of Clinical Nutrition, 2011, 94, 945-954.	2.2	39
1138	Comparative Effectiveness of Diuretic Regimens. New England Journal of Medicine, 2011, 364, 877-878.	13.9	18
1139	Wireless hemodynamic monitoring—a new approach for managing HF. Nature Reviews Cardiology, 2011, 8, 245-246.	6.1	3
1140	Hypoalbuminaemia and incident heart failure in older adults. European Journal of Heart Failure, 2011, 13, 1078-1086.	2.9	50
1141	Rationale and design of the multicentre, randomized, doubleâ€blind, placeboâ€controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). European Journal of Heart Failure, 2011, 13, 100-106.	2.9	68
1142	Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry. European Journal of Heart Failure, 2011, 13, 945-952.	2.9	60
1143	Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke. Circulation, 2011, 123, 750-758.	1.6	510
1144	Admission, Discharge, or Change in B-Type Natriuretic Peptide and Long-Term Outcomes. Circulation: Heart Failure, 2011, 4, 628-636.	1.6	199
1145	Associations Between Outpatient Heart Failure Process-of-Care Measures and Mortality. Circulation, 2011, 123, 1601-1610.	1.6	83
1146	Isolated Diastolic Hypotension and Incident Heart Failure in Older Adults. Hypertension, 2011, 58, 895-901.	1.3	44
1147	Are Quality Improvements in the Get With The Guidelines-Stroke Program Related to Better Care or Better Data Documentation?. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 503-511.	0.9	36
1148	Quality of Care and Outcomes in Women Hospitalized for Heart Failure. Circulation: Heart Failure, 2011, 4, 589-598.	1.6	46
1149	Discharge to a Skilled Nursing Facility and Subsequent Clinical Outcomes Among Older Patients Hospitalized for Heart Failure. Circulation: Heart Failure, 2011, 4, 293-300.	1.6	165
1150	Recent US Patterns and Predictors of Prevalent Diabetes among Acute Myocardial Infarction Patients. Cardiology Research and Practice, 2011, 2011, 1-8.	0.5	20
1151	ACCF/AHA 2011 Key Data Elements and Definitions of a Base Cardiovascular Vocabulary for Electronic Health Records. Circulation, 2011, 124, 103-123.	1.6	66
1152	Incremental Value of Clinical Data Beyond Claims Data in Predicting 30-Day Outcomes After Heart Failure Hospitalization. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 60-67.	0.9	96

#	Article	IF	Citations
1153	Clinical assessment of acute heart failure syndromes: emergency department through the early post-discharge period. Heart, 2011, 97, 1607-1618.	1.2	22
1154	Relationship between Stage of Kidney Disease and Incident Heart Failure in Older Adults. American Journal of Nephrology, 2011, 34, 135-141.	1.4	10
1155	Weighting Components of Composite End Points in Clinical Trials. Stroke, 2011, 42, 1722-1729.	1.0	23
1156	Outcomes in Mild or Rapidly Improving Stroke Not Treated With Intravenous Recombinant Tissue-Type Plasminogen Activator. Stroke, 2011, 42, 3110-3115.	1.0	187
1157	Improving Door-to-Needle Times in Acute Ischemic Stroke. Stroke, 2011, 42, 2983-2989.	1.0	313
1158	The American Heart Association's Recommendations for Expanding the Applications of Existing and Future Clinical Registries. Circulation, 2011, 123, 2167-2179.	1.6	100
1159	Hospital-Level Variation in Mortality and Rehospitalization for Medicare Beneficiaries With Acute Ischemic Stroke. Stroke, 2011, 42, 159-166.	1.0	120
1160	Comparison of Composite Measure Methodologies for Rewarding Quality of Care. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 610-618.	0.9	40
1161	The Need for Multiple Measures of Hospital Quality. Circulation, 2011, 124, 712-719.	1.6	62
1162	Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes. Circulation: Heart Failure, 2010, 3, 314-325.	1.6	134
1163	Process of Care Performance Measures and Long-Term Outcomes in Patients Hospitalized With Heart Failure. Medical Care, 2010, 48, 210-216.	1.1	85
1164	Rapid Change in Prescribing Behavior in Hospitals Participating in Get With The Guidelines–Stroke After Release of the Management of Atherothrombosis With Clopidogrel in High-Risk Patients (MATCH) Clinical Trial Results. Stroke, 2010, 41, 2094-2097.	1.0	12
1165	Adherence to Guideline-Recommended Adjunctive Heart Failure Therapies Among Outpatient Cardiology Practices (Findings from IMPROVE HF). American Journal of Cardiology, 2010, 105, 255-260.	0.7	38
1166	Quality of Care and In-Hospital Outcomes in Patients With Coronary Heart Disease in Rural and Urban Hospitals (from Get With the Guidelines–Coronary Artery Disease Program). American Journal of Cardiology, 2010, 105, 139-143.	0.7	33
1167	Influence of Renal Function on the Use of Guideline-Recommended Therapies for Patients With Heart Failure. American Journal of Cardiology, 2010, 105, 1140-1146.	0.7	45
1168	Outpatient Cardiology Practices With Advanced Practice Nurses and Physician Assistants Provide Similar Delivery of Recommended Therapies (Findings from IMPROVE HF). American Journal of Cardiology, 2010, 105, 1773-1779.	0.7	23
1169	Long-Term Outcomes of Medicare Beneficiaries With Worsening Renal Function During Hospitalization for Heart Failure. American Journal of Cardiology, 2010, 105, 1786-1793.	0.7	66
1170	Impact of Baseline Systolic Blood Pressure on Long-Term Outcomes in Patients With Advanced Chronic Systolic Heart Failure (Insights from the BEST Trial). American Journal of Cardiology, 2010, 106, 221-227.	0.7	44

#	Article	IF	Citations
1171	Comparison of Usefulness of Each of Five Predictors of Mortality and Urgent Transplantation in Patients With Advanced Heart Failure. American Journal of Cardiology, 2010, 106, 830-835.	0.7	26
1172	Effect of Serum Insulin on the Association Between Hyperuricemia and Incident Heart Failure. American Journal of Cardiology, 2010, 106, 1134-1138.	0.7	30
1173	Process Measures, Outcome Measures, and Heart Failureâ€"Reply. JAMA - Journal of the American Medical Association, 2010, 303, 35.	3.8	0
1174	Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction. Circulation, 2010, 121, 586-613.	1.6	3,508
1175	Age-Related Differences in Characteristics, Performance Measures, Treatment Trends, and Outcomes in Patients With Ischemic Stroke. Circulation, 2010, 121, 879-891.	1.6	192
1176	Comparison of Medical Therapy Dosing in Outpatients Cared for in Cardiology Practices With Heart Failure and Reduced Ejection Fraction With and Without Device Therapy. Circulation: Heart Failure, 2010, 3, 596-605.	1.6	75
1177	A Validated Risk Score for In-Hospital Mortality in Patients With Heart Failure From the American Heart Association Get With the Guidelines Program. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 25-32.	0.9	400
1178	Characteristics, Performance Measures, and In-Hospital Outcomes of the First One Million Stroke and Transient Ischemic Attack Admissions in Get With The Guidelines-Stroke. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 291-302.	0.9	296
1179	Regional Differences in Quality of Care and Outcomes for the Treatment of Acute Coronary Syndromes. Critical Pathways in Cardiology, 2010, 9, 1-7.	0.2	31
1180	Performance Achievement Award Program for Get With The Guidelines Coronary Artery Disease Is Associated With Global and Sustained Improvement in Cardiac Care for Patients Hospitalized With an Acute Myocardial Infarction. Critical Pathways in Cardiology, 2010, 9, 103-112.	0.2	8
1181	Race/Ethnicity, Quality of Care, and Outcomes in Ischemic Stroke. Circulation, 2010, 121, 1492-1501.	1.6	231
1182	Racial and Ethnic Differences in the Treatment of Acute Myocardial Infarction. Circulation, 2010, 121, 2294-2301.	1.6	137
1183	Relationship Between Early Physician Follow-up and 30-Day Readmission Among Medicare Beneficiaries Hospitalized for Heart Failure. JAMA - Journal of the American Medical Association, 2010, 303, 1716.	3.8	852
1184	Hospital Certification for Optimizing Cardiovascular Disease and Stroke Quality of Care and Outcomes. Circulation, 2010, 122, 2459-2469.	1.6	27
1185	Treatment and Risk in Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 309-315.	0.9	72
1186	Differential prognostic effect of systolic blood pressure on mortality according to leftâ€ventricular function in patients with acute heart failure. European Journal of Heart Failure, 2010, 12, 38-44.	2.9	42
1187	Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure. Circulation: Heart Failure, 2010, 3, 7-13.	1.6	72
1188	Impact of Reduced Kidney Function on Cardiopulmonary Fitness in Patients with Systolic Heart Failure. American Journal of Nephrology, 2010, 32, 226-233.	1.4	19

#	Article	IF	Citations
1189	Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. European Heart Journal, 2010, 31, 1752-1763.	1.0	111
1190	Translating Evidence Into Practice: A Decade of Efforts by the American Heart Association/American Stroke Association to Reduce Death and Disability Due to Stroke. Stroke, 2010, 41, 1051-1065.	1.0	46
1191	Frequency and Determinants of Lipid Testing in Ischemic Stroke and Transient Ischemic Attack. Stroke, 2010, 41, 232-238.	1.0	14
1192	Quality of Care and Outcomes in Patients With Diabetes Hospitalized With Ischemic Stroke. Stroke, 2010, 41, e409-17.	1.0	63
1193	Recent Nationwide Trends in Discharge Statin Treatment of Hospitalized Patients With Stroke. Stroke, 2010, 41, 1508-1513.	1.0	39
1194	Development of Stroke Performance Measures. Stroke, 2010, 41, 1573-1578.	1.0	97
1195	Patterns and Predictors of Discharge Statin Prescription Among Hospitalized Patients With Intracerebral Hemorrhage. Stroke, 2010, 41, 2271-2277.	1.0	3
1196	Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. European Journal of Heart Failure, 2010, 12, 423-433.	2.9	593
1197	Is Exercise Adherence Associated with Clinical Outcomes in Patients with Advanced Heart Failure?. Physician and Sportsmedicine, 2010, 38, 28-36.	1.0	31
1198	The "Golden Hour―and Acute Brain Ischemia. Stroke, 2010, 41, 1431-1439.	1.0	175
1199	Association Between Direct Measures of Body Composition and Prognostic Factors in Chronic Heart Failure. Mayo Clinic Proceedings, 2010, 85, 609-617.	1.4	135
1200	Glucose, Obesity, Metabolic Syndrome, and Diabetes. Journal of the American College of Cardiology, 2010, 55, 283-293.	1.2	174
1201	National Heart, Lung, and Blood Institute Working Group on Emergency Department Management of Acute Heart Failure. Journal of the American College of Cardiology, 2010, 56, 343-351.	1.2	76
1202	Treatments, Trends, and Outcomes of Acute Myocardial Infarction and Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2010, 56, 254-263.	1.2	382
1203	Troponin Elevation in Heart Failure. Journal of the American College of Cardiology, 2010, 56, 1071-1078.	1.2	371
1204	Risk Score for In-Hospital Ischemic Stroke Mortality Derived and Validated Within the Get With The Guidelines–Stroke Program. Circulation, 2010, 122, 1496-1504.	1.6	232
1205	Metformin Therapy and Outcomes in Patients With Advanced Systolic Heart Failure and Diabetes. Journal of Cardiac Failure, 2010, 16, 200-206.	0.7	88
1206	Comparison of Direct Body Composition Assessment Methods in Patients With Chronic Heart Failure. Journal of Cardiac Failure, 2010, 16, 867-872.	0.7	26

#	Article	IF	CITATIONS
1207	Are quality improvements associated with the Get With the Guidelines-Coronary Artery Disease (GWTG-CAD) program sustained over time?. American Heart Journal, 2010, 159, 207-214.	1.2	37
1208	Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). American Heart Journal, 2010, 159, 222-230.e2.	1,2	15
1209	Influence of dedicated heart failure clinics on delivery of recommended therapies in outpatient cardiology practices: Findings from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). American Heart Journal, 2010, 159, 238-244.	1.2	24
1210	Relationships between emerging measures of heart failure processes of care and clinical outcomes. American Heart Journal, 2010, 159, 406-413.	1.2	56
1211	Electronic health records and quality of care for heart failure. American Heart Journal, 2010, 159, 635-642.e1.	1.2	26
1212	Association of insurance status with inpatient treatment for coronary artery disease: Findings from the Get With the Guidelines program. American Heart Journal, 2010, 159, 1026-1036.	1.2	16
1213	Associations between worsening renal function and 30-day outcomes among Medicare beneficiaries hospitalized with heart failure. American Heart Journal, 2010, 160, 132-138.e1.	1.2	39
1214	Generalizability and longitudinal outcomes of a national heart failure clinical registry: Comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and non-ADHERE Medicare beneficiaries. American Heart Journal, 2010, 160, 885-892.	1.2	114
1215	Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). American Heart Journal, 2010, 160, 1130-1136.e3.	1.2	33
1216	Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study. Journal of the American Society of Hypertension, 2010, 4, 22-31.	2.3	58
1217	Equitable Improvement for Women and Men in the Use of Guideline-Recommended Therapies for Heart Failure: Findings From IMPROVE HF. Journal of Cardiac Failure, 2010, 16, 940-949.	0.7	29
1218	Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapies. American Heart Journal, 2010, 160, 605-618.e1.	1.2	21
1219	The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care. Heart, 2010, 96, 1798-1802.	1.2	119
1220	Improving Evidence-Based Care for Heart Failure in Outpatient Cardiology Practices. Circulation, 2010, 122, 585-596.	1.6	372
1221	Society of Chest Pain Centers recommendations for the evaluation and management of the observation stay acute heart failure patient $\hat{a} \in \mathcal{A}$ part 1. Acute Cardiac Care, 2009, 11, 3-42.	0.2	43
1222	Trends in the Use of Evidence-Based Treatments for Coronary Artery Disease Among Women and the Elderly. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 633-641.	0.9	73
1223	Heart Failure Performance Measures and Outcomes. JAMA - Journal of the American Medical Association, 2009, 302, 792.	3.8	83
1224	A Call to ACTION (Acute Coronary Treatment and Intervention Outcomes Network). Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 491-499.	0.9	187

#	Article	IF	Citations
1225	The relationship between body mass index, treatment, and mortality in patients with established coronary artery disease: a report from APPROACH. European Heart Journal, 2009, 30, 2584-2592.	1.0	121
1226	Quality of Care in Women With Ischemic Stroke in the GWTG Program. Stroke, 2009, 40, 1127-1133.	1.0	150
1227	Off-Hour Admission and In-Hospital Stroke Case Fatality in the Get With The Guidelines-Stroke Program. Stroke, 2009, 40, 569-576.	1.0	124
1228	Quality of Care for Acute Coronary Syndrome Patients With Known Atherosclerotic Disease. Circulation, 2009, 120, 560-567.	1.6	68
1229	Association of Hospital Primary Angioplasty Volume in ST-Segment Elevation Myocardial Infarction With Quality and Outcomes. JAMA - Journal of the American Medical Association, 2009, 302, 2207.	3.8	83
1230	Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack. Circulation, 2009, 119, 107-115.	1.6	505
1231	Fluid Retention Is Associated With Cardiovascular Mortality in Patients Undergoing Long-Term Hemodialysis. Circulation, 2009, 119, 671-679.	1.6	464
1232	Representativeness of a National Heart Failure Quality-of-Care Registry. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 377-384.	0.9	82
1233	Mammillary bodies and fornix fibers are injured in heart failure. Neurobiology of Disease, 2009, 33, 236-242.	2.1	85
1234	Early Vasoactive Drugs Improve Heart Failure Outcomes. Congestive Heart Failure, 2009, 15, 256-264.	2.0	119
1235	Differential Use of Warfarin for Secondary Stroke Prevention in Patients With Various Types of Atrial Fibrillation. American Journal of Cardiology, 2009, 103, 227-231.	0.7	36
1236	Door-to-Balloon Times in Hospitals Within the Get-With-The-Guidelines Registry After Initiation of the Door-to-Balloon (D2B) Alliance. American Journal of Cardiology, 2009, 103, 1051-1055.	0.7	63
1237	Age- and Gender-Related Differences in Quality of Care and Outcomes of Patients Hospitalized With Heart Failure (from OPTIMIZE-HF). American Journal of Cardiology, 2009, 104, 107-115.	0.7	104
1238	Patient Characteristics Associated With the Choice of Triple Antithrombotic Therapy in Acute Coronary Syndromes. American Journal of Cardiology, 2009, 104, 1171-1178.	0.7	25
1239	Brain Injury in Autonomic, Emotional, and Cognitive Regulatory Areas in Patients With Heart Failure. Journal of Cardiac Failure, 2009, 15, 214-223.	0.7	148
1240	Anemia, Kidney Disease, and Inpatient Outcomes for Heart Failure in California – 2000-2006. Journal of Cardiac Failure, 2009, 15, S102-S103.	0.7	0
1241	Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines. American Heart Journal, 2009, 157, 111-117.e2.	1.2	270
1242	Trends in the use of lipid-lowering medications at discharge in patients with acute myocardial infarction: 1998 to 2006. American Heart Journal, 2009, 157, 185-194.e2.	1.2	25

#	Article	IF	Citations
1243	Standardizing care for acute decompensated heart failure in a large megatrial: The approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). American Heart Journal, 2009, 157, 219-228.	1.2	36
1244	Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: Findings from IMPROVE HF. American Heart Journal, 2009, 157, 754-762.e2.	1,2	93
1245	Influence of age on the management of heart failure: Findings from Get With the Guidelines–Heart Failure (GWTG-HF). American Heart Journal, 2009, 157, 1010-1017.	1.2	58
1246	Influence of coronary angiography on the utilization of therapies in patients with acute heart failure syndromes: Findings from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). American Heart Journal, 2009, 157, 1018-1025.	1,2	41
1247	Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. American Heart Journal, 2009, 157, 995-1000.	1.2	344
1248	Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group. American Heart Journal, 2009, 157, 957-970.	1,2	48
1249	Weekend hospital admission and discharge for heart failure: Association with quality of care and clinical outcomes. American Heart Journal, 2009, 158, 451-458.	1.2	73
1250	The relationship between body mass index and cardiopulmonary exercise testing in chronic systolic heart failure. American Heart Journal, 2009, 158, S31-S36.	1.2	23
1251	Hospital performance recognition with the Get With The Guidelines Program and mortality for acute myocardial infarction and heart failure. American Heart Journal, 2009, 158, 546-553.	1.2	81
1252	Characteristics and in-hospital outcomes for nonadherent patients with heart failure: Findings from Get With The Guidelines-Heart Failure (GWTG-HF). American Heart Journal, 2009, 158, 644-652.	1.2	96
1253	Cardiac resynchronization therapy utilization for heart failure: Findings from IMPROVE HF. American Heart Journal, 2009, 158, 956-964.	1.2	48
1254	Depression and Clinical Outcomes in Heart Failure: An OPTIMIZE-HF Analysis. American Journal of Medicine, 2009, 122, 366-373.	0.6	97
1255	Clinical Implications of the Obesity Paradox in Patients with Coronary Artery Disease. American Journal of Medicine, 2009, 122, 1069.	0.6	13
1256	Acute Heart Failure Syndromes in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2009, 53, 254-263.	1.2	124
1257	Clinical Effectiveness of Beta-Blockers in Heart Failure. Journal of the American College of Cardiology, 2009, 53, 184-192.	1.2	295
1258	Hospital Variation and Characteristics of Implantable Cardioverter-Defibrillator Use in Patients With Heart Failure. Journal of the American College of Cardiology, 2009, 53, 416-422.	1,2	120
1259	Predictors of Cardiac Rehabilitation Referral in Coronary Artery Disease Patients. Journal of the American College of Cardiology, 2009, 54, 515-521.	1.2	236
1260	Quality of Care for Atrial Fibrillation Among Patients Hospitalized for Heart Failure. Journal of the American College of Cardiology, 2009, 54, 1280-1289.	1,2	129

#	Article	IF	Citations
1261	Micronutrient Deficiencies. Journal of the American College of Cardiology, 2009, 54, 1660-1673.	1.2	127
1262	National Efforts to Improve Door-to-Balloon Time. Journal of the American College of Cardiology, 2009, 54, 2423-2429.	1.2	176
1263	Role of carvedilol controlled-release in cardiovascular disease. Expert Review of Cardiovascular Therapy, 2009, 7, 483-498.	0.6	17
1264	Mode and mechanisms of death after orthotopic heart transplantation. Heart Rhythm, 2009, 6, 503-509.	0.3	60
1265	Differential effects of extended-release carvedilol and extended-release metoprolol on lipid profiles in patients with hypertension: results of the Extended-Release Carvedilol Lipid Trial. Journal of the American Society of Hypertension, 2009, 3, 210-220.	2.3	15
1266	Evidence of clinical practice heterogeneity in the use of implantable cardioverter-defibrillators in heart failure and post–myocardial infarction left ventricular dysfunction: Findings from IMPROVE HF. Heart Rhythm, 2009, 6, 1727-1734.	0.3	50
1267	The Obesity Paradox in the Elderly: Potential Mechanisms and Clinical Implications. Clinics in Geriatric Medicine, 2009, 25, 643-659.	1.0	265
1268	Reduced Body Weight and Adiposity With a High-Protein Diet Improves Functional Status, Lipid Profiles, Glycemic Control, and Quality of Life in Patients With Heart Failure. Journal of Cardiovascular Nursing, 2009, 24, 207-215.	0.6	70
1269	Sudden Cardiac Arrest Prevention Pathways and Tools. Critical Pathways in Cardiology, 2009, 8, 79-87.	0.2	4
1270	Regional and Practice Variation in Adherence to Guideline Recommendations for Secondary and Primary Prevention Among Outpatients With Atherothrombosis or Risk Factors in the United States. Critical Pathways in Cardiology, 2009, 8, 104-111.	0.2	68
1271	The Dissociation Between Door-to-Balloon Time Improvement and Improvements in Other Acute Myocardial Infarction Care Processes and Patient Outcomes. Archives of Internal Medicine, 2009, 169, 1411.	4.3	47
1272	Use of Aldosterone Antagonists in Heart Failure. JAMA - Journal of the American Medical Association, 2009, 302, 1658.	3.8	231
1273	The cardiorenal connection in heart failure. Current Cardiology Reports, 2008, 10, 190-197.	1.3	17
1274	Acute heart failure syndromes: Potential strategies to improve post-discharge outcomes. Current Treatment Options in Cardiovascular Medicine, 2008, 10, 349-357.	0.4	2
1275	Heart failure in African Americans: Earlier onset, different etiologies, and poorer prognosis. Current Cardiovascular Risk Reports, 2008, 2, 198-202.	0.8	0
1276	Risk Stratification in Women Enrolled in the Acute Decompensated Heart Failure National Registry Emergency Module (ADHEREâ€EM). Academic Emergency Medicine, 2008, 15, 151-158.	0.8	26
1277	Usefulness of B-Type Natriuretic Peptide and Cardiac Troponin Levels to Predict In-Hospital Mortality from ADHERE. American Journal of Cardiology, 2008, 101, 231-237.	0.7	149
1278	Relation of Low Hemoglobin and Anemia to Morbidity and Mortality in Patients Hospitalized With Heart Failure (Insight from the OPTIMIZE-HF Registry). American Journal of Cardiology, 2008, 101, 223-230.	0.7	155

#	Article	IF	CITATIONS
1279	Factors Associated With Discharge Lipid-Lowering Drug Prescription in Patients Hospitalized for Coronary Artery Disease (from the Get With the Guidelines Database). American Journal of Cardiology, 2008, 101, 1242-1246.	0.7	11
1280	Introduction. American Journal of Cardiology, 2008, 101, S1-S2.	0.7	2
1281	Cachexia: Common, Deadly, With an Urgent Need for Precise Definition and New Therapies. American Journal of Cardiology, 2008, 101, S8-S10.	0.7	55
1282	Nutritional and Anti-Inflammatory Interventions in Chronic Heart Failure. American Journal of Cardiology, 2008, 101, S89-S103.	0.7	157
1283	Weekend/Holiday Versus Weekday Hospital Discharge and Guideline Adherence (from the American) Tj ETQq1 1 Cardiology, 2008, 102, 663-667.	0.784314 r 0.7	rgBT /Overlo 17
1284	Introduction to ACCORD-PMI: The Advisory Council on Care Optimization to Reduce Death Post-MI. American Journal of Cardiology, 2008, 102, 1G-4G.	0.7	0
1285	Implementing Critical Pathways and a Multidisciplinary Team Approach to Cardiovascular Disease Management. American Journal of Cardiology, 2008, 102, 47G-56G.	0.7	28
1286	Directions for Research in the Post-Myocardial Infarction Patient with Left Ventricular Dysfunction. American Journal of Cardiology, 2008, 102, 57G-61G.	0.7	1
1287	Illicit Stimulant Use in a United States Heart Failure Population Presenting to the Emergency Department (from the Acute Decompensated Heart Failure National Registry Emergency Module). American Journal of Cardiology, 2008, 102, 1216-1219.	0.7	63
1288	Dosing of Beta-Blocker Therapy Before, During, and After Hospitalization for Heart Failure (from) Tj ETQq0 0 0 rgB American Journal of Cardiology, 2008, 102, 1524-1529.	BT /Overloc 0.7	ck 10 Tf 50 3 73
1289	Relation of Systolic Blood Pressure to Survival in Both Ischemic and Nonischemic Systolic Heart Failure. American Journal of Cardiology, 2008, 102, 1698-1705.	0.7	24
1290	Influence of Hospital Length of Stay for Heart Failure on Quality of Care. American Journal of Cardiology, 2008, 102, 1693-1697.	0.7	20
1291	Cardiorenal Interactions. Journal of the American College of Cardiology, 2008, 51, 1268-1274.	1.2	521
1292	Quality of Care of and Outcomes for African Americans Hospitalized With Heart Failure. Journal of the American College of Cardiology, 2008, 51, 1675-1684.	1.2	95
1293	Influence of Beta-Blocker Continuation or Withdrawal on Outcomes in Patients Hospitalized With Heart Failure. Journal of the American College of Cardiology, 2008, 52, 190-199.	1.2	203
1294	Predictors of In-Hospital Mortality in Patients Hospitalized for Heart Failure. Journal of the American College of Cardiology, 2008, 52, 347-356.	1.2	506
1295	Timing of Immunoreactive B-Type Natriuretic Peptide Levels and Treatment Delay in Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2008, 52, 534-540.	1,2	182
1296	Epidemiology and risk stratification in acute heart failure. American Heart Journal, 2008, 155, 200-207.	1.2	123

#	Article	IF	Citations
1297	Heart failure disease management programs: A cost-effectiveness analysis. American Heart Journal, 2008, 155, 332-338.	1.2	54
1298	Albumin levels predict survival in patients with systolic heart failure. American Heart Journal, 2008, 155, 883-889.	1.2	320
1299	Achieving rapid reperfusion with primary percutaneous coronary intervention remains a challenge: Insights from American Heart Association's Get With the Guidelines program. American Heart Journal, 2008, 155, 1059-1067.	1.2	77
1300	Body mass index and mortality in heart failure: A meta-analysis. American Heart Journal, 2008, 156, 13-22.	1.2	724
1301	Predictors of mortality after discharge in patients hospitalized with heart failure: An analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). American Heart Journal, 2008, 156, 662-673.	1.2	374
1302	Preventing tomorrow's sudden cardiac death today. American Heart Journal, 2008, 156, 613-622.	1.2	46
1303	Quality of care and outcomes among patients with heart failure and chronic kidney disease: A Get With the Guidelines—Heart Failure Program study. American Heart Journal, 2008, 156, 674-681.	1.2	71
1304	Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. American Heart Journal, 2008, 156, 1170-1176.	1.2	61
1305	Venous Thromboembolism Prophylaxis in Hospitalized Heart Failure Patients. Journal of Cardiac Failure, 2008, 14, 127-132.	0.7	23
1306	Incident Heart Failure Hospitalization and Subsequent Mortality in Chronic Heart Failure: A Propensity-Matched Study. Journal of Cardiac Failure, 2008, 14, 211-218.	0.7	139
1307	Statins and n-3 fatty acid supplementation in heart failure. Lancet, The, 2008, 372, 1195-1196.	6.3	28
1308	Comprehensive Adrenergic Blockade Post Myocardial Infarction Left Ventricular Dysfunction. Cardiology Clinics, 2008, 26, 79-89.	0.9	2
1309	Preface. Heart Failure Clinics, 2008, 4, xiii-xiv.	1.0	0
1310	Cardiac Troponin and Outcome in Acute Heart Failure. New England Journal of Medicine, 2008, 358, 2117-2126.	13.9	642
1311	Randomized Clinical Outcome Trials of Statins in Heart Failure. Heart Failure Clinics, 2008, 4, 225-229.	1.0	11
1312	Translating Evidence into Practice: Use of Statins in Real-World Patients with Heart Failure. Heart Failure Clinics, 2008, 4, 217-223.	1.0	0
1313	Sex Differences in Medical Care and Early Death After Acute Myocardial Infarction. Circulation, 2008, 118, 2803-2810.	1.6	455
1314	Heart Failure Care in the Outpatient Cardiology Practice Setting. Circulation: Heart Failure, 2008, 1, 98-106.	1.6	168

#	Article	IF	CITATIONS
1315	Translating Research Into Practice for Healthcare Providers. Circulation, 2008, 118, 687-696.	1.6	30
1316	A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. European Heart Journal, 2008, 29, 816-824.	1.0	131
1317	A smoker's paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF. European Heart Journal, 2008, 29, 1983-1991.	1.0	54
1318	Acute Heart Failure Treatment. Critical Pathways in Cardiology, 2008, 7, 103-110.	0.2	2
1319	Cyclooxygenase products sensitize muscle mechanoreceptors in humans with heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H1956-H1962.	1.5	21
1320	Influence of coronary artery disease and coronary revascularization status on outcomes in patients with acute heart failure syndromes: A report from OPTIMIZEâ€HF (Organized Program to Initiate) Tj ETQq0 0 0 rg 2008, 10, 1215-1223.	BT_/Overlo	ck 10 Tf 50 5
1321	Day of Admission and Clinical Outcomes for Patients Hospitalized for Heart Failure. Circulation: Heart Failure, 2008, 1, 50-57.	1.6	66
1322	Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia. Circulation, 2008, 117, 526-535.	1.6	248
1323	Factors Identified as Precipitating Hospital Admissions for Heart Failure and Clinical Outcomes <subtitle>Findings From OPTIMIZE-HF</subtitle> . Archives of Internal Medicine, 2008, 168, 847.	4.3	414
1324	Measures of Obesity and Outcomes After Myocardial Infarction. Circulation, 2008, 118, 469-471.	1.6	15
1325	Prevention of Heart Failure. Circulation, 2008, 117, 2544-2565.	1.6	485
1326	Impact of Time of Presentation on the Care and Outcomes of Acute Myocardial Infarction. Circulation, 2008, 117, 2502-2509.	1.6	127
1327	Use of Cardiac Resynchronization Therapy in Patients Hospitalized With Heart Failure. Circulation, 2008, 118, 926-933.	1.6	89
1328	State of the art: Using natriuretic peptide levels in clinical practice. European Journal of Heart Failure, 2008, 10, 824-839.	2.9	691
1329	Society of Chest Pain Centers Recommendations for the Evaluation and Management of the Observation Stay Acute Heart Failure Patient. Critical Pathways in Cardiology, 2008, 7, 83-121.	0.2	38
1330	Association of Patient Case-Mix Adjustment, Hospital Process Performance Rankings, and Eligibility for Financial Incentives. JAMA - Journal of the American Medical Association, 2008, 300, 1897.	3.8	68
1331	Cognitive Test Performance and Brain Pathology. Nursing Research, 2008, 57, 75-83.	0.8	25
1332	Risk Stratification. Critical Pathways in Cardiology, 2008, 7, 96-102.	0.2	2

#	Article	IF	CITATIONS
1333	Characteristics and Outcomes in African American Patients With Decompensated Heart Failure. Archives of Internal Medicine, 2008, 168, 1152.	4.3	44
1334	An Organized Approach to Improvement in Guideline Adherence for Acute Myocardial Infarction. Archives of Internal Medicine, 2008, 168, 1813.	4.3	112
1335	Discharge Criteria. Critical Pathways in Cardiology, 2008, 7, 111-115.	0.2	0
1336	A review of evidence-based beta-blockers in special populations with heart failure. Reviews in Cardiovascular Medicine, 2008, 9, 84-95.	0.5	9
1337	Managed care interventions for improving outcomes in acute heart failure syndromes. American Journal of Managed Care, 2008, 14, S273-86; quiz S287-91.	0.8	11
1338	Tipping the Scale. Circulation, 2007, 116, 588-590.	1.6	27
1339	The global burden of atherosclerotic vascular disease. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 530-531.	3.3	9
1340	Association Between Performance Measures and Clinical Outcomes for Patients Hospitalized With Heart Failure. JAMA - Journal of the American Medical Association, 2007, 297, 61.	3.8	420
1341	Impact of Early Initiation of Intravenous Therapy for Acute Decompensated Heart Failure on Outcomes in ADHERE. Cardiology, 2007, 107, 44-51.	0.6	95
1342	Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. European Heart Journal, 2007, 28, 980-988.	1.0	514
1343	Improved Treatment of Hospitalized Coronary Artery Disease Patients With the Get With The Guidelines Program. Critical Pathways in Cardiology, 2007, 6, 98-105.	0.2	71
1344	Influence of a Performance-Improvement Initiative on Quality of Care for Patients Hospitalized With Heart Failure. Archives of Internal Medicine, 2007, 167, 1493.	4.3	229
1345	Systolic Blood Pressure and Outcomes in Patients Hospitalized With Acute Heart Failure—Reply. JAMA - Journal of the American Medical Association, 2007, 297, 807.	3.8	1
1346	Atherosclerosis Secondary Prevention Performance Measures After Coronary Bypass Graft Surgery Compared With Percutaneous Catheter Intervention and Nonintervention Patients in the Get With the Guidelines Database. Circulation, 2007, 116, 1207-12.	1.6	57
1347	Performance Measures and Outcomes for Patients Hospitalized With Heart Failure—Reply. JAMA - Journal of the American Medical Association, 2007, 297, 1547.	3.8	0
1348	Early pharmacological treatment of acute heart failure syndromes: A systematic review of clinical trials. Acute Cardiac Care, 2007, 9, 10-21.	0.2	7
1349	Sex and Racial Differences in the Use of Implantable Cardioverter-Defibrillators Among Patients Hospitalized With Heart Failure. JAMA - Journal of the American Medical Association, 2007, 298, 1525-32.	3.8	365
1350	The paradox of dysfunctional high-density lipoprotein. Current Opinion in Lipidology, 2007, 18, 427-434.	1.2	174

#	Article	lF	CITATIONS
1351	Characteristics of Patients Hospitalized With Acute Decompensated Heart Failure Who Are Referred for Hospice Care. Archives of Internal Medicine, 2007, 167, 1990.	4.3	41
1352	Characterization and Prognostic Value of Persistent Hyponatremia in Patients With Severe Heart Failure in the ESCAPE Trial. Archives of Internal Medicine, 2007, 167, 1998.	4.3	300
1353	An obesity paradox in acute heart failure: Analysis of body mass index and inhospital mortality for 108927 patients in the Acute Decompensated Heart Failure National Registry. American Heart Journal, 2007, 153, 74-81.	1.2	426
1354	Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: An analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). American Heart Journal, 2007, 153, 82.e1-82.e11.	1.2	92
1355	Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). American Heart Journal, 2007, 153, 1021-1028.	1.2	336
1356	Improving the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting: The IMPROVE HF performance improvement registry. American Heart Journal, 2007, 154, 12-38.	1.2	103
1357	The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: A propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database. American Heart Journal. 2007, 154, 267-277.	1.2	63
1358	Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: A report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). American Heart Journal, 2007, 154, 277.e1-277.e8.	1.2	140
1359	Effects of carvedilol early after myocardial infarction: Analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN). American Heart Journal, 2007, 154, 637-644.	1.2	22
1360	Effects of a home-based exercise program on clinical outcomes in heart failure. American Heart Journal, 2007, 154, 877-883.	1.2	116
1361	Reply. American Heart Journal, 2007, 154, e21.	1.2	11
1362	Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: A report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). American Heart Journal, 2007, 154, 647-654.	1.2	56
1363	Management of Post-Myocardial Infarction Patients with Left Ventricular Systolic Dysfunction. American Journal of Medicine, 2007, 120, 109-120.	0.6	16
1364	High Prevalence of Renal Dysfunction and Its Impact on Outcome in 118,465 Patients Hospitalized With Acute Decompensated Heart Failure: A Report From the ADHERE Database. Journal of Cardiac Failure, 2007, 13, 422-430.	0.7	687
1365	Low Serum Albumin Levels Are Strongly Associated with Inflammation but Not with Body Mass Index in Advanced Heart Failure Patients. Journal of Cardiac Failure, 2007, 13, S102.	0.7	3
1366	Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2007, 49, 1943-1950.	1.2	440
1367	Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized for Heart Failure. Journal of the American College of Cardiology, 2007, 50, 768-777.	1.2	929
1368	Predictors of Delivery of Hospital-Based Heart Failure Patient Education: A Report from OPTIMIZE-HF. Journal of Cardiac Failure, 2007, 13, 189-198.	0.7	33

#	Article	IF	Citations
1369	Prospective Evaluation of Beta-Blocker Use at the Time of Hospital Discharge as a Heart Failure Performance Measure: Results From OPTIMIZE-HF. Journal of Cardiac Failure, 2007, 13, 722-731.	0.7	63
1370	Racial and survival paradoxes in chronic kidney disease. Nature Clinical Practice Nephrology, 2007, 3, 493-506.	2.0	98
1371	Comprehensive Coronary Artery Disease Care in a Safety-Net Hospital: Results of Get With The Guidelines Quality Improvement Initiative. Journal of Managed Care Pharmacy, 2007, 13, 319-325.	2.2	16
1372	Assessing Clinical Risk Prediction Tools. Annals of Emergency Medicine, 2007, 50, 741-742.	0.3	2
1373	CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Reverse Epidemiology beyond Dialysis Patients: Chronic Heart Failure, Geriatrics, Rheumatoid Arthritis, COPD, and AIDS. Seminars in Dialysis, 2007, 20, 549-553.	0.7	56
1374	Quality Indicators for the Care of Heart Failure in Vulnerable Elders. Journal of the American Geriatrics Society, 2007, 55, S340-6.	1.3	24
1375	Cardiac Resynchronization Therapy Response is Associated with Shorter Duration of Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 1363-1368.	0.5	36
1376	Usefulness of Preimplantation B-Type Natriuretic Peptide Level for Predicting Response to Cardiac Resynchronization Therapy. American Journal of Cardiology, 2007, 99, 242-246.	0.7	45
1377	Review of Current and Investigational Pharmacologic Agents for Acute Heart Failure Syndromes. American Journal of Cardiology, 2007, 99, S4-S23.	0.7	70
1378	Comparisons of Guideline-Recommended Therapies in Patients With Documented Coronary Artery Disease Having Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting Versus Medical Therapy Only (from the REACH International Registry). American Journal of Cardiology, 2007, 99, 1212-1215.	0.7	40
1379	Medical Therapies and Invasive Treatments for Coronary Artery Disease by Body Mass: The "Obesity Paradox―in the Get With The Guidelines Database. American Journal of Cardiology, 2007, 100, 1331-1335.	0.7	130
1380	Aberrant Central Nervous System Responses to the Valsalva Maneuver in Heart Failure. Congestive Heart Failure, 2007, 13, 29-35.	2.0	36
1381	Performance Measures for Patients Hospitalized With Heart Failure: Are They Predictive of Clinical Outcomes?. Congestive Heart Failure, 2007, 13, 342-346.	2.0	7
1382	Modifying the anti-inflammatory effects of high-density lipoprotein. Current Atherosclerosis Reports, 2007, 9, 57-63.	2.0	32
1383	Acute heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy. Heart Failure Reviews, 2007, 12, 97-104.	1.7	60
1384	Reinforcing a Continuum of Care: In-Hospital Initiation of Long-Term Secondary Prevention Following Acute Coronary Syndromes. Cardiovascular Drugs and Therapy, 2007, 21, 375-388.	1.3	14
1385	Hyponatremia in acute heart failure syndromes: A potential therapeutic target. Current Heart Failure Reports, 2007, 4, 207-213.	1.3	6
1386	Adherence to best practices: How do patient race and gender affect physician performance?. Current Cardiovascular Risk Reports, 2007, 1, 102-107.	0.8	10

#	Article	IF	Citations
1387	HDL function as a target of lipid-modifying therapy. Reviews in Cardiovascular Medicine, 2007, 8, 1-8.	0.5	4
1388	AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. Journal of the American College of Cardiology, 2006, 47, 2130-2139.	1.2	526
1389	Diabetic Cardiomyopathy. Endocrinology and Metabolism Clinics of North America, 2006, 35, 575-599.	1.2	49
1390	Epidemiology of Dialysis Patients and Heart Failure Patients. Seminars in Nephrology, 2006, 26, 118-133.	0.6	78
1391	B-Type Natriuretic Peptide Levels in Obese Patients With Advanced Heart Failure. Journal of the American College of Cardiology, 2006, 47, 85-90.	1.2	212
1392	Clinical Presentation, Management, and In-Hospital Outcomes of Patients Admitted With Acute Decompensated Heart Failure With Preserved Systolic Function. Journal of the American College of Cardiology, 2006, 47, 76-84.	1.2	848
1393	Gender Differences in In-Hospital Management and Outcomes in Patients With Decompensated Heart Failure: Analysis From the Acute Decompensated Heart Failure National Registry (ADHERE). Journal of Cardiac Failure, 2006, 12, 100-107.	0.7	168
1394	Total cholesterol levels and mortality risk in nonischemic systolic heart failure. American Heart Journal, 2006, 152, 1077-1083.	1.2	42
1395	Are registry hospitals different? A comparison of patients admitted to hospitals of a commercial heart failure registry with those from national and community cohorts. American Heart Journal, 2006, 152, 935-939.	1.2	36
1396	The Confounding Issue of Comorbid Renal Insufficiency. American Journal of Medicine, 2006, 119, S17-S25.	0.6	51
1397	An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. American Heart Journal, 2006, 151, 91.e1-91.e6.	1.2	125
1398	Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: Results of a national survey. American Heart Journal, 2006, 152, 976-981.	1.2	37
1399	Is aggressive or moderate lipid lowering more effective in slowing vascular calcification in postmenopausal women?. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 20-21.	3.3	0
1400	Hospital protocols and evidence-based therapies: The importance of integrating aldosterone blockade into the management of patients with post-acute myocardial infarction heart failure. Clinical Cardiology, 2006, 29, 4-8.	0.7	22
1401	High-density lipoprotein: Is it always atheroprotective?. Current Atherosclerosis Reports, 2006, 8, 405-411.	2.0	74
1402	Usefulness of a Home-Based Exercise Program for Overweight and Obese Patients With Advanced Heart Failure. American Journal of Cardiology, 2006, 97, 886-890.	0.7	41
1403	Relation of Loop Diuretic Dose to Mortality in Advanced Heart Failure. American Journal of Cardiology, 2006, 97, 1759-1764.	0.7	350
1404	Improving Outcomes in Post–Acute Myocardial Infarction Heart Failure: Incorporation of Aldosterone Blockade into Combination Therapy to Optimize Neurohormonal Blockade. American Journal of Cardiology, 2006, 97, 26-33.	0.7	51

#	Article	IF	Citations
1405	Impact of obesity on quality of life and depression in patients with heart failure. European Journal of Heart Failure, 2006, 8, 750-755.	2.9	32
1406	Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol. Expert Opinion on Pharmacotherapy, 2006, 7, 2533-2546.	0.9	13
1407	Systolic Blood Pressure at Admission, Clinical Characteristics, and Outcomes in Patients Hospitalized With Acute Heart Failure. JAMA - Journal of the American Medical Association, 2006, 296, 2217.	3.8	854
1408	AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. Circulation, 2006, 113, 2363-2372.	1.6	1,742
1409	Beta-blockers for the post-myocardial infarction patient: current clinical evidence and practical considerations. Reviews in Cardiovascular Medicine, 2006, 7, 1-9.	0.5	12
1410	Congestion in acute heart failure syndromes: importance of early recognition and treatment. Reviews in Cardiovascular Medicine, 2006, 7, 69-74.	0.5	6
1411	Proactive monitoring and management of the chronic heart failure patient. Introduction. Reviews in Cardiovascular Medicine, 2006, 7 Suppl 1, S1-2.	0.5	0
1412	How well are chronic heart failure patients being managed?. Reviews in Cardiovascular Medicine, 2006, 7 Suppl 1, S3-11.	0.5	4
1413	Heart failure with preserved ejection fraction: disturbing trends. Reviews in Cardiovascular Medicine, 2006, 7, 247-8.	0.5	0
1414	Treating to Low-Density Lipoprotein Goal. Critical Pathways in Cardiology, 2005, 4, 174-176.	0.2	0
1415	Beyond Coronary Sinus Angiography: The Value of Coronary Arteriography and Identification of the Pericardiophrenic Vein During Left Ventricular Lead Placement. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 185-190.	0.5	28
1416	Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and Implications for Treatment Under the Recent NCEP Writing Group Recommendations. American Journal of Cardiology, 2005, 96, 556-563.	0.7	257
1417	Effect of Statin Use Within the First 24 Hours of Admission for Acute Myocardial Infarction on Early Morbidity and Mortalityâ€â€A complete list of participating hospitals is available from ClinTrials Research, 1100 Weston Parkway, Cary, North Carolina 27513 American Journal of Cardiology, 2005, 96, 611-616.	0.7	235
1418	An Approach to Heart Failure and Diabetes Mellitus. American Journal of Cardiology, 2005, 96, 47-52.	0.7	26
1419	Pathophysiologic Targets in the Early Phase of Acute Heart Failure Syndromes. American Journal of Cardiology, 2005, 96, 11-17.	0.7	255
1420	Importance of In-Hospital Initiation of Evidence-Based Medical Therapies for Heart Failure: Taking Advantage of the Teachable Moment. Congestive Heart Failure, 2005, 11, 153-154.	2.0	2
1421	When to initiate beta-blockers in heart failure: Is it ever too early?. Current Heart Failure Reports, 2005, 2, 94-99.	1.3	5
1422	Overview of Acutely Decompensated Congestive Heart Failure (ADHF): A Report from the ADHERE Registry. Heart Failure Reviews, 2005, 9, 179-185.	1.7	140

#	Article	IF	Citations
1423	Safety and Feasibility of Autologous Myoblast Transplantation in Patients With Ischemic Cardiomyopathy. Circulation, 2005, 112, 1748-1755.	1.6	325
1424	Adherence to Heart Failure Quality-of-Care Indicators in US Hospitals. Archives of Internal Medicine, 2005, 165, 1469.	4.3	236
1425	Obesity Paradox as a Component of Reverse Epidemiology in Heart Failure. Archives of Internal Medicine, 2005, 165, 1797.	4.3	19
1426	Risk Stratification for In-Hospital Mortality in Acutely Decompensated Heart Failure <subtitle>Classification and Regression Tree Analysis</subtitle> . JAMA - Journal of the American Medical Association, 2005, 293, 572.	3.8	1,414
1427	In-Hospital Initiation of Statin Therapy in Acute Coronary Syndromes. Chest, 2005, 128, 3641-3651.	0.4	16
1428	Two-year follow-up of quality of life in patients referred for heart transplant. Heart and Lung: Journal of Acute and Critical Care, 2005, 34, 187-193.	0.8	24
1429	Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. American Heart Journal, 2005, 149, 168-174.	1.2	170
1430	Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). American Heart Journal, 2005, 149, 209-216.	1.2	1,811
1431	Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. American Heart Journal, 2005, 150, 1220-1227.	1.2	67
1432	Practical considerations of β-blockade in the management of the post–myocardial infarction patient. American Heart Journal, 2005, 149, 984-993.	1.2	20
1433	Depression in patients with heart failure. Journal of Cardiac Failure, 2005, 11, 30-35.	0.7	53
1434	Validity of Pedometers for Measuring Exercise Adherence in Heart Failure Patients. Journal of Cardiac Failure, 2005, 11, 366-371.	0.7	34
1435	Functional Abnormalities in Brain Areas That Mediate Autonomic Nervous System Control in Advanced Heart Failure. Journal of Cardiac Failure, 2005, 11, 437-446.	0.7	64
1436	In-Hospital Mortality in Patients With Acute Decompensated Heart Failure Requiring Intravenous Vasoactive Medications. Journal of the American College of Cardiology, 2005, 46, 57-64.	1.2	712
1437	High-Density Lipoprotein Function. Journal of the American College of Cardiology, 2005, 46, 1792-1798.	1.2	254
1438	Strategies to improve the use of evidence-based heart failure therapies. Reviews in Cardiovascular Medicine, 2005, 6 Suppl 2, S32-42.	0.5	2
1439	Genetic Basis of Atherosclerosis: Part I. Circulation, 2004, 110, 1868-1873.	1.6	166
1440	Heart Failure Disease Management Programs. Circulation, 2004, 110, 3506-3508.	1.6	35

#	Article	IF	Citations
1441	Improving Quality of Care Through Disease Management. Circulation, 2004, 109, 2651-2654.	1.6	103
1442	Genetic Basis of Atherosclerosis: Part II. Circulation, 2004, 110, 2066-2071.	1.6	74
1443	Beta Blocker and Angiotensin-Converting Enzyme Inhibitor Therapy Is Associated with Decreased $Th1/Th2$ Cytokine Ratios and Inflammatory Cytokine Production in Patients with Chronic Heart Failure. NeuroImmunoModulation, 2004, 11, 173-180.	0.9	78
1444	Early Withdrawal of Statin Therapy in Patients With Non–ST-Segment Elevation Myocardial Infarction <subtitle>National Registry of Myocardial Infarction</subtitle> . Archives of Internal Medicine, 2004, 164, 2162.	4.3	104
1445	ACCF/AHA Consensus Conference Report on Professionalism and Ethics. Circulation, 2004, 110, 2506-2549.	1.6	24
1446	Muscle mechanoreceptor sensitivity in heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H1937-H1943.	1.5	94
1447	Decompensated Heart Failure: Is There a Role for the Outpatient Use of Nesiritide?. Congestive Heart Failure, 2004, 10, 230-236.	2.0	4
1448	Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy in heart failure. American Journal of Cardiology, 2004, 93, 1007-1011.	0.7	52
1449	Role of in-hospital initiation of carvedilol to improve treatment rates and clinical outcomes. American Journal of Cardiology, 2004, 93, 77-81.	0.7	8
1450	Importance of in-hospital initiation of evidence-based medical therapies for heart failure—a review. American Journal of Cardiology, 2004, 94, 1155-1160.	0.7	50
1451	Anti-Inflammatory Properties of HDL. Reviews in Endocrine and Metabolic Disorders, 2004, 5, 351-358.	2.6	34
1452	Rapid clinical assessment of hemodynamic profiles and targeted treatment of patient with acutely decompensated heart failure. Clinical Cardiology, 2004, 27, 1-9.	0.7	14
1453	Assessment and treatment of acute heart failure-Case study: Dry and warm profile. Clinical Cardiology, 2004, 27, 14-15.	0.7	26
1454	Quality of care and outcomes in acute decompensated heart failure: The ADHERE registry. Current Heart Failure Reports, 2004, 1, 121-128.	1.3	40
1455	Azygos Vein Lead Implantation:. A Novel Adjunctive Technique for Implantable Cardioverter Defibrillator Placement. Journal of Cardiovascular Electrophysiology, 2004, 15, 780-783.	0.8	51
1456	Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. Journal of the American College of Cardiology, 2004, 43, 642-648.	1.2	319
1457	Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. Journal of the American College of Cardiology, 2004, 43, 1019-1026.	1.2	170
1458	Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. Journal of the American College of Cardiology, 2004, 43, 1439-1444.	1.2	584

#	Article	IF	Citations
1459	Task force 3: Disclosure of relationships with commercial interests: Policy for educational activities and publications. Journal of the American College of Cardiology, 2004, 44, 1736-1740.	1.2	12
1460	Is coping style linked to emotional states in heart failure patients?. Journal of Cardiac Failure, 2004, 10, 344-349.	0.7	77
1461	Organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF): rationale and design. American Heart Journal, 2004, 148, 43-51.	1.2	308
1462	Approach to the management of diabetic patients with heart failure: Role of thiazolidinediones. American Heart Journal, 2004, 148, 551-558.	1.2	21
1463	Managing the patient with diabetes mellitus and heart failure: issues and considerations. American Journal of Medicine, 2004, 116, 76-88.	0.6	23
1464	Thematic review series: The Pathogenesis of Atherosclerosis The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. Journal of Lipid Research, 2004, 45, 993-1007.	2.0	585
1465	Task Force 3: Disclosure of Relationships With Commercial Interests: Policy for Educational Activities and Publications. Circulation, 2004, 110, 2524-2528.	1.6	0
1466	Chronic heart failure: applying new findings to optimize care and improve survival. Introduction. Reviews in Cardiovascular Medicine, 2004, 5 Suppl 1, S1-2.	0.5	0
1467	Strategies to improve the use of evidence-based heart failure therapies: OPTIMIZE-HF. Reviews in Cardiovascular Medicine, 2004, 5 Suppl 1, S45-54.	0.5	8
1468	B-type natriuretic peptide: spectrum of application. Nesiritide (recombinant BNP) for heart failure. Heart Failure Reviews, 2003, 8, 321-325.	1.7	15
1469	In-hospital initiation of statin therapy in patients with acute coronary events. Current Atherosclerosis Reports, 2003, 5, 394-402.	2.0	2
1470	Lessons learned from recent lipid-lowering trials: Why physicians should change clinical practice. Clinical Cornerstone, 2003, 5, S11-S17.	1.0	1
1471	Use of two recipient lists for adults requiring heart transplantation. Journal of Thoracic and Cardiovascular Surgery, 2003, 125, 49-59.	0.4	87
1472	Effective strategies for long-term statin use. American Journal of Cardiology, 2003, 92, 27-34.	0.7	28
1473	Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. Journal of the American College of Cardiology, 2003, 41, 1529-1538.	1.2	458
1474	Comparison of in-hospital mortality in patients treated with nesiritide vs. other parenteral vasoactive medications for acutely decompensated heart failure: an analysis from a large prospective registry database. Journal of Cardiac Failure, 2003, 9, S81.	0.7	18
1475	Variation in heart failure quality of care indicators among U.S. hospitals: analysis of 230 hospitals in the ADHERE registry. Journal of Cardiac Failure, 2003, 9, S82.	0.7	9
1476	Secondary prevention after coronary bypass: the American Heart Association "Get with the Guidelines―program. Annals of Thoracic Surgery, 2003, 75, 758-760.	0.7	26

#	Article	IF	Citations
1477	Sleep-disordered breathing in heart failure. Current Treatment Options in Cardiovascular Medicine, 2003, 5, 459-467.	0.4	2
1478	Cardiac Troponin I Is Associated With Impaired Hemodynamics, Progressive Left Ventricular Dysfunction, and Increased Mortality Rates in Advanced Heart Failure. Circulation, 2003, 108, 833-838.	1.6	538
1479	Inflammatory/Antiinflammatory Properties of High-Density Lipoprotein Distinguish Patients From Control Subjects Better Than High-Density Lipoprotein Cholesterol Levels and Are Favorably Affected by Simvastatin Treatment. Circulation, 2003, 108, 2751-2756.	1.6	545
1480	Regional brain gray matter loss in heart failure. Journal of Applied Physiology, 2003, 95, 677-684.	1.2	196
1481	In-hospital Initiation of Cardiovascular Protective Therapies to Improve Treatment Rates and Clinical Outcomes. Critical Pathways in Cardiology, 2003, 2, 61-70.	0.2	6
1482	Role of Î <sup>2</sup> -Blocker Therapy in the Postmyocardial Infarction Patient With and Without Left Ventricular Dysfunction Consensus Guideline. Critical Pathways in Cardiology, 2003, 2, 239-246.	0.2	0
1483	Aggressive treatment of atherosclerosis: the time is now Cleveland Clinic Journal of Medicine, 2003, 70, 431-434.	0.6	2
1484	Support with the BVS 5000 assist device during treatment of acute giant-cell myocarditis. Texas Heart Institute Journal, 2003, 30, 50-6.	0.1	15
1485	Prevention of heart failure: effective strategies to combat the growing epidemic. Reviews in Cardiovascular Medicine, 2003, 4, 8-17.	0.5	12
1486	Combining natriuretic peptides and necrosis markers in determining prognosis in heart failure. Reviews in Cardiovascular Medicine, 2003, 4 Suppl 4, S20-8.	0.5	10
1487	The role of in-hospital initiation of cardiovascular protective therapies to improve treatment rates and clinical outcomes. Reviews in Cardiovascular Medicine, 2003, 4 Suppl 3, S37-46.	0.5	2
1488	In-hospital initiation of cardiovascular protective medications for patients undergoing percutaneous coronary intervention: taking advantage of the teachable moment. Journal of Invasive Cardiology, 2003, 15, 646-52.	0.4	4
1489	The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Reviews in Cardiovascular Medicine, 2003, 4 Suppl 7, S21-30.	0.5	83
1490	The management of the diabetic patient with prior cardiovascular events. Reviews in Cardiovascular Medicine, 2003, 4 Suppl 6, S38-49.	0.5	1
1491	Treating to goal: new strategies for initiating and optimizing lipid-lowering therapy in patients with atherosclerosis. Vascular Medicine, 2002, 7, 187-194.	0.8	9
1492	Obesity, weight reduction and survival in heart failure: Reply. Journal of the American College of Cardiology, 2002, 39, 1563-1564.	1.2	15
1493	Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. Journal of the American College of Cardiology, 2002, 39, 1780-1786.	1.2	640
1494	Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. Journal of Cardiac Failure, 2002, 8, 216-224.	0.7	306

#	Article	IF	CITATIONS
1495	Emotional well-being of heart failure patients and their caregivers. Journal of Cardiac Failure, 2002, 8, 300-305.	0.7	72
1496	Acupuncture inhibits sympathetic activation during mental stress in advanced heart failure patients. Journal of Cardiac Failure, 2002, 8, 399-406.	0.7	85
1497	Correlates of health-related quality of life in patients with heart failure. Heart and Lung: Journal of Acute and Critical Care, 2002, 31, 85-93.	0.8	90
1498	Giant cell myocarditis in a young man responsive to T-lymphocyte cytolytic therapy. Journal of Heart and Lung Transplantation, 2002, 21, 818-821.	0.3	11
1499	Hepatitis C-positive Donors in Heart Transplantation. American Journal of Transplantation, 2002, 2, 443-447.	2.6	71
1500	Recent Trends in Early Outcome of Adult Patients after Heart Transplantation: A Single-institution Review of 251 Transplants Using Standard Donor Organs1. American Journal of Transplantation, 2002, 2, 539-545.	2.6	42
1501	Statin therapy after acute myocardial infarction: Are we adequately treating high-risk patients?. Current Atherosclerosis Reports, 2002, 4, 99-106.	2.0	12
1502	Prevention of heart failure. Current Cardiology Reports, 2002, 4, 194-199.	1.3	7
1503	Treating to goal: new strategies for initiating and optimizing lipid-lowering therapy in patients with atherosclerosis. Vascular Medicine, 2002, 7, 187-194.	0.8	3
1504	Beta-blocker therapy for heart failure: the standard of care. Reviews in Cardiovascular Medicine, 2002, 3, 14-21.	0.5	10
1505	Pharmacologic therapies for acutely decompensated heart failure. Reviews in Cardiovascular Medicine, 2002, 3 Suppl 4, S18-27.	0.5	8
1506	Angiotensin receptor antagonist therapy fails to reduce heart failure mortality. Reviews in Cardiovascular Medicine, 2002, 3, 162-3.	0.5	0
1507	The role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes. Reviews in Cardiovascular Medicine, 2002, 3 Suppl 3, S2-S10.	0.5	6
1508	The impact of obesity on survival in patients with heart failure. Heart Failure Monitor, 2002, 3, 8-14.	0.7	24
1509	The relationship between obesity and mortality in patients with heart failure. Journal of the American College of Cardiology, 2001, 38, 789-795.	1.2	738
1510	Educational needs of patients with advanced heart failure and their caregivers. Journal of Heart and Lung Transplantation, 2001, 20, 766-769.	0.3	35
1511	Exaggerated muscle mechanoreflex control of reflex renal vasoconstriction in heart failure. Journal of Applied Physiology, 2001, 90, 1714-1719.	1.2	100
1512	Quality Indicators for the Management of Heart Failure in Vulnerable Elders. Annals of Internal Medicine, 2001, 135, 694.	2.0	22

#	Article	IF	CITATIONS
1513	Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). American Journal of Cardiology, 2001, 87, 819-822.	0.7	479
1514	In-Hospital Initiation of Lipid-Lowering Therapy for Patients With Coronary Heart Disease. Circulation, 2001, 103, 2768-2770.	1.6	76
1515	Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial Infarction. Circulation, 2001, 103, 38-44.	1.6	220
1516	Self-Study from Web-Based and Printed Guideline Materials. Annals of Internal Medicine, 2000, 132, 938.	2.0	127
1517	How old is too old for heart transplantation?. Current Opinion in Cardiology, 2000, 15, 97-103.	0.8	25
1518	Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverter-defibrillator. American Journal of Cardiology, 2000, 85, 981-985.	0.7	99
1519	Rationale and design of the cardiac hospitalization atherosclerosis management program at the University of California Los Angeles. American Journal of Cardiology, 2000, 85, 10-17.	0.7	76
1520	Exaggerated Renal Vasoconstriction During Exercise in Heart Failure Patients. Circulation, 2000, 101, 784-789.	1.6	85
1521	Interscan Variation in Coronary Artery Calcium Quantification in a Large Asymptomatic Patient Population. American Journal of Roentgenology, 2000, 174, 803-809.	1.0	70
1522	Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. American Heart Journal, 2000, 140, 840-847.	1.2	301
1523	The hemodynamic effects of isotonic exercise using hand-held weights in patients with heart failure. Journal of Heart and Lung Transplantation, 2000, 19, 1209-1218.	0.3	18
1524	Mechanical assist strategy using the BVS 5000i for patients with heart failure. Annals of Thoracic Surgery, 2000, 70, 59-66.	0.7	19
1525	Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. Journal of Lipid Research, 2000, 41, 1495-1508.	2.0	353
1526	Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. Journal of Heart and Lung Transplantation, 1999, 18, 1126-1132.	0.3	209
1527	Sexuality of patients with advanced heart failure and their spouses or partners. Journal of Heart and Lung Transplantation, 1999, 18, 1133-1138.	0.3	58
1528	Safety and Hemodynamic Effects of Intravenous Triiodothyronine in Advanced Congestive Heart Failure. American Journal of Cardiology, 1998, 81, 443-447.	0.7	196
1529	Skin test anergy in advanced heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. American Journal of Cardiology, 1998, 82, 323-328.	0.7	48
1530	Paraoxonase and coronary heart disease. Current Opinion in Lipidology, 1998, 9, 319-324.	1.2	177

#	Article	IF	Citations
1531	High density associated enzymes: their role in vascular biology. Current Opinion in Lipidology, 1998, 9, 449-456.	1.2	73
1532	Impact of a Comprehensive Heart Failure Management Program on Hospital Readmission and Functional Status of Patients With Advanced Heart Failure. Journal of the American College of Cardiology, 1997, 30, 725-732.	1.2	490
1533	Predictors of Natural Killer Cell-Mediated Cytotoxicity Deficiency in Advanced Heart Failure Secondary to Either Ischemic or Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 1997, 80, 234-236.	0.7	2
1534	Sustained Hemodynamic Efficacy of Therapy Tailored to Reduce Filling Pressures in Survivors With Advanced Heart Failure. Circulation, 1997, 96, 1165-1172.	1.6	201
1535	Impact of Acute Mental Stress on Sympathetic Nerve Activity and Regional Blood Flow in Advanced Heart Failure. Circulation, 1997, 96, 1835-1842.	1.6	87
1536	Improving survival for patients with atrial fibrillation and advanced heart failure. Journal of the American College of Cardiology, 1996, 28, 1458-1463.	1.2	208
1537	Improvement in exercise capacity of candidates awaiting heart transplantation. Journal of the American College of Cardiology, 1995, 25, 163-170.	1.2	167
1538	Improving survival for patients with advanced heart failure: A study of 737 consecutive patients. Journal of the American College of Cardiology, 1995, 26, 1417-1423.	1.2	206
1539	Evidence for Preserved Cardiopulmonary Baroreflex Control of Renal Cortical Blood Flow in Humans With Advanced Heart Failure. Circulation, 1995, 92, 395-401.	1.6	36
1540	Prediction of improvement in recent oncet cardiomyopathy after referral for heart transplantation. Journal of the American College of Cardiology, 1994, 23, 553-559.	1.2	148
1541	Intracoronary dexmedetomidine does not produce coronary vasoconstriction at therapeutic blood levels in chronically instrumented anaesthetized swine. Journal of Cardiothoracic and Vascular Anesthesia, 1994, 8, 4.	0.6	2
1542	Predicting death from progressive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. American Journal of Cardiology, 1993, 72, 62-65.	0.7	166
1543	Transesophageal echocardiography during radiofrequency catheter ablation of ventricular tachycardia. American Journal of Cardiology, 1993, 72, 658-661.	0.7	37
1544	Vasodilators. Drugs, 1992, 43, 15-36.	4.9	9
1545	Endothelin and the vascular choir in heart failure. Journal of the American College of Cardiology, 1992, 20, 854-857.	1.2	10
1546	Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: The Hy-C trial. Journal of the American College of Cardiology, 1992, 19, 842-850.	1.2	173
1547	Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization. US Cardiology Review, 0, 15, .	0.5	12